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Induction of myocardial ischaemia results in a cascade of left ventricular 
haemodynamic effects, resulting in myocyte necrosis, scar formation and eventual heart 
failure, for which treatment is limited. Fundamental to enhancing our understanding of 
cardiovascular pathophysiology and therapeutics is the assessment of ventricular pump 
properties. The main aim of this work was to gain a greater understanding of the 
myocardial-coronary and ventricular-arterial interaction in humans in health and 
diseased states.  
Methods 
Simultaneous invasive left ventricular (LV) pressure-volume (PV) (by use of a 
conductance catheter) and intra-coronary haemodynamic assessment (dual-sensor 
pressure-flow wire) were performed in the catheterisation laboratory. A novel software 
system was developed to perform simultaneous analysis of PV loop and coronary 
haemodynamic data. In-vitro and in-vivo studies were performed for calibration; PV 
loop recordings from patients were used for validation.  
Results 
1) Using wave intensity analysis, the origin of the coronary wave energies were 
described, and their temporal relationship with the cardiac cycle was established. In 
the absence of autoregulation a direct relationship was found to exist between LV 
elastance and coronary flow velocity. 
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2) Assessment of coronary haemodynamics and LV PV measurements were performed 
during supine exercise to provoke ischaemia, with a control group comparator. 
Ischaemia led to a rightward shift in end-systolic and end-diastolic PV relations; VA 
interaction was adversely affected during ischaemia compared to control. 
3) The effects of nitrates in patients with coronary artery disease were examined. 
Nitrates induced vasodilatation of the systemic vasculature and coronary circulation, 
decreasing myocardial oxygen consumption and inducing stenosis dilatation.  
4) 3D speckle tracking echocardiography was performed in patients with preserved LV 
function and coronary artery disease followed by PV loop assessment. Parameters of 
strain correlated well with contractility indices in-vivo; thus has potential for use in 
prognostication and risk stratification. 
5) The haemodynamic mechanisms of percutaneous ventricular restoration (PVR) 
therapy are not understood. Patients underwent PVR implantation and LV PV loops 
were recorded pre- and post-PVR and at 6-month follow up. PVR decreased 
dyssynchrony, LV volumes and induced reverse remodelling with improved 
contractility. 
Conclusions 
Development of software enabled understanding of the cardiac-coronary interaction: 
coronary wave energies were shown to be dependent on V-A interaction rather than 
myocardial-coronary interaction. Coronary systolic flow was directly related to LV 
elastance on abolition of autoregulation. Systemic response to demand ischaemia was 
described, as were the anti-anginal effects of nitrates; 3D deformation imaging was 
validated as a prognostic tool for subclinical heart disease and PVR was shown to 
induce reverse remodelling.  
iv	
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The main aim of this work was to gain a greater understanding of the myocardial-
coronary and ventricular-arterial interaction in humans in health and diseased states.  
 
Main Hypotheses Investigated 
Examination of the interaction between the myocardium, coronary arteries and systemic 
vasculature will enable the following hypotheses to be investigated:  
1) Coronary blood flow impediment is a function of left ventricular elastance 
2) The diastolic dysfunction accompanying ischaemia is dependent on systolic function  
3) The anti-anginal effects of nitrate is due to its action on vascular smooth muscle 
4) The therapeutic effect of percutaneous ventricular restoration therapy results from a 
reduction in dyssynchrony 
 
Chapter 1 provides a detailed literature review on the cellular mechanisms of 
contraction; the relationship between coronary blood flow and myocardial mechanics 
the assessment of systolic and diastolic properties on a macroscopic level, and the 
impact of ischaemic heart disease on contractile function. 
 
Chapter 2 Assessment of myocardial pump properties and coronary blood flow was 
performed using invasive left ventricular pressure-volume assessment (by use of a 
conductance catheter) and intra-coronary haemodynamic assessment (dual-sensor 
pressure-flow wire) in human subjects in the cardiac catheterisation laboratory. This 
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chapter describes the current software and hardware tools used for invasive LV and 
coronary data acquisition and the catheter laboratory techniques used to perform this 
work. Techniques that incorporate invasive coronary and left ventricular haemodynamic 
assessment do not exist, previous work have examined these either in isolation or 
independently, the disadvantages are that these do not provide continuous assessment of 
the interaction between the two. 
 
Chapter 3 Describes the results of how these methodological issues were addressed for 
the purposes of this body of work; novel techniques are described that include hardware 
configuration to enable real-time data acquisition in human subjects. This chapter also 
describes a novel software system that was developed as part of the work toward this 
doctoral thesis: matrix laboratory programming language was used, to employ 
automated algorithms that analyse left ventricular (LV) pressure-volume (PV) loop and 
coronary haemodynamic (pressure and velocity) data simultaneously in humans. The 
results of in-vitro (phantom flow model) and in-vivo (human) calibration are described, 
with validation using human subjects. This system was applied to investigate the origin 
of the coronary wave energies, and their temporal relationship with the cardiac cycle 
and the relationship between instantaneous LV properties and coronary blood flow 
velocity; the results of which are detailed. 
 
Chapter 4: Describes the results of an investigation into left ventricular haemodynamics 
and coronary blood flow during dynamic exercise; exercise-induced ischaemia was 
examined with a control group comparator. At low impact, exercise demonstrated a 
beneficial effect in both groups, but adversely affected haemodynamic variables in 
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patients with significant coronary artery disease. The precise affects on end-diastolic 
and end-systolic pressure volume relations are reported. 
 
Chapter 5: The anti-ischaemic mechanism of nitrates was examined with focus on the 
interaction between the myocardium, coronary arteries and systemic vasculature in 
patients with ischaemic heart disease, by use of invasive catheter laboratory techniques 
and the aforementioned software analysis programme. 
 
Chapter 6: This details the results of a human validation (first-in-man) study of non-
invasive strain parameters correlated with invasive assessment of contractile 
performance; the predictive value of 3D speckle tracking echocardiography was also 
examined. 
 
Chapter 7: Percutaneous ventricular restoration (PVR) therapy is a novel treatment in 
patients with ischaemic cardiomyopathy; the precise cardiovascular effects are not 
understood. In this study, ten patients underwent PVR implantation in the cardiac 
catheter laboratory with invasive LV PV loop assessment. This chapter describes the 
haemodynamic outcomes associated with PVR. 
	1 INTRODUCTION 
In this introductory chapter the basic concepts underlying cardiac contraction and 
relaxation are discussed stretching from a cellular level to a macroscopic description of 
cardiac function and assessment using the pressure-volume loop diagram; the 
application of wave intensity analysis in the coronary circulation with focus on the 
myocardial-coronary interaction is also described. There follows a brief literature 
review on the physiological changes associated with exercise, the underlying 
mechanisms of myocardial ischaemia and the action of organic nitrates as anti-anginal 
agents and the pathophysiology of end-stage ischaemic heart disease. 
1.1 CARDIAC STRUCTURE AND FUNCTION 
In this following section, the cellular mechanisms underlying cardiac contraction are 
described. 
1.1.1 MYOCYTE ARCHITECTURE 
The mechanisms underlying cardiac contraction are at the level of the myocytes and 
work under cellular control.1 Cardiac myocytes are specialised muscle cells, 30 
micrometers in diameter and 100 micrometers in length; these are composed of bundles 
of myofibrils that contain microfilaments, Figure 1. Myofibrils repeat in distinct 
anatomical units known as sarcomeres and it is these that form the base of the myocytes' 
contractile properties. The sarcomere, the region of myofilament structures between two 
Z lines, is approximately 2 micrometers in length and is composed of thick (myosin) 
and thin (actin) filaments.1 Interaction between these enables the sarcomere to shorten, 
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with thin filaments sliding over the thick filaments. The thin filaments are composed of 
troponin (Tn), tropomyosin and actin which comprise the regulatory protein complex. 
The Tn complex is composed of TnT (attaches to tropomyosin), TnC (binding site for 
calcium) and TnI, which acts to inhibit the myosin binding site on actin. On calcium 
binding, a conformational change in the Tn complex moves TnI away from the myosin 
binding site on the actin making it accessible to the myosin head. When calcium is then 
removed from the complex, it resumes its inactive position, inhibiting myosin-actin 
binding. This mechanism underlies excitation-contraction coupling.2,3 
Figure 1 Cardiac myocyte.  
These are composed of myofibril bundles, which are in turn comprised of 
myofilaments; the sarcomere is the region of the myofilament between two Z-lines and 




1.1.2 CARDIAC EXCITATION-CONTRACTION COUPLING 
 
 
Figure 2 Calcium Release.  
Entry of calcium into a myocyte triggers calcium release from the sarcoplasmic 
reticulum. Abbreviations: Ca Calcium, SR sarcoplasmic reticulum, Na Sodium, H 
hydrogen, K Potassium, ATP pumps, PLB phospholamban. Adapted from 5 
 
Excitation-contraction coupling is the process from electrical excitation of the heart to 
cardiac contraction. During the cardiac action potential, calcium (Ca) enters the cell: 
electrical depolarisation increases the probability of sarcolemmal calcium channel 
opening with calcium influx. A rise in calcium concentration follows in the sub-
sarcolemmal space near the lateral cisternae of the sarcoplasmic reticulum (SR), this 
rise in local calcium concentration drives the release of an even larger pool of calcium 
from the SR (calcium-induced calcium-release), increasing the intra-cellular calcium 
concentration markedly, Figure 2. This intracellular Ca then binds to TnC inducing the 
aforementioned conformational change, thus exposing the actin molecule and enabling 
INTRODUCTION 
4		
it to bind the myosin ATPase on the myosin head; energy is supplied by hydrolysis to 
enable the conformational change and sliding of the filaments, thereby shortening the 
sarcomere. The Ca influx into the cell then slows, sequestered by the Ca ATP pumps 
within the sarcoplasmic reticulum; reduced calcium induces a conformational change in 
the troponin complex, and TnI once again inhibits the actin binding-site and ADP is 
displaced by an ATP molecule on the myosin head. Calcium is therefore fundamental to 
cardiac contraction, the more calcium made available to the cell increases the force of 
contraction. ATP production provides an energy source for the heart, this is derived 
from oxidative phosphorylation within the mitochondria, one third is used for 
excitation-contraction coupling and basal metabolism; the other two thirds are expended 
















1.1.3 FORCE OF CONTRACTION 
The beta-adrenoceptor mechanism increases calcium availability to the myocytes, 
stimulation of which occurs when sympathetic drive is activated. This leads to an 
increase in cyclic adenosine monophosphate and therefore activation of protein kinase-
facilitated Ca entry into the cell. This protein kinase activation also phosphorylates and 
releases phospholamban (an inhibitor of SR calcium uptake), therefore reuptake of 
calcium by the SR is more rapid; thus beta-adrenergic stimulation increases the force 
and velocity of contraction (positive inotropy) but also increases the rate of relaxation 
(lusitropy).9,10 The increased contractile state increases oxygen consumption, driven 
almost entirely by the increased energy demand of excitation-contraction coupling 
(1.1.2).  
 
Figure 3 Sarcomere length and force generation.  
Length versus the relative systolic and diastolic (µN) generated force exerted by muscle 
(A) sarcomere length (µm) related to the maximum tension (%) generated force (B). 




Other mechanisms that influence contractility include force-length relations (Starling's 
law) calcium sensitivity.12,13 Cardiac muscle length exerts a major influence on force 
production (strength of contraction); cardiac muscle length is directly proportional to 
sarcomere length. The optimal sarcomere length is 2.3 micrometers, this constitutes 
ideal overlap between the thick and thin filaments, and if this distance is shorter then 
less force is generated. Force-length relationships are conveniently used to characterise 
the systolic and diastolic contractile properties of cardiac muscle.14,15 If a muscle is 
stretched from its slack length (the length at which no force is generated), both the 
resting (end-diastolic) tension and the peak (end-systolic) tension increase, Figure 3. 
 
The end-diastolic force-length relationship is non-linear and exhibits a shallow slope at 
short lengths and a steeper slope at longer lengths, which is a reflection of the non-
linear mechanical restraints imposed by the sarcolemma and extracellular matrix to 
prevent overstretch of the sarcomeres. End-systolic force increases with increasing 
muscle length to a much greater degree than end-diastolic force.14 The difference in 
force at end-diastole as compared with end-systole increases as muscle length increases 
and indicates a greater amount of developed force as the muscle is stretched. Inotropic 
agents do not affect the end-diastolic force-length relationship, rather calcium 
availability and sensitivity, thus administration of inotropic agents drives an upward 
shift in the end-systolic force-length relationship, such that at any given length the 
muscle can generate more force. These force-length relationships can be described on a 
larger scale; at the level of the ventricle, these pressure-volume relations are the 
macroscopic counterpart of cellular markers of contractility; therefore are fundamental 
to assessing ventricular systolic and diastolic properties.  
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1.2 ASSESSMENT OF CARDIAC FUNCTION 
In the following section, the physiological measurements derived from the pressure-
volume loop diagram are described. This includes measures of both preload and 
afterload, the interaction between the heart and the great vessels (ventriculo-arterial 
coupling) manifesting in ventricular efficiency, and gold standard measures of 
contractility and diastolic properties. In addition to these invasive measurements of 
cardiac function, the potential for non-invasive assessment in the form of 3D 
echocardiographic strain imaging is discussed. 
1.2.1 CARDIAC CYCLE AND THE PRESSURE-VOLUME LOOP 
Figure 4 The cardiac cycle.  
This is depicted over two cardiac cycles (heart beats); aortic pressure (black), 
ventricular pressure (blue), left atrial pressure (grey) and left ventricular volume (red) 
plotted as a function of time, adapted from 4. 
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The cardiac cycle is divided into systole and diastole. In systole, myocardial 
transformation in the form of cell membrane depolarisation enables calcium entry and 
cross-bridge formation to the point of maximal mechanical activation. During diastole, 
muscle relaxation and cross-bridge uncoupling restores the myocardium to its resting 
state. Systole comprises isovolumic contraction and ejection; diastole comprises 
isovolumic relaxation and filling. The cardiac cycle is commonly represented by 
plotting changes in left ventricular pressure and volume over time, Figure 4. At the start 
of the cardiac cycle, passive filling of the left ventricle (LV) is followed by atrial 
depolarisation and kick; electrical activation of the ventricle leads to depolarisation and 
contraction triggering mitral valve closure as left ventricular pressure (LVP) exceeds 
left atrial pressure (LAP); there follows rising LV pressure in the face of constant LV 
volume (isovolumic contraction) until the point at which LVP exceeds aortic valve 
pressure and the aortic valve opens. At this point LVP and aortic pressure remain 
relatively similar and the LV volume reduces as blood is ejected from the LV into the 
aorta. The duration of systole is predominantly governed by aortic stiffness. As 
myocardial contractility reaches it maximal state of contraction, ejection slows, LVP 
starts to fall and the myocardium begins to relax. The aortic valve closes once LVP 
drops below aortic pressure and the ventricle is at end-systole, with minimal volume. 
The myocardium continues to relax as denoted by the further drop in LVP, with no 
change in volume (isovolumic relaxation). Once LVP drops below LAP, the mitral 




Assessing the changes in contractility within a patient and furthermore between groups 
of patients is a challenge. However, as alluded to earlier, force-length relations are a 
good indicator of contractility; these force-length relationships can be described on a 
larger scale; at the level of the ventricle, thus pressure-volume relations are the 
macroscopic counterpart of these cellular measures of contractility; thus to perform 
measurements of contractility in humans, it is necessary to generate data in the form of 
a ventricular pressure-volume loop. Plotting ventricular pressure against volume in the 
form of a pressure-volume loop produces a powerful and accurate approach to 
determining both contractile function and diastolic properties of the heart. 
Figure 5 The left ventricular (LV) pressure-volume loop.  
The cardiac cycle is depicted by describing pressure as a function of volume, mitral 
valve closure (A), aortic valve opening (B), aortic valve closure (C), mitral valve 
opening (D). Adapted from 11 
 
In Figure 5, the corresponding stages of the cardiac cycle (initially seen in Figure 4) 
have been marked on the PV loop demonstrating the sequence of events that take place 
in the left ventricle (LV) over one cardiac cycle; each cycle is represented by a single 
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loop travelling in an anticlockwise direction. At the point of mitral valve closure, filling 
is complete, electrical depolarisation triggers ventricular contraction; a period of 
isovolumic contraction takes place in the presence of aortic and mitral valve closure 
until aortic pressure is exceeded and the aortic valve opens with ejection. A reduction in 
LV volume follows as ejection takes place, with continued contraction, until the point of 
maximal contraction (elastance) is reached; LVP falls as the rate of contraction slows 
until LVP drops below aortic pressure and the aortic valve closes. With both valves 
closed, a period of isovolumic relaxation follows until LVP falls below left atrial 
pressure (LAP) and the mitral valve opens and passive LV filling takes place; the 
ventricle continues to relax thus pressure continues to drop despite an increase in 
volume. Volume in the LV increases to the point of maximal volume at end-diastole and 
the cycle repeats. Depiction of the cardiac cycle as a pressure-volume loop enables 
measurement of haemodynamic parameters.  
 
1.2.1.1 PRESSURE AND VOLUME INDICES 
A number of physiological measurements, markers of contractility and relaxation as 
well as the total mechanical energy generated by the heart can be derived from the PV 
loop. In its simplest application, indices of volume and pressure can be derived. In 
Figure 6 (A) the maximum LV volume is achieved at end-diastole, at this point, end-
diastolic volume (EDV) can be measured. The importance of deriving end-diastolic 
volume is that it represents sarcomeric stretch, therefore is a direct indicator of preload; 
the end-diastolic pressure (EDP) Figure 6(B), measured at the end-diastolic point, is the 





Figure 6 Physiological parameters derived from the PV loop.  
Left: volume indices, right: pressure indices. Abbreviations: LV left ventricle, ESV end-
systolic volume, EDV end-diastolic volume, SV stroke volume, SBP systolic blood 
pressure, Pes end-systolic pressure, DBP diastolic blood pressure, EDP end-diastolic 
pressure, LAP left atrial pressure. 
 
The minimum volume in the ventricle is at end-systole, which is the end-systolic 
volume (ESV), thus stroke volume (SV) can be derived from EDV and ESV. 
Furthermore, by incorporating heart rate, the cardiac output (CO) can be calculated, 
Equation 1. 
Equation 1  !" =  !" ! !" 
In Figure 6(B) the maximum pressure in the ventricle at any point in the absence of 
aortic valve disease equals systolic blood pressure (SBP); the point of aortic valve 
opening is equal to diastolic blood pressure (DBP); end-systolic pressure (Pes) can be 
derived at end-systole and LAP at the point of mitral valve opening. 
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On the PV loop we see that through one cardiac cycle, the ventricle moves from a state 
of maximal contraction at end-systole to a relaxed state at end-diastole. At this point, 
the myocardium is in a state of maximal relaxation and it is possible to describe the 
diastolic properties of the heart. 
1.2.2 MEASURING DIASTOLIC PROPERTIES AND RELAXATION 
 
Figure 7 End-diastolic pressure volume relations. EDPVR intersects the x-axis at V0 
when extrapolated backward (A); it forms the lower boundary on the PV loop, 
intersecting the loop at the end-diastolic pressure-volume point (B), adapted from 11. 
 
At the end of diastole, the heart is in a state of maximal relaxation. The relationship 
between pressure and volume at end-diastole is described in 
Equation 2 where EDP is the end-diastolic pressure, V is the volume inside the 
ventricle, Po is the pressure asymptote at low volumes (generally close to 0 mmHg), 
and α and β are constants, which specify the curvature of the line, which is in turn 





Equation 2 !"# =  !" +  !"! 
 
 
The curve is called the "end-diastolic pressure-volume relationship" (EDPVR),  
Figure 7. LV EDPVR is the most important means of characterising passive ventricular 
properties; it is the global, integrated expression of chamber geometry, wall thickness, 
and all aspects of passive material properties of the myocardial wall.17,18 This 
relationship is non-linear (compliance falls as volume increases); however, at pressures 
of less than 2-5 mm Hg the pressure-volume relationship is linear (with α approaching 
zero).16 The EDPVR curve, generated by preload reduction, can be extrapolated back to 
the horizontal axis, intersecting at the point V0; this represents the minimum volume 
required to cause a change in LV pressure and is known as the unstressed volume. By 
definition, the EDPVR indicates the amount of diastolic filling that will occur for a 
specified filling pressure and is therefore a key physiological determinant of preload. 
Furthermore diastolic filling is a well-known determinant of LV function.19,20 The α 
constant is unaffected by changes in initial volume and directly altered only by changes 
in wall stiffness, it can therefore be used as a quantitative index of wall stiffness; the β 
constant, although directly related to wall stiffness, is inversely related to the initial 
volume of the ventricular chamber (V0).16 Changes in this relationship occur in health 
and disease and can result from cardiomyopathy, myocardial infarction and scar.16,19 
At end-systole, the myocardium is in a state of maximal activation. At this end-systolic 





1.2.3 MARKERS OF CONTRACTILITY 
1.2.3.1 END-SYSTOLIC PRESSURE VOLUME RELATIONS 
During systole, the extent of myofilament activation achieved in one beat is dependent 
not only on the amount of calcium available to the myofilaments but also on the length 
of the muscle. As mentioned previously (1.1.3) the shape of the end-systolic tension 
length relation (ESTLR) varies with contractile state.21 This is likely related to either 1) 
muscle fibre affinity to calcium or 2) calcium release dependent on muscle length.22,23 
The shape of the ventricular end-systolic pressure-volume relationship (ESPVR; the 
ventricular level counterpart of ESTLR) is linear within physiological ranges of preload 
and afterload, independent of contractile state.  The ESPVR slope reflects the contractile 
state and describes the myocardium at end-systole during maximum activation, Figure 
8.24,25 
Figure 8 The end-systolic pressure volume relationship (ESPVR).  
The slope Ees can be extrapolated to V0 on the x-axis and forms the upper boundary of 




The advantage of ESPVR as a measure of contractility is that it has been shown in many 
studies to separate poorly contracting ventricles from normal ones more accurately than 
ejection fraction or end-systolic volume.26 The slope of the end-systolic pressure-
volume relationship line is designated Ees.25 The ESPVR line intersects the x-axis at a 
positive finite value V0, this can be calculated as shown in Equation 3, where Pes is the 
end-systolic pressure, V is the volume of interest and Ees is the slope of the linear 
relation based on experimental observations.25 V0 varies over time from end-diastole 
(the unstressed volume) to end-systole, however varies very little at end-systole, thus 
for calculations V0 can be viewed as a constant.26 
Equation 3 !"# =  !"# (!− !!) 
 
Whilst describing the myocardium during contraction, instantaneous pressure and 
volume are the two most fundamental variables; during contraction and relaxation the 
instantaneous pressure and volume can be related in a simple manner as seen in 
Equation 4, where E(t) is the slope of the curve over time and follows the same basic 
(linear) shape, Figure 927 This instantaneous pressure-volume relationship over time is 
known as the time varying elastance E(t) and the peak is Emax. 
Equation 4 !(!)  =  !(!)/[! (!)  −  !!] 
 
The time-varying elastic diagram can be used to relate the instantaneous pressure to 
volume at any point throughout the cardiac cycle. Thus if the E(t) function and the time 
course of volume change is known, it can be possible to predict pressure changes 
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throughout the cardiac cycle. The function E(t) is unaffected by end-diastolic volume or 
arterial pressure, however it is affected by changes in inotropic state. Furthermore on 
increasing contractile state, both peak E(t) increases and time to peak E(t) shortens.25 
Figure 9 Time varying elastance. E(t) (right) generated from the instantaneous pressure 
volume relationship at various stages in time (hypothetical straight lines) during 
contraction (left) and relaxation (middle), adapted from 11. 
 
Due to the fact that end-systole and end-ejection are not the same (coincidentally in the 
left ventricle, ejection normally finishes shortly after end-systole), end-systole can be 
difficult to determine; thus by using the time varying elastance, end-systole can be 
designated at the point of Emax when the ventricle is in its maximal contractile state.26 
The slope of the ESPVR line (Ees), can therefore be calculated based on estimations of 
Emax generated from time-varying elastance curves. These calculations provide 
increased accuracy because the slope of the instantaneous pressure-volume relation, 
known as E(t), increases with time until it reaches a point Emax. The true ESPVR slope 
(Ees) is generated from connecting points on the left uppermost corner of the PV loop, 
thus is similar but not identical to Emax; for the purposes of simplicity and single beat 




The energy consequences of time-varying elastance provide the theoretical basis for 
understanding cardiac energetics. An increase in the time-varying elastance and the 
counterclockwise transition of the systolic PV relation enables us to total mechanical 
energy. 
1.2.3.2 CARDIAC ENERGETICS 
The subject of myocardial energetics has been much debated in the past.28-30 The most 
dominant line of investigation into myocardial energetics is the measure of total 
mechanical energy generation of the ventricle. Invasive measurement using pressure-
volume loops is the current gold standard measurement of total mechanical energy. PV 
loop measurement has enabled direct determination of contractile efficiency and the 
quantification of total mechanical energy, thus the use of the PV loop diagram extends 
beyond haemodynamic parameters, entering into cardiac energetics and mechano-
energetic coupling and is the best way to quantify cardiac efficiency.8 
Time-Varying Elastance and Mechanical Energy 
The total area bounded by the systolic component (isovolumic contraction through 
ejection) of the PV loop and the EDPVR and ESPVR lines, generates two smaller areas: 
the area of the PV loop or external stroke work (EW or SW) and the potential energy 
(PE). Thus pressure-volume area (total mechanical energy expenditure) is therefore 
equal to SW+PE, Figure 10.8  
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Figure 10 Total mechanical energy.  
This is also known as PVA or pressure volume area, and is comprised of EW: external 
work (the area of the PV loop) and PE: potential energy, the PVA is bound by the 
ESPVR and EDPVR lines (left). PVA is linearly related to myocardial oxygen 
consumption VO2 (right), adapted from 8 
 
The potential energy comprises the energy used for basal metabolism and excitation-
contraction coupling, but the majority is seen as heat. SW is the actual produced work 
of contraction and is seen as useful energy. The importance of this model of total 
mechanical energy is that it correlates with myocardial oxygen consumption (VO2) in 
excised, cross-circulating canine hearts under varying loading, heart rate and inotropic 
conditions. There is a linear relationship between PVA and VO2. The relationship 
consists of a baseline "unloaded VO2" primarily for basal metabolism and excitation-
contraction coupling and the "excess VO2-PVA” relationship, Figure 10. Thus by 
measuring PVA, we can accurately estimate myocardial oxygen consumption. This 
energy output by the heart is essentially the force multiplied by displacement and is 
measured in Joules, thus PV loop area (expressed in mmHg.mL) must be converted into 
Joules: 1mmHg.ml = 1.33x10-4 Joules.29 With variations in contractility either during 
exercise or with dobutamine, the upward shift in the PVA-VO2 relationship is 
consistently seen, i.e. for a higher contractility (with inotropic intervention), there is a 
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higher oxygen cost of PVA, as explained earlier, this is due to the increase energy 
consumption of excitation-contraction coupling, because the slope of the PVA-VO2 
relation remains unchanged. 31-33 
Ventricular Efficiency 
Efficiency of the heart is the conversion of oxygen to useful work, in other words, the 
work performed by the ventricle in relation to myocardial oxygen consumption, and can 
been defined in a number of ways. Clinically the only work seen by the vascular system 
is the stroke work; therefore the most appropriate definition of efficiency is believed to 
be the SW to VO2 ratio.31,32 This is the product of two stages, firstly the conversion of 
myocardial oxygen consumption to total mechanical energy; and secondly the efficiency 
of energy transfer of PVA to SW. Put more simply, SW/PVA is the efficiency of 
conversion of total mechanical energy to external stroke work, and SW/VO2 is the 
efficiency of conversion of metabolic energy to stroke work. Under normal conditions 
efficiency of VO2 to SW conversion is in the region of 25%, with the rest lost as heat.8 
 
For the purposes of this study, we examine the efficiency of energy transfer of PVA to 
SW. In the absence of arterio-venous sampling, VO2 cannot be directly measured, thus 
the SW: PVA ratio is used as a surrogate marker of ventricular efficiency. Importantly 
loading conditions can influence pressure-volume area and ventricular efficiency. 




1.2.4 MEASURES OF AFTERLOAD 
The left uppermost point on the PV loop is where we measure Pes; the importance of 
Pes is that it corresponds to mean arterial blood pressure, therefore can be utilised in 
estimation of systemic vascular resistance. Systemic vascular resistance (SVR) is 
calculated as the ratio of mean aortic pressure (minus right atrial pressure) to cardiac 
output. This is an accurate measure of peripheral vasomotor tone.34 SVR is a frequently 
used index to estimate left ventricular afterload; however, this measures only one 
component of LV afterload, the non-pulsatile component of peripheral tone, and does 
not incorporate left ventricular internal fibre load, i.e. factors internal to the 
myocardium.35,36 LV systolic performance is inversely related to the force opposing LV 
fibre shortening (afterload), therefore utilisation of the pressure-volume diagram can 
generate a simplified measure of arterial load known as arterial elastance or Ea, Figure 
11. Ea is the ratio of end-systolic pressure to stroke volume. This incorporates the 
principal elements of vascular load including peripheral resistance, vascular 
compliance, impedance and systolic and diastolic time intervals, and closely 
approximates arterial load obtained from aortic impedance and arterial compliance data, 
although this model does not account for reflected waves, the net effects of these are 
functionally accounted for in the PV loop.34,37 The arterial elastance can be extended to 
examine ventricular-arterial coupling: the arterial elastance to end-systolic elastance 
ratio (Ea:Ees). This is an important parameter that measures the interaction between the 
left ventricle and the arterial system; it is a determinant of net ventricular performance 
and cardiac energetics.37,38 Ea: Ees falls between a range of 0.7 to 1.2, where the heart 
and great vessels are working optimally to provide the greatest work, power and 
efficiency.39,40 Previous modeling by Burkhoff et al. have demonstrated that stroke work 
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(effective external work performed by the heart) is at its maximum when Ea is equal to 
Ees.31 Therefore, measurements of afterload can greatly enhance our understanding of 
the ventricular-arterial interaction. Measures of afterload used in this thesis are: 1) end-
systolic pressure (Pes) 2) systemic vascular resistance (SVR) 3) arterial elastance (Ea) 
and 4) ventricular-arterial coupling (Ea:Ees ratio). 
Figure 11 Arterial elastance (Ea).  
This is calculated as the ratio of end-systolic pressure to stroke volume, and can be used 












1.2.5 DEFORMATION IMAGING 
Until this point, we have described invasive measurements of cardiac contraction, in the 
following section, we describe the potential of echocardiographic deformation imaging 
as a tool for the non-invasive assessment of left ventricular function. 
 
Assessing the impact of coronary artery disease on cardiac function is a key task in 
clinical assessment and remains difficult to quantify non-invasively. Echocardiography 
in the assessment of regional myocardial function is advantageous over other modes of 
assessment such as computed tomography and cardiac magnetic resonance imaging due 
to its widespread availability, safety and high temporal resolution.41 Tissue Doppler 
imaging during echocardiography can be used to quantify regional myocardial function; 
by measuring changes in phase shift of the returning ultrasound signals from the 
myocardium, tissue velocities can be determined; 42however, tissue velocities represent 
the net effect of the contractile and elastic properties of the area in question. Thus 
myocardial strain or deformation is thought to be more representative of local 
myocardial function.43,44 Strain is a dimensionless index and represents deformation, in 
other words fractional change from the original dimensions, produced by the application 
of stress. This can be described as positive strain (lengthening or expansion) or negative 
strain (shortening or contraction). 44,45 The ideal would to be to measure Langranian 
strain defined in Equation 5. 
 Equation 5 !" =  (!!!")!  
Where L0 is the length corresponding to zero strain and L is the instantaneous length; 
however this is often replaced by initial muscle length or end-diastolic length. Strain 
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rate, the temporal derivative of strain is the rate of deformation measured as units per 
second, which also correlates with the shortening velocity per fibre length.44  
 
Tissue velocities are a function of the local rate of deformation, therefore it could be 
argued that velocities and strain rate provide the same information, however in regional 
wall motion abnormalities following dobutamine administration in coronary artery 
disease, tissue velocities were also seen to decline in the non-ischaemic segments, 
whereas regional strain remained unchanged, suggesting that tissue velocities (as a 
measure of cardiac function) are influenced by the ischaemic regions due to the 
tethering of myocardium, whereas strain is not.46 The principles types of myocardial 
strain described are longitudinal, radial, circumferential and rotational. Although these 
strain measures are assessed individually, the reality is that these strain vectors occur in 
a 3D integrative manner due to myocardial fibre orientation. 
1.2.5.1 SPECKLE TRACKING AND INDICES OF CONTRACTILITY 
The most recent approach to myocardial strain is echo-derived speckle tracking, Figure 
12. This is a post-processing computer algorithm of grey-scale images applied to a user-
defined region of interest that automatically defines regions into blocks of pixels 
tracking stable patterns of speckles. Subsequent frames are analysed locating these 
speckles. Spatial and temporal data from the location shift is used to calculate the 
velocity vectors and temporal alterations in these stable speckle patterns are identified 
as moving further apart or closer together thus creating regional strain vectors; these are 
not reliant on the Doppler angle of incidence like tissue Doppler imaging strain thus 
enhancing the robustness of analysis.46,47 
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Figure 12 3D speckle tracking echocardiography.  
Left: diagram of speckle tracking, information about strain is generated by changes in 
speckles from frame to frame. Right: an example of speckle tracking longitudinal strain 
using a four chamber apical view, adapted from 41. 
 
Significant insights from the addition of strain imaging has refined the ability of 
echocardiography to detect patterns of ischaemia and infarction, through its ability to 
differentiate passive motion from active contraction; strain has been shown to improve 
on restoration of flow during coronary angioplasty or acute infarction, which has been 
validated in animal models.48,49 There is also a role for strain imaging during 
dobutamine stress echo, improving the sensitivity and specificity when compared to 
visual assessment alone.50-52 Interestingly, a study examining rat hearts found further 
advantages to strain assessment, specifically they found longitudinal and 
circumferential strain to correlate with invasive markers of contractility derived from 
LV pressure-volume assessment; the potential for this type of application is vast: strain 
could provide accurate non-invasive information regarding contractility indices, far 
superior to our currently used methods.53 This has not yet validated been in humans, and 
isthe main focus of strain application in this thesis.  Assessment of myocardial function 
in the presence of preserved LV function can provide valuable information with respect 
to outcome, particularly in the patient with ischaemic heart disease. It is believed that in 
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subjects with preserved left ventricular function at rest, that 3D speckle tracking 
echocardiography is able to detect underlying coronary artery disease through detection 
of subclinical LV systolic dysfunction, thus enabling a more accurate assessment for 
both risk stratification and further ongoing treatment.  
 
Accurate assessment of contractile function is fundamental to our understanding of 
cardiovascular pathophysiology; however, to fully understand pump properties, it is 
important to assess the components of the system. The myocardium and coronary 
vasculature are in close proximity such that an interaction between the two occurs. This 















1.3 FUNCTIONAL ARRANGEMENT OF CORONARY CIRCULATION 
The coronary circulation is a complex system of branching vessels comprising the 
epicardial vessels, intramural vessels and veins,  
Figure 13.54,55 The myocardium and coronary vasculature are in close proximity such 
that a two-way interaction known as cross talk occurs. This predominates between the 
myocardium and the intra-myocardial vessels, which can be further separated into 
intramural vessels and the microcirculation. The microcirculation is composed of more 
than 1010 arterioles and capillaries. Intramural vessels ranging from 20-300 micrometers 
in diameter penetrate the myocardium from the subepicardium to the subendocardium.56 
Figure 13 The coronary circulation.  
A, a cast of the coronary circulation depicting the epicardial vessels branching and 
subdividing; B The left anterior descending artery and its intramural; branches 





The microcirculatory bed is the major site of resistance in the coronary circulation, 
impeding the blood flow during myocardial contraction. Pressure measurements in 
differently sized arteries and arterioles have indicated that under normal conditions, 45-
50% of total coronary vascular resistance resides in vessels larger than 100 µm.58,59 The 
number of resistance vessels in the subendocardium is higher than that in the 
subepicardium, the result being that during diastole, flow is approximately 10% greater. 
However, there is a preferential decrease in subendocardial flow during systole as a 
result of intramural compressive forces. Despite the differences in structure of the 
vascular bed to compensate for these compressive forces, the subendocardium is more 
vulnerable to ischaemia than the subepicardium due to perfusion heterogeneity; the 
greater impedance in flow on the subendocardial layers during contraction is only 
somewhat compensated for by the increased vascularity.60-62 Intramural systolic 
compressive forces render subendocardial flow entirely dependent on the relative 
duration of diastole, or the diastolic time fraction (DTF), which is the ratio between the 
time the heart is in diastole and the duration of a complete heart cycle.63 The DTF 
decreases with increasing heart rate, although the two are not uniquely related, and at a 
fixed perfusion pressure, subendocardial perfusion is dependent on DTF.64,65 It follows 
on that at lower perfusion pressures (in the presence of a coronary stenosis) at the 
ischaemic threshold, subendocardial perfusion decreases more than proportionally with 
DTF than perfusion pressure. Under normal conditions however, oxygen supply is well 




1.3.1 AUTOREGULATORY MECHANISMS 
The relationship between coronary pressure and blood flow is strongly determined by 
autoregulation. This is the capacity of an organ to regulate blood flow in the face of 
changing perfusion pressures. As coronary perfusion is essential to cardiac function, 
under normal conditions oxygen supply is matched very well to demand. As myocardial 
oxygen extraction is near maximal under resting conditions, coronary perfusion is the 
major determinant of oxygen supply.66 
  
Figure 14 Autoregulation of coronary blood flow.  
This maintains a stable plateau when perfusion pressure is within the normal range. The 
level of the plateau is related to the metabolic state of the heart. The dashed line 
indicates maximal pharmacological vasodilatation. The dotted line shows the maximal 
physiological dilatation, which is smaller than can be reached pharmacologically. The 
flow reserve is given by the ratio (B+A)/A, adapted from 67. 
 
This is regulated in a number of ways, broadly divided into extrinsic (humoral-nervous) 
and intrinsic regulation (autoregulation).68-70 Autoregulatory mechanisms are an 
integrated, coordinated interaction of 3 main control mechanisms that enable 
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modulation of the mechanistic properties of the vasculature, such that in the face of 
changing perfusion pressures the organ can create an autoregulatory "plateau", Figure 
14, whereby flow is relatively independent of perfusion pressure: 
• Myogenic control: this is the response of vascular smooth muscle to changes in 
intra-luminal pressure. In the presence of rising pressure, there is a resulting 
constriction of arterioles; in response to a drop in perfusion, dilatation occurs.67,71,72  
• Metabolic adaptation: cardiac muscle plays an important role in coronary 
autoregulation. The level of the plateau is dependent on cardiac muscle metabolism, 
such that as metabolism increases, e.g. during exercise, the plateau increases thus 
coronary flow increases, Figure 14. This metabolic adaptation enables increased 
supply in the face of increasing metabolic demand. 
• Endothelial based control: shear stress on the endothelium resulting from an 
increase in flow, triggers a response in the form of release of endothelial-derived 
factors including nitric oxide (and its derivatives), a known relaxant of underlying 
vascular smooth muscle, leading to vasodilatation.73,74 
Thus autoregulatory processes influence the mechanistic properties of the coronary 
vasculature, and it is these dimensional changes that regulate blood flow to the artery. 
However, in the presence of a coronary stenosis although blood flow can remain stable 
at baseline, the greater the pressure drop, the more marked the reduction in flow; this 





1.3.2 PRESSURE GRADIENT-VELOCITY RELATIONSHIP 
The principles of pressure loss across a coronary artery stenosis are based on theories of 
fluid dynamics in rigid tubes, Figure 15.75,76 The two main anatomical characteristics 
that influence the pressure drop are 1) the narrowing of the arterial lumen and 2) its 
abrupt expansion when returning to the normal artery size.  
Figure 15 Effect of a coronary artery stenosis on coronary blood flow. The two principle 
sources of pressure loss across a stenosis are 1) frictional losses at the entrance and 
throat of stenosis (related to flow, Q) and 2) exit losses which describe inertial loss due 
to flow separation which occurs following the sudden expansion at the exit of the 
stenosis (increase with square of the flow). Abbreviations: An normal vessel diameter, 
As stenosis diameter, ΔP -pressure drop across the stenosis, Q flow in the reference 
vessel, Ls length of stenosis. Adapted from 77 
 
Viscous friction losses occur when the flow of blood slides against itself and against the 
endothelium of the artery, this happens in normal and diseased arteries; however, it is 
more marked in a narrow lumen because vascular resistance to flow is inversely related 
to the fourth power of the lumen diameter, Equation 6, where R is resistance to flow and 





Equation 6  R = 1D! 
This pressure loss is also related to the length of the stenosis, the viscosity of the blood 
and coronary blood flow velocity. Exit losses due to rapid expansion of the artery are 
dependent on flow just before exit, which is inversely related to the square of the 
stenotic area when expressed in terms of volumetric flow rate.78 Pulsatility of coronary 
flow has little influence on such losses thus the instantaneous pressure is solely 
determined by the friction and exit losses. Thus the pressure drop (ΔP) across a stenosis 
can be described as the quadratic equation, Equation 7, where v is the volumetric flow, 
A is the constant of pressure loss due to friction and B is the constant of pressure loss 
due to exit losses.79 
Equation 7  !" =  !"+ !!! 
 
This quadratic pressure gradient-flow relationship can be plotted and has been validated 
in vivo. With increasing flow, adenosine-induced hyperaemia for example, the change 
in pressure increases in a non-linear upward fashion, since the pressure gradient is 
raised to the second power of flow. At low or normal flow rates, the pressure drop is 
influenced by pressure loss due to friction but at higher flow rates, this becomes 
influenced by exit losses as this is raised to the function of the second power of 
velocity.80 Figure 16 describes how for an increase in coronary blood flow velocity, the 
pressure gradient changes more markedly in coronary stenosis. 
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Figure 16 Pressure drop-velocity relationships.  
Obtained at different stages of treatment by a dual-sensor guide wire in patients; 
obtained before (pre) and after successive treatment of the stenosis; note that the 
relations are curvilinear and become less steep at subsequent stages of vessel treatment. 
(UPstent indicates upsized stent; arrows indicate maximum flow achievable if 
microvascular resistance had remained at pretreatment level). The main observation of 
the solid spots taken from a vessel with stenosis is that as the coronary flow velocity 
increases, there is a more marked drop in pressure across the stenosis that increases in a 
curve-linear manner. Adapted from 80 
 
At baseline, in the presence of a stenosis, flow can remain relatively stable, with 
compensatory vasodilatation of the resistance vessels preserving basal coronary blood 
flow; the vasodilatory capacity is however exhausted as stenosis resistance (SR) 
increases, such that on induction of hyperaemia, the maximal flow rates that can be 
achieved markedly decrease and the perfusion pressure decreases with square of the 
flow Figure 17.81,82 Thus either an increase in demand or increase in stenosis resistance 




Figure 17 Changes on blood flow with increasing degree of stenosis severity.  
Adapted from 83. 
 
Importantly, we can measure pressure and velocity distal to a stenosis at rest or during 
hyperaemia, enabling us to further understand the complex interaction of stenosis with 
coronary blood flow during resting and ischaemic states. Intra-coronary derived 
physiological parameters are used to measure functional stenosis severity. This is most 
commonly in the form of Fractional Flow reserve (FFR) derived from intra-coronary 
pressure measurements or coronary flow velocity reserve (CFVR) derived from intra-
coronary Doppler indices.  
1.4 INVASIVE MEASUREMENTS OF CORONARY BLOOD FLOW 
As coronary angiographic data are not sufficient to assess the functional significance of 
a coronary artery lesion particularly in intermediate lesions, increasingly intra-coronary 
physiological measurements are being used in clinical practice: coronary flow velocity 
reserve (CFVR) and fractional flow reserve (FFR). 
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1.4.1 CORONARY FLOW RESERVE 
CFR is based on the concept that under normal conditions, coronary flow increases with 
increased myocardial oxygen demand, as is the case with exercise or pharmacological 
stimuli.78,79,84 CFR is the ratio of maximal flow to flow at rest at the same perfusion 
pressure.79 In the absence of coronary stenosis, in epicardial artery subtending normal 
myocardium, coronary blood flow can increase by more than 3 fold. However, in the 
presence of a flow limiting stenosis, at rest, compensatory vasodilatation of the 
resistance beds occurs to account for the pressure drop and maintain coronary flow in 
the face of a drop in perfusion pressure distally. Therefore the capacity of the 
microcirculation to vasodilate further decreases, thus a stenosis results in a reduction in 
CFR, of epicardial coronary disease. 
Figure 18.85 Coronary flow velocity reserve (CFVR) is a surrogate for CFR; this uses 
Doppler-derived velocity measurements. In adults with completely normal epicardial 
arteries and normal myocardium a CFVR in the range of 3.5-5.0 would be expected.86,87 
However, in patients with unobstructed epicardial coronary arteries but with risk factors 
for ischaemic heart disease, the normal range is closer to 2.7 (likely due to 
microcirculatory disease) with the cut off for ischaemia at <2.0.85 CFVR however, is the 
summed response of both epicardial and microvascular flow to hyperaemia, and can 
vary with physiological changes in basal and hyperaemic flow (heart rate, contractility, 
age, gender).88 This variability leads clinicians to use this less in the assessment of 
stenosis severity and more in the determination of microvascular disease in the absence 
of epicardial coronary disease. 
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Figure 18 Stenosis severity (A) Effect of a stenosis on CFR: Solid lines represent the 
coronary pressure-flow relationship at baseline and maximal vasodilation (maximally 
dilated) without a stenosis. Changes in baseline and hyperemic flow affect coronary 
vasodilatory reserve (vertical arrows). CFR is represented by the ratio of flow at 
maximal dilation (QMax) to flow at baseline (Qcontrol). A stenosis progressively decreases 
the maximal flow (dashed lines) because the resistance of the stenosis is added to the 
resistance of the microcirculation. Flow reserve with a stenosis (the ratio of QMax, stenosis, 
to Qcontrol) is therefore markedly diminished. 83 
1.4.2 FRACTIONAL FLOW RESERVE 
Under normal circumstances, in the absence of appreciable coronary or microcirculatory 
disease, the perfusion pressure transmitted to the myocardial bed in the distal coronary 
vasculature is equal to the aortic pressure minus left ventricular end-diastolic pressure 
(or central venous pressure). As a concept initially born in 1977, Gould and colleagues 
devised an intra-coronary physiological measurement based on the theory that a 
pressure drop across a stenosis (pressure gradient) would be proportional to a drop in 
coronary flow. It follows that in the context of hyperaemia, or maximal coronary flow, 
the ratio of distal perfusion pressure to the aortic pressure would give a ratio or a 
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fraction of normal flow: Fractional Flow Reserve (FFR).89 Pijls et al demonstrated that 
FFR can give functional indication of stenosis severity, measuring the ischaemic 
potential of a stenotic lesion.90 This model assumes that at hyperaemia, resistance is 
minimal in the myocardium and is uniform across the myocardial beds, such that blood 
flow is directly proportional to perfusion pressure. The FFR calculation is simplified to 
hyperaemic Pd/Pa because venous pressure is commonly considered negligible in 
comparison to Pa, Figure 19. A normal FFR value is 1.0; this makes interpretation of 
FFR easier for the clinician and makes FFR a favourable physiological index over other 
indices. Interestingly, although there may have been an initial indication in animal 
studies, human studies have shown no variability in "normal" FFR with age, heart rate, 
blood pressure or contractility.91 Furthermore FFR has been validated in large 
experimental and clinical studies as a functional indicator of stenosis severity and 
predictor of ischaemic capability of coronary lesions. 91,92  
Figure 19 Fractional Flow Reserve. 
(A) The calculation simplified (B) Model of the coronary circulation: top and bottom 
circuits represent equivalent myocardial mass, without a stenosis in the bottom, RminN 
= RminS, Qc (collateral flow)=0, Qs=QN where Q is volumetric flow and Pd = Pa. Qs 
indicates hyperaemic flow with stenosis, QN =hyperaemic flow without stenosis, 




FFR has a few limitations based on the assumptions made: 1) it presumes pressure is 
directly proportional to flow, however we see above that this is a non-linear relationship 
particular marked at higher velocities; also neglecting the effect of cardiac contraction 
on hyperaemic blood flow and 2) it assumes homogeneity of microvascular resistance, 
and that microvascular resistance is minimal. Interestingly FFR and CFVR contradict in 
approximately 30% of cases, in instances of high microvascular resistance, CFVR 
reduces and FFR increases (as flow is reduced but distal pressure is high, and vice 
versa. 93,94 
 
As there are limitations to derived indices of coronary flow or coronary pressure in 
isolation,77 there is benefit to measuring both, not only to determine true flow and 
pressure drop across a stenosis but also to identify the driving factors of coronary blood 
flow. Real-time measurements of coronary blood flow velocity and pressure can be 
performed using a dual sensor tipped wire; not only does this enable us to accurately 
assess coronary haemodynamics but also increases our understanding of pressure-flow 
wave propagation, which is responsible for these measured profiles. This wave intensity 
analysis has the potential to increase our knowledge of the complex interactions 







1.5 CORONARY WAVE INTENSITY ANALYSIS 
The basis of modern arterial haemodynamics is that the heart acts as a pump generating 
pulsatile pressure and flow waves through a series of elastic tubes (arterial system). 
These waves can be broken down into smaller waves (or wavelets) from which the 
summation makes a larger wave. One method of interpreting these waveforms is by 
analysing them in the time domain as successive wave fronts. This enables coronary 
wave intensity analysis (cWIA) to be performed; this can be used to describe the 
coronary pressure and flow waves at a certain time point (or sampling period).  
 
Wave intensity analysis was developed just over two decades ago as a new approach to 
analysing waves.95 It is understood that within the coronary circulation, wave intensity 
analysis (cWIA) generates forward and backward travelling waves. The following 
description refers to previously published descriptions of cWIA.96,97 The forward waves 
are believed to arise upstream, although as a result of left ventricular ejection and 
relaxation, these waves are believed to be transmitted from the aorta to the coronary 
artery, thus are forward travelling. Backward travelling waves identified within the 
coronary artery are thought to originate directly from the myocardium, and are 
generated from the transmission of downstream events in a retrograde manner through 
the coronary artery. Waves that cause a pressure increase are referred to as compression 
waves; waves causing a decrease in pressure are referred to as suction or expansion 
waves. The effect on coronary blood velocity can then be determined by both the origin 
(forward or backward) and the change in pressure (compression or expansion); for 
example an increase in coronary blood velocity can be generated either by a forward 
travelling compression wave (increase in pressure) or a backward travelling expansion 
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wave, a decrease in coronary blood velocity can be caused by a forward expansion wave 
or a backward travelling compression wave, . 
Figure 20 Coronary wave intensity analysis. 
A description of flow propagating waves, the forward travelling compression wave 
(arising proximally during systole), and the backward travelling expansion wave 
(arising distally during diastole), adapted from 98. 
 
Therefore in the coronary circulation, wave intensity (cWIA) can differentiate between 
forward waves arriving via the aorta and backward waves originating in the 
microcirculation.96 Hence, wave intensity is a powerful tool to investigate cardiac-
coronary interaction and it is increasingly being used to interpret clinical data. The 
relevance of wave intensity analysis when investigating coronary blood flow is that it 






1.5.1 APPLICATION OF CWIA 
The theoretical explanation for the timings of each of these waves has been previously 
described.96,99 cWIA enables us to separate the events in the cardiac cycle into forward 
and backward waves, the theoretical background to the waves is as follows: during 
systole, 1) an early systolic backward compression wave (BCW) is generated by 
isovolumic contraction, as a result of the increase in intra-myocardial wall tension 
compressing the intramural vessels, this drives an increase in pressure but a decrease 
coronary blood velocity; 2) following isovolumic contraction, aortic valve opening and 
LV ejection results in a forward compression wave (FCW), this increases pressure and 
increases coronary blood flow velocity (the myocardium has reached its maximum 
contractile state, thus further compression of the coronary vessels is prevented); 3) at 
the onset of diastole, the decay in aortic pressure leads to a suction effect arising 
proximally thus generating a (3) forward expansion wave (FEW) which reduces 
coronary pressure and reduces blood velocity; ventricular relaxation during diastole also 
has a direct effect on the myocardium, as tension is released a 4) backward  expansion 
wave (BEW) is generated that is a result of a decrease in distal pressure, this drives an 
increase in coronary blood velocity. Aortic valve closure at end-ejection generates a 
small (4) late forward compression wave, Figure 21. The reality is the events are not 
completely separated in time and there is overlap; moreover, there is continued interest 
in the clinical utility of these tracings. Corresponding intra-ventricular changes with 
changes in coronary pressure and flow have not been measured in humans, but to date 
this is the best descriptive predictor of how cardiac contraction influences coronary 
pressure and flow waveforms. The cardiac-coronary interaction remains complex, and 
INTRODUCTION 
41		
there is still much to be understood of the mechanical events in the cardiac cycle driving 
coronary flow.96,100,101  
 
Figure 21 Wave separation. 
Coronary pressure and coronary flow plotted against time with the average pressure and 
flow (black) and the separated forward (blue) and backward (red) components (top). 
The physiological events in the cardiac cycle driving individual waves driving changes 
in pressure and flow (bottom). 
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1.5.1.1 WAVE SPEED 
The speed of wave travel (pulse wave velocity, c) is a fundamental parameter for 
separating net wave intensity into the forward and backward components, and is 
dependent on the density and stiffness of blood and the cross-sectional area of the 
artery.102 This can be simplified using the Moens-Korteweg equation (Equation 8), 
which relates pulse wave velocity to the stiffness of the arterial wall. 
Equation 8  ! = !.!"#$!.!  
In other words, pulse wave velocity (c) is proportional to the square root of the 
incremental elastic modulus (Einc) of the vessel wall given constant ratio of wall 
thickness to vessel radius (D), under the assumption that wall thickness (h) and vessel 
radius do not significantly change. Separation into forward and backward travelling 
components requires knowledge of pulse wave velocity at the point of measurement, 
which ideally should be calculated by assessing the transit time between pressure 
waveforms that are set a known distance apart.103 This is known as the foot-to-foot 
method but cannot be accurately performed in the coronary arteries. Thus another 
method has been developed known as the single point technique (SPc), which uses a 
single point estimate of the local coronary wave speed, obtained using the sum of 
squares method96: 




Local wave speed was shown to correlate well with the foot-to-foot technique in the 
systemic circulation. Furthermore, Rolandi et al demonstrated that at baseline, single 
point calculated wave speed was equal to direct measurement of coronary wave speed in 
normal coronary arteries.104 This has been validated against measured waves speeds in 
the human coronary artery, and although the accuracy in diseased vessels is not known, 
it is within limits for calculating wave separation in cWIA. 
1.5.1.2 MEASUREMENT OF CWIA 
Net wave intensity (dI) can be defined at any point as the energy flux per unit area 
(J/m2) and is the product of change in pressure and change in velocity: 
Equation 10  !" = !".!" 
The net wave intensity affected by the sampling time, it is normalised to time: 
Equation 11  
!" =  !"!" .!"!"  
Mathematical equations have been used to separate net wave intensity into it's forward 
and backward component. A positive value for wave intensity suggests the changes in 
pressure and velocity caused by the forward wave is greater than those caused by the 
backward wave and a negative value suggests the opposite,97 when the forward (+) and 
backward (-) components are separated.99   
 
 
Equation 12 !"± =  ± !!"# !"!" ± !"!"!" ! 
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1.5.1.3 MYOCARDIAL-CORONARY INTERACTION 
Although the major determinant of coronary blood flow is the aortic pressure gradient, 
it is clear that coronary pressure and flow are not merely a function of aortic pressure. 
The myocardium and coronary vasculature are within close proximity of each other and 
a two-way interaction known as cross-talk exists. Coronary blood flow velocity is 
determined by both upstream and downstream events. The coronary circulation is 
unique in that its driving force and impedance to flow are dynamic functions of 
myocardial contraction, thus cardiac muscle affects the coronary vasculature.105,106 
Contraction of the left ventricle not only increases coronary perfusion pressure but also 
immediately prior to this at end-diastole increases compression of the microcirculation. 
Conversely, relaxation of the left ventricle decreases perfusion pressure but also reduces 
compression of the microcirculation. As cardiac contraction impedes coronary flow in 
systole, coronary flow predominates in diastole thus coronary flow is dependent on the 
length of diastole relative to the cardiac cycle. This unique property of the coronary 
circulation is due to its functional arrangement in the myocardium. A number of studies 
have elucidated, at least in part, this complex interplay; the ground-breaking work by 
Davies et al applied wave intensity analysis to enhance our understanding of the 
cardiac-coronary interaction. Lockie et al examined the underlying mechanism behind 
warm up angina, they hypothesised that a reduction in microvascular resistance lead to 
an increase in the BEW seen in second relative to first exercise.101 However Rolandi et 
al suggest that coronary waves represent left ventricular mechanical change, contrary to 
initial understanding: a marked drop in dP/dT and was associated with a similar 
reduction in the wave energies.100 This followed on from work by Sun et al, who 
examined the effects of contractility (Emax) and coronary resistance on systolic flow 
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impediment, they found at the greatest contractility and least resistance that coronary 
systolic flow was markedly impaired, and the backward compression wave was at its 
greatest at this point. They concluded that coronary systolic flow impediment driven by 




















1.6 COORDINATED CARDIOVASCULAR RESPONSE TO EXERCISE 
Thus far cardiac contraction and coronary blood flow have been described in isolation; 
however it is the combination of these mechanisms and the heart’s interaction with the 
rest of the cardiovascular system that is of particular clinical importance in both normal 
and diseased states. There follows a description below of the cardiovascular response to 
exercise. 
  
From an evolutionary and survival-of-the-fittest point of view, the ability of the body to 
adapt to exercise by markedly increasing delivery of oxygen and nutrients to the 
peripheries is one of the most important circulatory adjustments the body has to 
make.108-114 The cardiovascular responses to exercise necessitated by the increased 
metabolic requirements of skeletal muscle are driven by the autonomic nervous 
system.115-118 A reduction in cardiac parasympathetic activity and an increase in 
sympathetic activity to the cardiac, renal and splanchnic regions together increase heart 
rate, stroke volume and therefore cardiac output and facilitate the redistribution of blood 
flow to the active skeletal muscles, Figure 22. 
1.6.1 PERIPHERAL VASCULAR RESPONSES 
From resting state to maximal exercise, blood flow to the skeletal muscle groups can 
increase by up to forty times. Blood flow increases linearly with increasing metabolic 
rate in exercising skeletal muscle, myocardium and exocrine glands.109,114 This is known 
as metabolic hyperemia and is caused by an increase in vasodilatation through the direct 
action of vasodilator substances adenosine and its derivatives, and potassium and 
hydrogen ions on vascular smooth muscle cells to stimulate endothelium derived 
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relaxing factor (EDRF) production. Dilatation of the main artery is then accompanied 
by dilatation of resistance vessels due to flow induced EDRF production.73  
Figure 22 Blood flow and exercise. 
The redistribution of blood flow from rest (left) and during maximal exercise (right), 
adapted from 119. 
 
Due to the marked oscillation of blood flow during muscle contraction-relaxation, the 
majority of this hyperaemia occurs during resting phases. Hyperaemia continues for two 
to three minutes after exercise to repay the oxygen debt in both skeletal and cardiac 
muscle. Dynamic exercise differs from static exercise in that mean pressure rises very 
little, by 20mmHg or less, systolic pressure and pulse pressure do increase to a greater 
extent but there is little increase in diastolic pressure. Muscle vasodilatation causes a 
drop in systemic vascular resistance (SVR), creating a vital permissive effect in light of 
the increased cardiac output. A drop in SVR is compensated for by vasoconstriction of 
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the splanchnic circulation, this vasoconstrictor response supports the arterial pressure. 
Therefore, maintenance of central venous pressure is possible through the action of 
sympathetic vasomotor nerves driving splanchnic vasoconstriction and skeletal muscle 
pump compression, which result in central venous pooling.109,110 
1.6.2 CARDIAC RESPONSES 
 
Figure 23 Myocardial oxygen consumption (VO2) at the onset of exercise.  
An early increase in heart rate and cardiac output drives an increase in VO2 
(animation). 
 
Even in an untrained adult, the maximum cardiac output can reach approximately 20 
litres per minute, a roughly four-fold increase from rest. For every additional litre of 
oxygen consumed, cardiac output increases by approximately 6 litres per minute. Thus 
dynamic exercise is associated with an increase in myocardial oxygen consumption. 
This is particularly the case during the first minute of sustained exercise, where there is 
a very rapid increase in heart rate and cardiac output and a more gradual increase in 
mean blood pressure.111,120 During this first minute of exercise, the oxygen consumption 
                                 
   
   
   
   
   
   
   
   
   
   
















of the heart increases rapidly to match the intensity of exercise, plateauing when supply 
meets demand. If exercise intensity increases, a point is reached whereby myocardial 
oxygen consumption plateaus, i.e. the maximum oxygen consumption achievable by the 
heart, Figure 23. Thus, despite an increase in workload there is no further increase in 
consumption. The increase in myocardial oxygen consumption in the face of increasing 
whole-body demand, can be summarised using the Fick equation (Equation 13) where !"2 = oxygen consumption, !"  = cardiac output and !"#2 and !"#2 are arterial and 
mixed venous oxygen saturations respectively.110  
Equation 13 !"# = !"(!"#$− !"#$) 
 
Heart rate (HR) has a direct, almost linear relationship with oxygen consumption; 
during intense exercise, HR can reach a maximum of 180-200 beats per minute. This 
tachycardic response is due to both sympathetic stimulation and removal of vagal 
inhibition.109,114  
1.6.2.1 CORONARY BLOOD FLOW 
There is distinct lag of three to four seconds before coronary vasodilatation occurs in 
exercise, there then follows a sharp rise in coronary blood flow. Increased heart rate has 
been shown to increase coronary blood flow as has flow-mediated dilatation, which 
relies on an intact endothelium. The endothelium acts as a mechano-transducer that 
senses changes in shear stress (resultant increased flow and widening of the central 
pulse pressure) and subsequently modifies the output of dilating factors including 
prostaglandins, adenosine triphosphate and nitric oxide. Flow mediated dilatation dilates 
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vascular smooth muscle and maintains a constant concentration of nitric oxide on the 
luminal surface of vascular endothelium.121-123 
1.6.2.2 STROKE VOLUME AND CARDIAC OUTPUT 
Cardiac output has a similar relationship to oxygen consumption and is the product of 
heart rate and stroke volume, Equation 1. Posture during exercise influences the 
overarching driving factor to the increase in cardiac output. In a supine position, the 
increase in cardiac output is almost entirely driven by heart rate, with stroke volume 
only increasing by 10-20%. In the upright position however, stroke volume can increase 
by 50 to 100%. The increase in end-diastolic volume is driven by central venous 
pooling as described above, the increased filling pressure and increase in myocardial 
contractility as a result of increased sympathetic drive together drive a reduction in end-
systolic volume.124 External cardiac work or stroke work (SW) increases the volume, 
pressure and velocity of blood in the circulation, the work involved in displacing this 
pressurised volume of blood is the product of SV and mean pressure rise, which is the 
area of the ventricular pressure-volume loop. Mechanical efficiency is equal to the 
stroke work relative to total energy expended. In resting states this is only around 5-
10%; this includes energy expended during isovolumic contraction, generation of this 
tension requires energy but generates no external work. Importantly during dynamic 
exercise in healthy subjects, SV increases more than arterial pressure, and efficiency 
increases to 15%.32 This can be understood better in terms of ventricle-arterial coupling, 
which is described in section1.6.2.3. 
 
The importance of the coordinated cardiovascular response is reflected in studies 
whereby only one stimulus is changed. If the heart rate is increased in isolation in a 
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paced heart, the cardiac output does not change because stroke volume falls: an increase 
in heart rate transfers the whole-body blood volume to the systemic circulation, thus 
increasing afterload and offloading the right heart resulting in reduced filling pressure 
(or end-diastolic pressure). An increase in artificial pacing favours the shortening of 
diastole, thus reducing filling time. The result is a marked decrease in cardiac output at 
high pacing rates, rather than simulation of the physiological adaptation to 
exercise.121,125,126   
1.6.2.3 VENTRICULO-ARTERIAL COUPLING 
Due to the complex interplay between the heart and the peripheral vascular system 
during exercise, exercise provides a powerful tool to examine the response of the 
cardiovascular system to stress. Few studies have examined this interaction closely. 
Arterial elastance (Ea) is the global characterisation of arterial load. (4) End-systolic 
elasatance (Ees, the slope of ESPVR) is the gold standard index of left ventricular 
contractility; thus the Ea:Ees ratio is the measure of the interaction between the left 
ventricle and the arterial system; importantly they are measured in the same units thus 
derivation of this ratio gives a non-dimensionless measurement of net cardiac 
performance, expressed as a fraction (optimal 0.7-1.2).37,38 During exercise, arterial 
stiffness has a greater impact on Ea than on systemic vascular resistance. Thus with 
exercise, Ea increases but SVR falls. The importance of the Ea:Ees ratio, is that 
appropriate matching results in optimal stroke work and efficiency. During exercise this 
ratio drops, both Ea and Ees increase, however Ees increases to a greater extent in 
healthy subjects thus reducing this ratio by up to 65% in some cases.32,127,128 
Ventricular-arterial coupling has not been examined in patients with ischaemic heart 
disease with effort angina; however in systolic heart failure, patients have a high resting 
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Ea:Ees ratio due to high Ea (increased arterial stiffness) and low Ees (poor 
contractility).129 Therefore it is predicted than on induction of ischaemia during exercise 
in coronary artery disease, that the Ea:Ees ratio will increase in patients suggesting a 




1.7 PATHOLOGICAL CARDIOVASCULAR RESPONSES 
In this section, there follows a description of ischaemic heart disease, its prevalence and 
the pathophysiological response to exercise and the manifestation of end-stage disease 
resulting in ischaemia cardiomyopathy. 
1.7.1 IMPACT OF ISCHAEMIC HEART DISEASE 
Figure 24 Death from cardiovascular disease in Europe. 
Adapted from 130 
 
Cardiovascular disease (CVD) is a huge public health burden. CVD was a direct cause 
of more than 4 million deaths in Europe in the year 2000 increasing to more than 4.3 
million in 2005, Figure 24.130 Furthermore, CVD is responsible for just under 2 million 
premature deaths a year in Europe in the under-75 age group. The cost of CVD to the 
European Union in 2006 exceeded 190 billion Euros, more than 110 billion of this was 
on healthcare costs, and of this, more than half was spent on inpatient hospital care. The 
majority of deaths from CVD are preventable, an increased understanding of which may 
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aid the development of therapeutic interventions.131,132 Of all CVD, ischaemic heart 
disease is the most prevalent, the clinical manifestation of which, is angina pectoris. 
1.7.2 MECHANISM OF ANGINA 
Angina pectoris, classically described as a retrosternal crushing or burning, is the 
clinical manifestation of myocardial ischaemia; it occurs late in the ischaemic cascade 
and is a result of myocardial oxygen supply-demand mismatch, Figure 25.133,134  
Figure 25 The ischaemic cascade. 
Angina pectoris presents late following a cascade of haemodynamic events, adapted 
from. 
 
Supply-demand mismatch can occur at rest as a result of atheroma expansion, 
endothelial erosion and plaque rupture with platelet aggregation. Supply-demand 
mismatch during stress (exercise) will manifest when severe obstructive lesions prevent 
the necessary increase in coronary blood flow during exercise, thus 1) myocardial 
oxygen supply is reduced and 2) myocardial oxygen demand is increased (the 
physiological response to exercise) from an increase in heart rate (HR), blood pressure 
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(BP) and contractility, Figure 26.121,135 A critical duration and severity of ischaemia is 
required for a subject to experience pain, although it is important to note that the cause 
of ischaemia does not influence the features of angina. For example, the character of 
pain may be similar in a patient with chronic stable angina episodes who experiences 
unstable angina or myocardial infarction.136 
Figure 26 Pathophysiological mechanisms of myocardial ischaemia. 
These result in adverse outcomes in stable angina, adapted from 133. 
 
At the turn of the century it was proposed that ischaemic pain was as a result of 
distension of the left ventricle: the mechanical hypothesis.137 However, just over three 
decades later, it was suggested that ischaemic pain was elicited by the release of 
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substances during ischaemia that cause pain: the chemical hypothesis.138,139 In the 
1990s, studies carried out further supported the chemical hypothesis, consistently 
demonstrating adenosine to be the mediator of cardiac pain: adenosine-induced pain is 
through stimulation of A1 receptors and is potentiated by substance P.140 This nervous 
activity is fed back to the cortex via the cardiac, mediastinal and thoracic ganglia where 
it is modulated and interpreted as a painful sensation.141,142 The negligible contribution 
of left ventricular (LV) dilatation to ischaemic sensation of pain has been shown on 
ergonovine-induced ischaemic episodes, whereby the rate and degree of mechanical 
dilatation was similar in painless and painful sensations.143 This is further substantiated 
by the recognition that episodes of acute left ventricular failure resulting in LV 
dilatation are painless. Although peri-arterial mechanoreceptor stimulation on stretching 
the epicardial coronary arteries during angioplasty has been shown to contribute the 
pain of myocardial ischaemia, its role in angina episodes has not been completely 
examined.142,144 
1.7.3 SUPPLY-DEMAND MISMATCH 
Figure 27 The cycle of myocardial ischaemia, adapted from 133. 
The initial trigger of myocardial ischaemia can be either increased myocardial oxygen 
demand or a reduction in coronary blood flow. What follows is a vicious cycle or 
cascade of events amounting to what we know to be an ischaemic episode; this results 
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in a further increase in myocardial oxygen demand and decrease in blood flow, Figure 
27. Increase myocardial oxygen demand leads to an increased heart rate, left ventricular 
dilatation and increased left ventricular end-diastolic pressure and catecholamine 
release, which in the setting of coronary disease can lead to myocardial ischaemia.145,146 
Catecholamine release drives a further increase in heart rate, systolic and diastolic blood 
pressure, which further increases myocardial oxygen demand. Increased heart rate 
reduces the diastolic time fraction, the fraction of the cardiac cycle that the heart is in 
diastole where coronary flow predominates; this coupled with increased end-diastolic 
pressure results in a reduction of coronary blood flow.133 This complex interplay of the 
myocardium and coronary blood flow is intuitive as the coronary circulation and the 














1.7.4 REGIONAL ISCHAEMIA AND PRESSURE-VOLUME LOOPS 
In an animal model, the effects of regional ischaemia on contractility in the isolated 
canine heart have demonstrated a parallel rightward shift in the ESPVR without 
significant change of the slope Ees. This resultant shift changes the V0 intercept on the 
X-axis, with the degree of rightward shift related to the degree of ischaemia as studied 
by microspheres. Curvi-linearity of the Ees slope was also observed in regional 
ischaemia. This is in contrast to global ischaemia in which a change in the Ees slope 
occurs without an observed change in the V0 intercept.147,148 Following this animal 
work, Kass et al. performed balloon occlusion during coronary angioplasty in humans 
with pressure volume analysis of the left ventricle. They found a combination of the 
findings above: a rightward shift of the ESPVR line (representing the LV working at 
higher volumes) and a downward shift in the slope of the line. As contractility is 
measured by the gradient of the slope, a rightward shift alone would not suggest a 
change in contractility. However, a downward shift would be consistent with this. 
Associated with this, an increase in end-diastolic and end-systolic volumes (ESV) were 
seen, measured by left ventriculography, with a marked decrease in dP/dt.149 Although 
only performed in 10 patients, these changes were seen consistently and the greater the 
starting ESPVR, the greater the decrease observed in Ees slope. Diastolic changes were 
manifest initially as higher filling pressures then followed impairment of diastolic 
function as shown by an upward shift of the EDPVR slope.149 A similar study by 
Remmelink et al, 20 years on, showing balloon occlusion during angioplasty found 
similar changes: a decrease in diastolic function as demonstrated by prolonged time 
constant of relaxation (Tau, i.e. the time required for dP/dtmin to reduce by half), an 
increase in end-diastolic pressures (EDP) and end-diastolic volumes (EDV). Reduced 
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systolic function was demonstrated by a rightward shift in the ESPVR slope, decreased 
dP/dT, decreased ejection fraction, and increased ESV. 150 A study by the same group 
examining reperfusion post acute myocardial infarction in humans demonstrated the 
greatest effect of reperfusion was on diastolic indices. A reduction in EDP/EDPVR and 
end-diastolic wall strain was shown and thus an improvement in the passive diastolic 
properties on reperfusion, but no change in active diastolic properties (filling/tau).151 
 
With regard to demand ischaemia, Dawson et al performed pacing-induced ischaemia in 
humans using ventriculography and an LV micromanometer to construct PV loops. 
They demonstrated a prolongation of Tau (relaxation time constant), increase in EDP 
and an upward shift of the EDPVR curve.152 Pacing-induced ischaemia and balloon 
coronary occlusion appear to have opposing effects in the ischaemic myocardium of 
dogs. Early studies comparing the two demonstrated an upward shift in the pressure-
segment length relation with pacing compared to an outward bulge and rightward shift 
with balloon coronary occlusion. Suggesting that decreased diastolic distensibility with 
a minor reduction in systolic shortening characterised ischaemic myocardium during 
pacing, whereas increased distensibility and replacement of systolic shortening with 
passive outward bulging was the hallmark of ischaemia secondary to occlusion.125,153 
Further studies comparing the two changes in man showed there was an upward shift 
both in the end-diastolic pressure volume curve and pressure-length relations in both 
cases, with a greater upward shift (reduction in diastolic distensibility noted) on pacing 
induced ischaemia.154 Persistent systolic shortening (i.e. preserved systolic function) of 
ischaemic myocardium was demonstrated to be a prerequisite for a decrease in diastolic 
distensibility of the ischaemic segment. With a correlation between the degree of 
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diastolic dysfunction and the persistence of systolic shortening.154,155 Consistent with 
these latter findings, a retrospective analysis examining the changes incurred by pacing-
induced ischaemia compared to balloon coronary occlusion in fact found that the mode 
of ischaemia was less relevant than the effect on contractility; the more contractility is 
affected, the farther rightward and downward the EDPVR shifts. 155 
 
In a canine model of control versus induced coronary stenosis, Steendijk et al assessed 
the effects of a critical stenosis on global systolic function, demonstrating that regional 
ischaemia induces global LV changes. At baseline, the canines with induced stenoses 
already experienced a substantial increase in resting end-systolic volume.156 With low-
dose dobutamine, systolic function improved in this group; however, this declined on 
higher doses (with a rightward shift of the ESPVR), suggesting a biphasic response, 
whereas the control group showed a continued improvement in systolic function as 
expected with increased ESPVR slope thus increased global systolic function and 
contractility.156  
 
There is continued debate with regard to the effects of a critical stenosis on systolic 
function. A combination of factors could produce the observed effects. This includes the 
duration and extent of ischaemia, the technique used to provoke ischaemia, and the 
affect on contractility. The majority of anginal episodes are triggered by exercise, thus 
the aim of the investigation into demand ischaemia was to examine the changes incurred 
with exercise-induced angina to delineate the changes. Furthermore, an understanding 
of the changes incurred by ischaemia, would enable us to examine and better understand 
the anti-anginal effects of nitrates.  
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1.7.5 NITRATES IN ISCHAEMIC HEART DISEASE 
Organic nitrates are the most commonly used anti-anginals worldwide. They are 
available in multiple formulations including glyceryl-trintrate, isosorbide mononitrate 
and isosorbide dinitrate. First noted in 1879, the administration of long acting nitrates 
relieved angina and was found to prevent subsequent anginal episodes.134,157 Nitrates are 
now frequently used worldwide as a treatment for angina including chronic stable 
angina, unstable angina and even in heart failure.135,157 Their safety profile makes them 
an attractive choice for initial anti-anginal therapy. The main limitation of nitrates is the 
development of tolerance, although detailed work has been performed in this area, this 
is not within the scope of this investigation. 
1.7.5.1 PHARMACOLOGY AND MECHANISMS OF ACTION 
 
Figure 28 Metabolism of isosorbide dinitrate. 
The major metabolites are isosorbide-2-mononitrate and isosorbide-5-mononitrate, 
adapted from 157. 
 
Isosorbide dinitrate (ISDN) when given orally experiences first past metabolism 
through the liver, Figure 28. Although initially thought to render it inactive, later studies 
have shown that despite this, its haemodynamic and anti-anginal effects remain marked. 
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ISDN is rapidly metabolised with a half-life of 20 to 40 minutes.158-160 Orally 
administered nitrates are pro-drugs, which need to be metabolised to have therapeutic 
effects. This biological transformation includes denitration of the nitrate with liberation 
of nitric oxide, this stimulates the enzyme gunaylyl cyclase to convert guanosine 
triphosphate to cyclic guanosine monophosphate, which in turn is responsible for 
vasodilatation.157,158,160 Interestingly, nitric oxide also known as endothelial derived 
relaxing factor, exerts vasodilatory effects, but in addition to this reduces platelet 
adhesion and aggregation; controls endothelial function and is also thought to have a 
positive effect on myocardial contractility. In the presence of endothelial dysfunction, 
nitric oxide production is reduced, thus administration of exogenous nitrates, may 
replete these and thus have a beneficial effect.74,161   
 
It is believed that the haemodynamic actions of nitrates work through the dilatation of 
the capacitance vessels and conductive arteries, thus reducing ventricular volume and 
preload, thus lowering myocardial oxygen requirements and improving sub-endocardial 
flow.162,163 Dilatation of the systemic arteries, in combination with reduction in preload 
then acts to reduce afterload and is thought to reduce myocardial oxygen consumption 
through a decrease in systolic wall tension; the reduction in diastolic filling may 
improve the transmural distribution of blood flow by reducing extrinsic diastolic 
compression of the sub-endocardial vessels.164-166 It is hypothesised that the anti-anginal 
action of nitrates is through dilatation of epicardial coronary vessels leading to stenosis 
dilatation and increased collateral supply. Thus increasing blood flow to areas of 
coronary ischaemia, particularly sub-endocardial flow. It is most likely however that the 




Early invasive studies of pressure-volume (PV) relations repeatedly demonstrated a 
leftward, downward shift of the PV loop with nitrates. These studies supported a 
predominant preload and afterload reduction on the ventricle rather than a change in 
myocardial diastolic compliance. Later studies found conflicting results with a change 
in the time constant of LV pressure decay (tau) suggestive of direct diastolic effect, 
which does not seem to be a feature of other anti-anginals.166,172 One study suggested 
that the dominant effect of nitrates varies according to patients' baseline characteristics: 
afterload reduction predominated in those with marked hypertension compared to a 
preload reduction in those with normal ventriculo-vascular coupling.164 Thus the 
complexities of this drug are much debated; with novel technology and software, 
however, delineation of this complex anti-anginal mechanism is certainly achievable 












1.7.6 ISCHAEMIC CARDIOMYOPATHY AND LEFT VENTRICLE 
PARTITIONING 
1.7.6.1 EPIDEMIOLOGY AND PATHOPHYSIOLOGY 
Coronary artery disease is the commonest cause of heart failure worldwide. Chronic 
heart failure remains a huge unsolved problem and is one of the most prevalent causes 
of death. Up to half of patients develop severe left ventricular (LV) impairment 
following acute myocardial infarction (MI). Left ventricular dilatation and remodelling 
following acute myocardial infarction (AMI) is most commonly associated with anterior 
AMI and has been well documented in both experimental and clinical investigations, 
Figure 29.173-175 One third of patients enrolled in the GISSI-3 trial (n=13,679) 
demonstrated evidence of this progressive LV dilatation and remodelling following 
AMI.176 Treatment advances have led to increased survival from AMI. However, this 
may have led to a larger population at risk of congestive heart failure (CHF). 177 Despite 
huge advances in pharmacological and device therapies, the onset of CHF is associated 
with a 32% 1-year mortality.178 LV remodelling following AMI leads to scar formation, 
distorted geometry, increased wall stress and eventual dilatation. Thus LV volume 
assessment in CHF can be used as an independent predictor of clinical outcomes.178 An 
important measure of therapeutic efficacy is the demonstrable improvement in LV 




Figure 29 Ischaemic cardiomyopathy.  
A diagrammatic representation of the multi-factorial components of ventricular 
remodelling; abbreviations: ECM extra-cellular matrix, RAAS renin-angiotensin-
aldosterone system, CO cardiac output, SVR systemic vascular resistance, LV left 
ventricle, AII angiotensin II, TGF β transforming growth factor beta. 179 
 
1.7.6.2 LEFT VENTRICULAR PARTITIONING DEVICE 
The aim of percutaneous ventricular restoration (PVR) therapy in this cohort of CHF 
patients is to reduce LV volumes and thus reduce wall stress; remodelling of the LV 
thus increasing synchronicity can lead to a more effective ejection without the increased 
morbidity and mortality associated with surgery. 180,181 PVR is a catheter-based 
approach to delivery of a compliant partitioning (PARACHUTE) device to the LV apex, 
thus partitioning the akinetic myocardium; the conical nitinol frame with ePTFE 
membrane enables device compression and therefore percutaneous implantation, Figure 
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30. The Parachute system includes the Parachute device, the pre-shaped delivery 
catheter and dilator, and the balloon delivery system that facilitates expansion of the 
device Figure 30.The Parachute device is composed of a self-expanding nitinol frame 
(16 struts; radio-opaque), an ePTFE impermeable membrane, and an atraumatic 
polymer foot available in 4 sizes (65, 75, 85 and 95mm) with two different “foot” 
heights. The tips of the struts anchor the device on the myocardium and the atraumatic 
foot provides contact between the LV apex and the device, orientating it toward the LV 
outflow tract.  
 
However data on the haemodynamic consequences are lacking, perticularly, the effect 
of the device on preload, afterload and dyssynchrony. Accurate assessment of cardiac 
performance is critical in CHF to gauge prognosis and assess therapeutic response. 
Although ejection fraction is the most commonly used measure of cardiac function, the 
gold standard for assessing cardiac performance and its interaction with the arterial 
system is pressure-volume (PV) analysis. In CHF ventricular-arterial uncoupling occurs, 
this can accurately be measured by PV analysis as the ratio of Ea:Ees where Ea is a 
measure of net arterial load and Ees is a load-independent measure of LV contractility, 







Figure 30 Parachute Device Illustration. The left panel demonstrates an illustration of 
the Parachute device implanted in a dilated left ventricle (A); the right panels 
demonstrate an open Parachute device (B), various shapes of the delivery catheters (C), 










In the following chapter the methodology used to undertake this research including the 
invasive measurement of pressure-volume loops, invasive measurement of coronary 
blood flow and 3-dimensional echocardiographic techniques are described. The detail 
included is such that accurate reproducibility is possible. The methods describe 
commercially available tools and their respective software for data acquisition and 
protocol specific techniques.  
2.2 MEASUREMENTS: REAL-TIME LV HAEMODYNAMICS 
In this section there follows a detailed discussion with regard to the acquisition of left 
ventricular haemodynamic measurements. 
2.2.1 CONDUCTANCE CATHETER 
Simultaneous LV pressure and volume measurements were performed using a 
conductance catheter (CD Leycom, Zoetermeer, Netherlands), Figure 31. This 
equipment is capable of real-time acquisition and analysis of left ventricular pressure 
and volume data via the Intra-Cardiac Analyser console (INCA) (CD Leycom, 
Zoetermeer, Netherlands). The conductance catheters are commercially available; CE 
marked for research techniques. The two available sizes are: 4Fr (no lumen) and 7Fr 
(lumen, over the wire) with a choice of electrode spacing. These catheters are flexible 
and have a pigtail shaped end to aid placement in the left ventricle. The catheters are 
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equipped with solid-state high fidelity pressure sensor (to prevent drift of tracing) that 
sits in the mid-LV cavity and twelve electrodes spaced at regular intervals to enable 
acquisition of volume data. The 4Fr CC was used for radial or simultaneous data 
acquisition; the 7Fr CC was used in study protocol five, section 7 (PVR).  
Figure 31 Conductance catheter.  
The driving electrodes are on either end with multiple segmental electrodes and a solid-
state pressure sensor between electrodes 5 and 6 (left); the pigtail end facilitates 




2.2.1.1 CONDUCTANCE CATHETER POSITION 
The correct position of the conductance catheter is verified fluoroscopically, and on 
inspection of the segmental conductance signals and assessment of the total pressure-
volume loop generated. Optimal pressure-volume recordings are highly dependent on 
catheter size selection (based on LV dimensions) and appropriate and stable positioning 




2.2.2 VOLUME CALCULATION 
2.2.2.1 THE IMPEDANCE METHOD 
Figure 32 Impedance method.  
The conductance catheter is in a vertical position in the left ventricle (left); segmental 
calculated volumes are shown (middle) and the total volume as a sum of these segments 
(right), adapted from 183. 
 
Essential information for the assessment of cardiovascular performance can be obtained 
by measuring intra-cardiac pressure and volume. As intra-cardiac volume is primarily a 
dynamic variable, real-time accurate measurements are extremely valuable; the 
conductance method calculates continuous left ventricular (LV) volume tracings by 
measuring parallel electric conductance between adjacent electrodes. The benefit of the 
conductance catheter method in enabling measurement of simultaneous LV volumes 
and pressures is that it provides invasive measures of cardiac mechanics and 
haemodynamics. Generation of pressure volume loops therefore: (1) provides a 
characterisation of pump performance that allows loading factors to be reasonably 
separated from ventricular properties; (2) identifies both diastolic and systolic properties 
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in common terms and therefore helps clarify their interrelationship; (3) provides a 
description of coupling between ventricle and vasculature, which enables predictions of 
stroke volume and stroke work response to various loading interventions. The technique 
of using electrical conductance, or impedance measurement of intravascular volume 
was first developed for pump function assessment in humans in the early 1980s.183 
Validation of this technique has been performed against cine computed tomography and 
electro-conductive balloons in animals; thus the conductance catheter is capable of 
reproducing accurate global LV volumes and estimates of stroke volume as well as 
segmental volume calculation.184,185 The conductance catheter method used today 
enables online beat-to-beat assessment of left ventricular volume. The time-varying 
electrical conductance of separated segments of blood in the left ventricle is 
proportional to the intra-ventricular volume (Ohm’s law), therefore an alternating 
current (0.4mA) is applied establishing an electrical field in the LV cavity (proximal 
and distal electrodes); five segmental volumes (time-varying segmental conductance) 
defined by the 10 remaining electrodes (S1 to S5) are measured, and the sum is the total 











2.2.2.2 SLOPE FACTOR AND PARALLEL CONDUCTANCE 
The conical apex is excluded from the segmental calculation, normally corrected for by 
the addition of 1/3 of the 1st segmental volume. This can also be calculated using a slope 
factor (value between 0.5-1.0), determined by Equation 14. The reference stroke volume 
is calculated by thermo-dilution techniques (2.2.3.4). 
Equation 14 ! = !"#$%!&'#!( !"#$%& !"#$%&!"#"!"$%" !"#$%& !"#$%&  
Parallel conductance of the myocardium, which can lead to overestimation of LV 
volume, is corrected for using the correction volume, determined by hypertonic saline 
administration. This drives a transient change in blood conductivity, performed by 
injecting 5% (10% under general anaesthesia) hypertonic saline into the pulmonary 
artery via a pulmonary artery catheter, to extrapolate the effects.183 This is only 
necessary when the intervention is driving acute volume changes. Therefore this 
correction method is only relevant for Chapter 7. Importantly, the correct volume can 




2.2.3 INTRA-CARDIAC ANALYSER 
2.2.3.1 HARDWARE 
 
Figure 33 INtra-Cardiac Analyser (INCA®) 
INCA (left); the Pro-Cart trolley setup: INCA on shelf and PC tablet monitor with 
Conduct NT software running real-time data acquisition (right). 
 
The INCA® is an integrated, stand-alone system for the acquisition, display and 
analysis of intra-ventricular pressure and volume (by conductance) data in humans to 
which the conductance catheter is connected, Figure 34. The data analysed by the INCA 
is displayed on a tablet PC (windows 32-bit operating system) and runs with Conduct 
NT© (version 3.18.1) software, (CD Leycom, Zoetermeer, Netherlands); the tablet and 
INCA are connected via an ethernet cable. The conductance catheter has two external 
connecting cables feeding into the INCA. The pressure cable is connected to the 
corresponding port on the INCA, which detects and automatically calibrates the 
pressure. The volume cable is connected to the corresponding port on the INCA. In 
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Figure 34 a live recording is demonstrated. The tablet PC can display measured LV 
haemodynamic indices (top right), real-time PV loops (bottom right), and 
haemodynamic tracings (left). This enables both optimisation of recorded signals and an 
immediate appreciation of the underlying physiology.	 
Figure 34 Real-time display.  
A zoomed-in view of the tablet PC seen in Figure 33; total LV volume (top left panel); 
LV pressure (second panel); dP/dT (third panel) and the intra-cardiac ECG (bottom 
left); PV loop generated (bottom right hand corner) from the real-time pressure and 
volume data; calculated and measured haemodynamic indices (top right of display). 
 
 
2.2.3.2 INCA SETUP AND CALIBRATION 
Equipment setup and device calibration is performed prior to conductance catheter (CC) 
insertion. Two cable leads arise from the distal end of the CC, one for pressure 
connection and one for volume. The sterile proximal (pigtail) end with electrodes and 
pressure sensor is fully submerged in normal saline for 10 seconds (operator 1); the 
pressure cable (arising distally, not sterile) is connected to the INCA (operator 2). On 
connection, the PC software performs pressure calibration. For additional accuracy, 
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following measurements, the CC is externalised and the pressure tracing is recorded to 
document the zero offset and applied offline to selected data sets as necessary. For 
volume calibration, an extension cable is attached to the CC volume cable (operator 1), 
which is connected to the INCA (operator 2) The CC is inserted into the participant via 
arterial access and placed into the left ventricle. Volume is calibrated in the LV using 
invasive calibration methods (section 2.2.3.3) or with volumetric data obtained by either 
3D echocardiographic or cardiac magnetic resonance imaging (section 2.2.3.4). 
2.2.3.3 NON-INVASIVE VOLUMETRIC DATASET 
3-Dimensional transthoracic echocardiography performed, ideally immediately prior to 
the procedure, is used to acquire the volume datasets necessary for calibration. This 
volumetric data collection enables volume calibration using the ConductNT software. 
The software allows input of direct values of end-diastolic and end-systolic volumes 
obtained from the 3D echo measurements, this can be used to calibrate all data files 
recorded in the same patient. 3D volume dataset acquisition is described in section 2.4. 
2.2.3.4 INVASIVE CALIBRATION 
Invasive calibration is more accurate but requires more instrumentation. 7Fr Right 
femoral venous access enables insertion of a 7Fr pulmonary artery catheter (PAC) into 
the right pulmonary artery via the right ventricle. Standard thermo-dilution techniques 
involve injection of 10 mL bolus of cold saline via the proximal port of the PAC, 
repeated three times. This calculates the reference volume, to incorporate the slope 
factor alpha, accounting for the conical shape of the left ventricular apex. Hypertonic 
saline (5% for sedated; 10% for general anaesthesia due to respiratory irritation) is 
injected in 3x10mL boluses into the pulmonary artery. This calculates the correction 
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factor to account for parallel conductance of the myocardium. During injection, the 
dataset is recorded and inputted into the stroke volume calculator function available on 
the software in real-time. 
2.2.4 CONDUCT NT SOFTWARE 
2.2.4.1 DATA ACQUISITION 
Data capture was performed using the dedicated data acquisition and analysis software 
(Conduct NT, version 3.18.1, CD Leycom, Zoetermeer, Netherlands). At least three 
baseline datasets were recorded; each dataset is recorded separately and in sequence 
because signal optimisation cannot be performed during the recording. These data files 
are stored according to participant ID and date in numerical order for later export and 
analysis. Conduct NT acquires all necessary LV chamber haemodynamics; however, for 
the purposes of this study, a number of additional calculated LV indices and coronary 
haemodynamic measurements were necessary, which negated the use of this software in 
isolation. This includes measurements of cardiac energetics, single beat estimation of 
EDPVR and ESPVR slopes and time-varying elastance. The development of an 
analytical software system for this purpose is described in the results chapter, section 3.  
2.2.4.2 DATA VARIABLES 
The collection of raw variables during live acquisition is essential prior to the 
calculation of derived parameters. These are as follows: 
• Intra-cardiac ECG: an ECG sensor is present on the CC mid-LV cavity; this enables 
accurate timing of events, and determination of end-diastole and end-systole. 
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• Instantaneous LV volume: segmental volumes directly measured via the electrodes, 
are summed and calibrated to provide total LV volume (LVV), from which end-
diastolic (EDV), end-systolic (ESV) are therefore stroke volumes  (SV) are derived. 
• Instantaneous LV pressure: measured directly from the solid-state high-fidelity 
pressure sensor in the mid-LV cavity, from which end-diastolic (EDP) and end-
systolic pressure (ESP) are derived.  
• Pressure-volume loop: generated from instantaneous LV pressure and LV volume, 
from which stroke work (SW) (area of the PV-loop) can be derived. The PV loop 
enables determination of the end-systolic pressure-volume (ESPVR) and end-
diastolic pressure-volume points (EDPVR).  
• Rate of LV pressure change: directly measured by the pressure sensor over time to 
derive the maximum rate of pressure rise (dP/dTmax) and decay (dP/dTmin)  
Derived parameters: 
• Contractility: Cardiac output: (HR x SV) and ejection fraction (SV/EDV x100). 
• Load-independent markers of contractility: starling contractile index (SCI) (dP/dT 
max to EDV ratio); preload recruitable stroke work (PRSW) (SW to EDV ratio)  
• Load independent markers of relaxation: EDPVR, and the time constant of 
relaxation: Tau, defined as the time required for the cavity pressure at dP/dTmin to be 
reduced by 1/e, expressed in milliseconds.186  
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2.3 MEASUREMENTS: INVASIVE CORONARY HAEMODYNAMICS 
In this section there follows a detailed discussion with regard to the acquisition of 
coronary haemodynamic measurements. 
2.3.1 COMBOWIRE AND COMBOMAP CONSOLE 
Figure 35 Animation of Combowire. 
The pressure and flow transducers are located at the distal end, images courtesy of 
Volcano Corp, USA. 
 
For the purposes of complete assessment of coronary haemodynamics, intravascular 
blood pressure and blood flow velocity in the coronary artery were measured using the 
ComboWire® (Volcano Therapeutics, USA). This dual sensor pressure and flow 
(Doppler) wire is manufactured commercially to standard guidewire specifications 
(0.014" diameter; 185cm), Figure 35. The flow sensor (Doppler crystal) is located at the 
distal most tip, with the high-fidelity, solid state pressure sensor offset by 1.5cm. This is 
the only available guidewire capable of simultaneous measurement (via the ComboMap 
6800 system) of coronary pressure and blood flow velocity in the coronary artery for 
interventional and research procedures; and is the most accurate means of coronary data 
acquisition. The distal pressure transducer receives pressure signals, which are sent to 
the Combomap Console, which processes and displays these in waveforms and 
numerical values. The flow transducer transmits and receives ultrasound signals, which 
are processed by the Combomap, which calculates the coronary blood flow velocity 
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based on the Doppler shift, thus displaying a spectral waveform as well as measured and 
calculated parameters. 
2.3.2 CALIBRATION AND DATA ACQUISITION 
To perform accurate measurements, adequate device setup and calibration is necessary. 
The sterile ComboWire® comprises the guidewire (inserted into participant) and two 
connecting ports, one for pressure and one for velocity, these are connected to the 
ComboMap console via the patient interface module (PIM) prior to insertion. This 
ComboMap console is a PC monitor on a trolley that runs the ComboMap software on 
Windows XP (together these comprise the ComboMap system). The PC has a Touch 
Screen monitor for input of participant details, and for later optimisation of flow and 
pressure signals and display, Figure 36. 
Figure 36 ComboMap Display.  
Haemodynamic parameters displayed numerically and as pressure and spectral 
(Doppler) waveforms, the latter has a blue envelope from which the IPV is derived. 
Calculated parameters top left hand corner. 
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Prior to the start of the case, the distal pressure filters are enabled to reduce noise, which 
implements a delay between coronary pressure and velocity that is corrected for on 
post-hoc analysis. For intra-coronary measurements a wall filter is set and fixed at 
200Hz. The monitor is set on live mode and the catheter lab operator connects the 
pressure plug via an Ethernet connection on the patient interface module (PIM), once 
the pressure is calibrated, the flow plug is connected to the PIM and the wire is ready 
for insertion. In the aortic root, the distal (combowire) and proximal pressure (aortic 
pressure from physio monitor) signals are normalised (Pd/Pa equals 1.0). ComboWire 
calibration triggers the recording until it is manually stopped. The ComboWire is 
advanced down the target vessel beyond the lesion into a steady position, and the 
position of the wire tip (anterograde or retrograde) determines the flow settings on the 
ComboMap system. The flow signal is then optimised by fluoroscopic positioning of 
the wire and by assessment of flow velocity traces by varying the instantaneous peak 
velocity (IPV) upper and lower thresholds and by adjusting the display scales. The 
importance of this step is that during analysis, coronary flow velocity tracings measured 
equate to the spectral Doppler envelope, the true spectral Doppler waveform cannot be 




2.3.3 DATA VARIABLES 
Simultaneous measurement of intracoronary pressure and blood flow velocities allows 
for the generation of multiple indices of haemodynamic assessment. 
Direct Measurements:  
• Distal coronary pressure (Pd) is measured directly via the pressure sensor, proximal 
aortic (Pa) pressure (low fidelity; measured by fluid filled manometry) and the 
continuous ECG tracing are transduced via the Physiology Monitoring System in the 
cardiac catheter lab provided as a low level input.  
• The coronary flow velocity is displayed in real-time as a Doppler signal and can be 
viewed on the PC monitor during recording (live and on playback settings). 
Derived Measurements:  
• Pd/Pa, the ratio of distal coronary pressure to proximal aortic pressure  
• Instantaneous peak velocity (IPV) is sampled in real time, every 5 ms (200Hz), from 
the most recent cardiac cycles.  
• Mean coronary blood flow (U) is calculated from 3 cardiac cycles and is the IPV 
averaged over the number of cardiac cycles where x is the number of cycles +1 
(Equation 15); mechanical systole and diastole are estimated from the ECG. 
Equation 15 ! (!"/!"#) =  !"# (!)!"!!!!!!!" − !1  
• Velocity time integral (VTI) is the integral under the IPV curve, this is calculated as 
the sum of the IPV sample magnitude multiplied by the value over the number of 
cardiac cycles divided by the number of cycles (shown for 2 cardiac cycles, 
Equation 16 ): 
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Equation 16 !"# (!"/!"!#$) = 0.012 !"# (!!!!!!!!! ) 
• Fractional Flow Reserve (FFR) is the minimum value of the normalised pressure 
ratio during hyperaemia (maximal vasodilatation), which equates to the ratio of 
distal coronary pressure minus venous pressure to proximal aortic pressure minus 
venous pressure. 
• Hyperaemic Stenosis Resistance (HSR) is an indicator of stenosis resistance, which 
may be compromised by a flow-limiting lesion or microvascular disease. It is the 
ratio of the proximal distal pressure mean gradient (Pa - Pd) to the peak U (U-P). 
The data is captured at the peak APV sample (Equation 17): 
Equation 17 !"# = [ℎ!! − ℎ!!)]/ℎ! 
• Hyperaemic Microvascular Resistance (HMR) is an indicator of microvascular 
resistance, which may be compromised by microvascular disease. It is the ratio of 
the distal pressure (Pd) to the peak U (U-P). The data is captured at the peak APV 
sample (Equation 18): 




2.4 ECHOCARDIOGRAPHY PROTOCOL 
Echocardiography was performed either immediately before or after the cardiac catheter 
lab procedure. Echocardiographic examinations were performed with Philips or Vivid, 
GE ultrasonic system. All patients were examined in the left supine position, using the 
parasternal short axis view at the level of the papillary muscle, and both 2, and 4-
chamber apical views of the LV and parasternal long access view of the LV, with 
emphasis on high quality recordings of all LV walls. Three consecutive cardiac cycles 
were stored during breath-hold. Images were stored digitally. All grey-scale images 
were obtained with a minimum frame rate of 50 frames/sec. 
2.4.1 ECHO ANALYSIS 
Left Ventricular Ejection Fraction by echocardiography was assessed by the modified 
biplane Simpson's method from the apical 2 and 4-chamber grey-scale recordings. End-
diastole was defined as the frame closest to the R-wave and end-systole was defined as 
the minimal cavity area just before mitral valve opening. Strain measurements were 
performed using TomTec 4D analysis software. The strain software identifies the 
endocardial border, and myocardial motion is automatically tracked in each grey-scale 
imaging view. Segmental longitudinal and circumferential strain curves reflect the 
average strain value of all the acoustic markers within each segment. Segments with 
poor tracking were readjusted by the observer. Results are reported as the peak systolic 
strain and strain rate during the whole cardiac cycle. Furthermore, measurements from 
the individual LV apical and parasternal segments were averaged and reported as LV 
global longitudinal or circumferential strain and strain rate. Global strain was calculated 
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as an average of strain measurements from 16 LV segments. In addition, time to peak 
strain was measured from the aortic valve opening to peak negative strain. 
2.5 INSTRUMENTATION AND TECHNICAL CONSIDERATIONS 
This subsection deals with the technical considerations and equipment selection for 
certain aspects of the data collection protocol. The importance of this study centres 
around simultaneous acquisition; however, both the INCA and ComboMap console 
were designed to be used in isolation, thus their design hinders their use in combination 
in-vivo. Overcoming this initial challenge required adjustments to be made to the 
equipment used to acquire the data. 
2.5.1  CONDUCTANCE CATHETER DIAMETER 
The 4Fr CC (no inner lumen), is a pigtail shaped catheter with an outer diameter of 
1.4mm, a guide catheter is required to deliver this to the left ventricle. The outer 
diameter necessitates delivery with a minimum of a 6Fr guide catheter, the inner 







Table 1 Sheath sizes. Inner and outer diameters of arterial sheaths are specified. 
 
Sheath Size (Fr) Inner Diameter Outer Diameter 
5 1.7mm/0.066” 7-8Fr 
6 2.0mm/0.079” 8-9Fr 
7 2.3mm/0.092” 9-10Fr 
8 2.7mm/0.105” 10-11Fr 
9 3.0mm/0.118” 11-12Fr 
10 3.3mm/0.131” 12-13Fr 
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To perform simultaneous measurement from a single access site, both the ComboWire 
and the CC are introduced via the same guide catheter. The combined outer diameter of 
both is 1.8mm; thus for measurements via the femoral artery an 8Fr guide catheter was 
used. Radial access site was used for Protocol 2 (supine cycle ergometry), for which the 
maximum deliverable sheath size is 6Fr (outer diameter of 2.7mm, inner diameter 
2mm), Table 1. Using standard equipment this would need to be performed via femoral 
access thus precluding bicycle exercise. The solution is to deliver a guide with an 
equivalent inner diameter of an 8Fr standard guide catheter, without the need for an 
arterial sheath (8Fr arterial sheath OD 3.3mm). The commercially available 7.5Fr Asahi 
Sheathless Guide™ (Vascular Perspectives, UK), has an outer diameter just smaller 
than a 6Fr sheath and an inner diameter equivalent to that of an 8Fr standard guide 
catheter, thus enabling single site radial access with simultaneous introduction of 
conductance catheter and ComboWire, Figure 37.  
 
The 7Fr conductance catheter is a pigtail shaped catheter with an inner lumen. This 
catheter can be delivered over the wire via femoral access into the left ventricle. The 
inner lumen requires a 0.25" super stiff guide wire (Terumo). In the absence of 
simultaneous measurements in Protocol 5 (left ventricular partitioning device) the 7Fr 
CC was used in isolation; the 7Fr is more stable in dilated left ventricles. The outer 
diameter of the 7Fr CC is 2.3mm, necessitating a minimum 8Fr femoral sheath, Table 1. 




Figure 37 Asahi Sheathless Guide.  
The outer  (OD) and inner diameters (ID) are compared to those of standard arterial 
sheaths, images courtesy of Vascular Perspectives, UK. 
2.5.2 EQUIPMENT ALTERATION 
The conductance catheters were designed as a diagnostic tool, to be delivered via 
femoral access. Their length therefore precludes delivery through a standard guide 
catheter (100cm). For electrode measurements in the left ventricle, the distal end of the 
conductance catheter needs to be exposed. Therefore commercially available, 80cm 8Fr 
guide catheters were used for research procedures performed via femoral access. 
Data acquisition performed via radial access raised two issues: 
• The distance from the radial puncture site to the coronary ostia is greater than via 
the femoral route; further catheter length loss is incurred by tortuosity of the arterial 
tree in this region; thus conductance catheter measurements could not be performed 
via the artery in patients over 175cm. This limited the exercise cohort in Protocol 2. 
Diagnostic catheterisation was therefore performed in the first instance in all 
patients (100cm catheters), to measure this distance prior to enrollment. 
• Asahi Sheathless Guides are commercially available in only one size (100cm). 
Guide catheters had to therefore be manually shortened under sterile conditions by 
the operator, on a case-by-case basis. Sterile 7" angled scissors were used to cut a 
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10cm segment out of the proximal end of the 7.5Fr guide. A 1.5cm section of the 
lumen of a 6Fr sheath (pre-dilated with an 8Fr dilator) was used to reattach the 
severed ends, to create a temporary seal. The proximal end can be seen in Figure 38 




Figure 38 Proximal end of the ASG.  
Reattachment of two severed ends of guide catheter can be seen. The ASG is connected 
to the Y-connector. 
 
Figure 39 The distal end of ASG.  




2.6 CATHETER LABORATORY PROTOCOL 
The following protocols describe the catheter lab set-up and methodology necessary for 
data acquisition. Further detail is provided in the specific results chapters. All research 
interventions were approved by the UK National Research Ethics Committee. The 
patient information sheet with quoted risk and the protocol submitted for all catheter 
laboratory based procedures is in the Appendix. 
2.6.1 Set-Up And Calibration 
2.6.1.1 RADIAL ACCESS: 
Diagnostic Procedure:  
• 5Fr radial access 
• 5000 IU heparin injected into aortic root.  
• Diagnostic angiography using 5Fr JL3.5 and JR4.  
• Residual catheter distance measurement. 
• Identification of target vessel lesion. 
Research Protocol: 
• 7.5Fr ASG guide shortened proximally (10cm) with 7"angled scissors. 
• 1.5cm section of 6Fr femoral sheath lumen to reattach ASG. 
• Introducer inserted into ASG. 
• Setup of angioplasty kit as per routine clinical protocol. 
• 5Fr radial sheath exchange for 7.5Fr ASG over 300cm diagnostic J-wire. 
• Introducer removed in the ascending aorta. 
• ASG intubation of target vessel coronary ostium. 
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• Further intra-arterial Heparin to achieve 70IU/kg and the target vessel with guide 
catheter. 
 
2.6.1.2 FEMORAL ACCESS: 
Diagnostic Procedure: 
• 8Fr femoral access  
• Diagnostic angiography using 6Fr JL4 and JR4 
• Residual catheter distance measurement 
• Identification of target vessel lesion 
Research Protocol: 
• 8Fr 80cm Medtronic Launcher Guide Catheter 
• Intubation of target vessel coronary ostium 















2.6.1.3 COMBOWIRE INSERTION: 
Calibration and Insertion: 
• Research participant details recorded 
• Appropriate pressure and flow settings selected 
• Auxiliary cables connected to INCA   
• ECG lead connected to Physio Monitor 
• ComboWire connected to patient interface module and calibrated 
• ComboWire inserted into guide catheter 
• Signal normalised in aortic root or coronary ostium - triggers continuous recording 
• ComboWire advanced to distal target vessel beyond lesion 
• Optimisation of flow signal 














2.6.1.4 CONDUCTANCE CATHETER INSERTION: 
Calibration: 
• Research Participant details recorded on panel PC 
• Catheter number selected  
• Submergence of Conductance Catheter (CC) in normal saline -10 seconds 
• CC Pressure cable connected to corresponding INCA port 
• Pressure calibration confirmation 
• Volume cable placed in sterile bag with porthole and connected to CC volume 
cable on one end and corresponding INCA port at the other end. 
Insertion: 
• CC pigtail angled away from Y-arm on introduction into the guide catheter. 
• CC advanced to aortic root and across aortic valve into LV apex. 
• Stable position confirmed by stability of PV loop trace and fluoroscopic 
confirmation. 
• Exclusion of electrodes outside of LV (for accurate volume calculation)  
• Volume calibration performed with baseline dataset recording using invasive 
calibration or predetermined non-invasive volumes (EDV and ESV). 
• Serial recordings and data collection followed 
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2.6.2 PROCEDURAL TECHNIQUES 
The following section focuses on the details of the specific interventions performed in 
each study cohort following ComboWire and conductance catheter insertion. 
2.6.3 BASELINE SIMULTANEOUS MEASUREMENTS 
Figure 40 Fluoroscopic confirmation of conductance catheter position 
 
Baseline measurements were taken with the patient in a resting supine position. Signals 
were optimised and recorded for 30 seconds to 1minute. Measurements are repeated 
three times to account for any variability or loss of signal, Figure 40. 
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2.6.4 VASODILATOR ADMINISTRATION: ISOSORBIDE DINITRATE 
2mL of sterile 0.1% ISDN solution was diluted 1:5 in 10ml 0.9% Saline. The resulting 
approximate drug concentration was 2mg/10mL. On manual injection outside the 
patient through the manifold, 1-2mg ISDN was delivered via the guide catheter into the 
patients' aortic root. Injection was mandated over 5 seconds; however due to intra-and 
inter-operator variability, aortic root size and proximity to the coronary ostia, the rate of 
injection and coronary infiltration could not be controlled for. Dataset recording was 
commenced at the onset of manual injection and continued for 2 minutes, this captured 
the immediate changes induced in the coronary artery, left ventricle and peripheral 
vasculature. Further recordings were performed on return to baseline. ISDN 
administration was performed twice. 
2.6.5 ADENOSINE INDUCED HYPERAEMIA 
Prior to the start of the procedure, the research participant underwent sterile peripheral 
venous cannulation, either in the left (preferable) or right ante-cubital fossa. This 
provided venous access for the purposes of administration of adenosine infusion. The 
adenosine infusion was attached via an intravenous giving set to the peripheral cannula 
and the adenosine administered using a syringe driver at a rate of 140mcg/kg/min 
(calculations based on the patient weight and height determined the rate of infusion). 
Dataset recording was commenced at the onset of the infusion. The adenosine was 
administered for a minimum of 90 seconds, until a steady state was achieved. Dataset 
recording continued for the duration of adenosine and continued for a further 1 minute 




2.6.6 DYNAMIC EXERCISE: SUPINE CYCLE ERGOMETRY 
Dynamic exercise was performed solely in the cardiac catheter laboratory. This was 
performed prior to the angioplasty procedure. The supine cycle ergometer (Ergosana®, 
Schiller, Germany) is a specialist device, placed on the catheter laboratory table and 
secured to underlying structures. The patient performed a trial, 15-20 second attempt at 
supine cycle ergometry to ensure feasibility. Dataset recording on the INCA, of both 
coronary and LV measurements was recorded from the start and for the duration of 
exercise, and 1 minute into recovery. Supine cycle ergometer exercise was started at 60 
rpm, at 30 Watts for the 1st minute. This increased incrementally by 20 Watts per 
minute maintaining a cadence of 60rpm where possible on a pre-specified ergometer 
protocol. Continuous intra-cardiac ECG monitoring was provided by the CC. This was 
continued for 5 minutes or until the research participant experienced any of the 
following: 1) chest pain 2) fatigue 3) >3mm ST depression on intra-cardiac ECG 4) 
arrhythmia 5) maximal age-related heart rate. 
2.6.7 LEFT VENTRICULAR PARTITIONING DEVICE: PV LOOP SUB-STUDY 
Prior to insertion of the device all patients underwent baseline evaluation with: 3D 
echocardiography, Cardiac CT for device sizing and placement, Cardiac MRI and 
coronary angiography (Figure 41). Suitability for Parachute device implantation was 
discussed for all patients in multi-disciplinary team meeting. Based on further core lab 
assessment, the optimal parachute device was selected. 
 
Via the left femoral artery (LFA) a 6Fr sheath (non-interventional access site) was 
introduced and remained in-situ. Intra-arterial Heparin was administered to maintain an 
activated clotting time of greater than 250, via left venous access a 7Fr sheath was 
METHODS 
95		
introduced and remained in situ, through this a pulmonary artery catheter (PAC) was 
floated in the pulmonary artery. This enabled administration of hypertonic saline (5-
10%) and thermodilution techniques to calibrate the INCA. Via the LFA, a 7Fr 
conductance catheter was introduced into the ventricle over a 0.025” super stiff 240cm 
wire. Once the conductance catheter (CC) was in position, thermodilution and 
hypertonic saline administration was performed three times and LV haemodynamic 
recordings were taken pre-device implantation. The CC was then removed in 
preparation for device implantation; the pulmonary artery catheter remained in situ.  
 
Figure 41 Baseline Patient Evaluation.  
Anatomical assessment is performed using echocardiography with contrast to 
demonstrate aneurysmal apical wall and exclude thrombus (A). Device selection was 
based on multi-slice computed tomography, which also allowed for identification of 
pseudochordae or severe calcification, precluding safe deployment (B). Cardiac 
magnetic resonance imaging with late gadolinium enhancement confirms scarring of the 
LV apical wall secondary to myocardial infarction, white arrow (C). 
 
A 5Fr 125cm (long) diagnostic pigtail catheter was then introduced via the LFA and 
used to cross the aortic valve into the left ventricle. A left ventriculogram was 
performed to visualise apical hypokinesia, and the optimal view device positioning. 
This was then retracted into the aortic root. Right femoral arterial access was then 
obtained using an 8Fr sheath, (the device access site) through which the Parachute 
device was delivered, the access site was pre-prepared with two closure devices 
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(Perclose Proglide, Abbott Vascular). A 2nd 125cm (long) pigtail was introduced 
through the sheath in the right femoral artery, this again crosses the aortic valve and was 
placed in the left ventricle using a soft j-tipped wire, which was then exchanged for a 
preshaped Safari wire™ (Boston Scientific); the pigtail was retracted and the safari wire 
remained in the left ventricle. A superstiff Safari wire provided enough support for 
exchange of the 8Fr with a 16Fr Vascular Sheath (Edwards, US). The Parachute 
delivery catheter was then introduced using pigtail into left ventricle across aortic valve, 
during which time the PARACHUTE® device was prepared. The Guide Catheter and 
Delivery Catheter were advanced together so that the PARACHUTE® Implant Foot is 
in contact with the apex. The delivery catheter position was maintained while the pigtail 
catheter was retracted, leaving a clear attachment zone. Parachute deployment Figure 
42: the position of the PARACHUTE implant foot is maintained in the LV apex, whilst 
holding this in place, the guide catheter is withdrawn to completely expose the 
PARACHUTE® implant; 20cc. of 50:50 contrast-saline mixture is then injected into the 
delivery catheter balloon and inflation maintained for 1-2 minutes. The delivery catheter 
balloon was then deflated and guide catheter advanced over the deflated delivery 
system, the entire system was removed and LAO and RAO views confirm positioning 
of the device. The 7Fr CC was then reinserted, thermodilution and hypertonic saline 












Figure 42 Parachute Study Procedure.  
The sequence of parachute implantation in the LV: LV angiography is performed with a 
pigtail catheter in the LV (A) followed by pre-procedure PV measurements, the delivery 
catheter is position in the apex (B), the Parachute foot is then exposed and contact is 
made with the antero-apical wall, confirmed in LAO (C) and RAO (D) views. Device 
delivery is facilitated by 20cc balloon expansion (E), retraction of the delivery system, 
followed by fluoroscopic confirmation of position in LAO (F) and RAO (G) views. LV 
angiogram confirms partitioning of akinetic myocardium (H) and immediate post-
procedure LV PV measurements are performed. 
	3 THE MECHANICAL DETERMINANTS OF 
CORONARY BLOOD FLOW: A NOVEL 
ANALYTICAL SOFTWARE SYSTEM  
ABSTRACT 
Coronary blood flow is phasic in nature, increasing in diastole and markedly decreasing 
in systole. Several hypotheses have been used to describe systolic flow impediment 
however data are conflicting. Recently, coronary wave intensity analysis (WIA), a time 
domain method for investigating incremental changes in coronary pressure and velocity 
described in terms of successive wave fronts, has been used to describe the impact of 
myocardial contraction on coronary blood flow morphology, making it a potentially 
powerful research tool. Previous work in this area have measured coronary and LV 
haemodynamics independently, reassembling to provide beat-to-beat averages, the 
disadvantages are that these do not provide continuous assessment of the interaction 
between the two. This study describes a novel software system that employs automated 
algorithms to perform simultaneous analysis of left ventricular (LV) pressure-volume 
(PV) loop and coronary haemodynamic data.  
METHODS 
The software was written using matrix laboratory programming language written by by 
Simon Rivolo with my input; integration of myocardial energetics and single beat 
estimations of pressure-volume relations make this a superior analytical tool to those 
currently available. Software calibration (temporal alignment of LV and coronary data) 
was performed using in-vitro (phantom flow model) and in-vivo experimentation. 
Subsequently real-time LV pressure-volume loop recordings from 15 patients in the 
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catheter laboratory setting were used to compare haemodynamic outputs from the new 
software with the gold standard CE marked software; furthermore, coronary wave 
energies were aligned with instantaneous LV pressure-volume changes and the impact 
of LV elastance on coronary blood flow velocity was examined. 
RESULTS 
Validation demonstrated statistical and clinical agreement between the novel and gold 
standard LV PV loop software; wave energies were aligned to the LV pressure volume 
loop: forward and backward travelling wave energies generated in the coronary artery 
were found to be strongly dependent on the ventriculo-arterial interaction, forward 
waves were delimited by diastolic blood pressure and backward waves by aortic valve 
opening; in the absence of autoregulation, coronary blood flow velocity was found to be 
closely related to LV elastance, suggesting that coronary blood flow velocity 
morphology is dependent on myocardial contractile properties and microvascular 
resistance during resting conditions. 
CONCLUSIONS 
The unique ability of this novel technology to describe the ventriculo-arterial and 
coronary interaction in terms of continuous real-time assessment enables an in depth 
examination of the relationship between coronary and LV haemodynamics; furthermore 
this tool was developed to facilitate future work in this area with a view to enhancing 
our understanding of pathophysiological mechanism of disease states and therapeutic 
interventions. 
  




There has been a long-standing interest in the interaction of cardiac contraction with 
coronary perfusion.72,187 Coronary blood flow is phasic in nature, increasing in diastole 
and markedly decreasing in systole. Several hypotheses have been used to describe 
systolic flow impediment including the time-varying elastance theory of Suga et al, 
whereby the myocardium conducts elastance directly to the coronary arteries, however 
data are conflicting.107,188-190 More recently, coronary wave intensity analysis (WIA) has 
been used to describe the impact of myocardial contraction on coronary blood flow 
morphology.96,107 Coronary WIA is a time domain method for investigating incremental 
changes in coronary pressure and velocity, described in terms of successive wave 
fronts.97 It has been proposed that wave energies measured by wave intensity analysis 
may be related to contractile properties of the ventricle, making it a potentially powerful 
clinical research tool.100,191 To perform wave intensity analysis, invasive assessment of 
coronary haemodynamics with simultaneous measurement of both coronary pressure 
and blood flow velocity by means of spectral Doppler is necessary. However, WIA has 
several limitations, both in terms of signal calculation and invasive validation. 
Differencing of the WIA inputs generates noise and relies on operator smoothing of the 
signals to derive wave energies thus inducing variability in derived measurements; 
furthermore application of the single point technique to derive WIA in the coronary 
arteries limits its application during hyperaemic states.104,192 In an attempt to describe 
cWIA in terms of changes in left ventricular haemodynamics, measurements of left 
ventricular pressure and wave energies have been measured independently and 
reassembled to provide beat-to-beat averages; the disadvantages are these methods do 
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not provide continuous assessment of the cardiac-coronary interaction and are unable to 
accurately measure contractile force independent of loading conditions. 
 
Left ventricular pressure and volume measurements and their relationship has been the 
mainstay in describing myocardial properties since their early description a few decades 
ago; recently, advances in technology have enabled application of the conductance 
catheter method to enhance our understanding of myocardial disease states and the 
assessment of therapeutic interventions.193-195 This method accurately measures left 
ventricular volume by way of an insulated catheter placed in the left ventricle. In 
summary, several evenly spaced electrodes measure intervening voltages from the 
current applied from the base of the ventricle to the apex; the solid-state pressure sensor 
derives high fidelity LV pressure measurements, thus enabling simultaneous assessment 
of left ventricular volumes and pressure.183 The instantaneous LV pressure-volume 
relationship allows for determination of contractile and diastolic properties independent 
of the impact of loading conditions on the heart. 
 
To address these issues, it was considered necessary to create a tool for the 
simultaneous continuous assessment of both left ventricular myocardial function and 
coronary blood flow velocity that would be comparable to each of these gold standards 
in terms of accuracy and reproducibility. We present a novel software analysis system 
that supports assessment of simultaneous coronary pressure and velocity measurements 
and left ventricular pressure-volume relations. The aim of this work was to create a 
clinical research tool that enabled analysis of LV PV loop data and coronary blood flow 
measurements (with wave intensity analysis) that were acquired simultaneously, and to 
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create a software programme that was accessible for future work in this area.  This 
system was validated using ConductNT software (CD Leycom, Zoetermeer, 
Netherlands) as the “gold standard” measure of LV pressure-volume loop assessment. 
Incorporation of an adaptive filter (Savitsky-Golay) that uses automated algorithms for 
smoothing was used to remove inter- and intra-observer variability; application of 
baseline pulse wave velocity to the measurement of cWIA during hyperaemic states was 
used to decrease error.192,196,197 Subsequently, real-time recordings utilising the 
conductance catheter hardware system (INCA, CD Leycom, Zoetermeer, Netherlands) 
with electronic routing of ComboWire (Volcano corp, Philips, USA) haemodynamic 
data were performed in human subjects; the software system was used to temporally 
align coronary and LV changes over one cardiac cycle to 1) the LV mechanical 
determinants of coronary wave energies; 2) accurately determine the relationship 
between instantaneous LV properties and coronary blood flow at rest and on abolition 
of microvascular resistance.198,199 
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3.2 METHODS 
The hardware and software components of the coronary-PV analysis system 
(SimpleWires) are described. This is includes temporal alignment of the LV and 
coronary signals by in-vitro and in-vivo experimentation methods. This is followed by 
validation against the gold standard and delineation of the relation between LV 
myocardial properties, coronary blood flow and wave intensity analysis. 
3.2.1 HARDWARE CONFIGURATION 
Coronary pressure and flow velocity and LV pressure-volume were simultaneously 
acquired using a ComboWire (Volcano Corp) and conductance catheter (CC) 
respectively. Data acquisition was performed using the commercially available 
hardware consoles. The conductance catheter signal provides real-time beat-to-beat 
measurement of LV pressure-volume assessment; the hardware consists of the cardiac 
function laboratory (CFL-M) known as the INCA device (CD Leycom, Zoetermeer, 
Netherlands), connected to a panel PC with hard-disk running 32-bit Windows 7 
operating system. The INCA is accessed using the built-in Conduct NT software (CD 
Leycom, Zoetermeer, Netherlands), which performs as a data acquisition and analysis 
tool. The conductance catheter is pressure calibrated in normal saline prior to placement 
in the left ventricle, following this; volume calibration is performed against baseline 
dataset recordings using volumetric data obtained from three-dimensional 
echocardiographic assessment of left ventricular volume.  
 
The Combowire is calibrated outside the patient following connection to the 
ComboMap 6800 system via a patient interface module; in the aortic root, the coronary 
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pressure sensor is normalised to aortic pressure readings from the catheter laboratory 
physiology monitor prior to delivery down the target coronary vessel. Coronary 
pressure and flow velocity signals are acquired and interpreted by the ComboMap 6800 
system, filters implemented during data acquisition (smoothing of haemodynamic 
pressure trace) apply a 55ms delay between coronary pressure and flow velocity, signals 
are digitally archived at 200Hz. Traditionally, following data acquisition on the 
ComboMap console, coronary data is digitally stored for later offline analysis using 
Study Manager Software (Amsterdam Medical Centre, Netherlands) to display files 
(.sdy) as haemodynamic tracings over time. This programme facilitates identification 
and extraction of relevant and optimal cardiac cycles for further analysis, data are then 
exported as snapshots (.txt) and uploaded (in our institution) to Cardiac Waves (in-
house custom made programme for coronary haemodynamic analysis (KCL, London); 
this software generates numerical data and is capable of performing wave intensity 
analysis.  
 
However, for the purposes of simultaneous acquisition and real-time display of 
coronary and LV haemodynamic data, we performed electronic routing of the 
ComboMap signals to the INCA device via the auxillary input ports (Figure 43). The 
INCA console runs on Conduct NT software (CD Leycom, Netherlands), this acquires 
LV PV loop data and can also be used to visualise data in real-time and analyse data 
offline. ConductNT enables auxiliary inputs to be viewed alongside haemodynamic 
variables (Figure 43). Coronary tracings on the ConductNT software were displayed as 
voltages: coronary pressure (1V/100mmHg) and velocity (1V/50 cm/s). Following 
electronic routing of the coronary data, the INCA introduced a time-delay between the 
coronary and LV signals; this was determined by in-vitro and in-vivo experimentation. 
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Figure 43 Electronic routing of the coronary signal into the INCA. 
Displayed on the tablet PC (INCA). Abbreviations: LVP left ventricular pressure, LVV 
left ventricular volume, U mean coronary flow velocity, Pa aortic pressure (provided by 
fluid filled manometer in guide catheter)), Pd distal coronary pressure. 
 
3.2.2 TIME-PHASE DELAY  
In the early phase of software development, a time phase misalignment at end-diastole 
was noted between the left ventricular pressure signals (acquired by the INCA and ECG 
gated) and the signals routed from the ComboMap (coronary and aortic haemodynamic 
traces). The ECG gating of end-diastole on the LV pressure trace did not coincide with 
end-diastole on the aortic pressure trace. This can be visually appreciated in Figure 44, 
which demonstrates the real-time recording on the ConductNT software and offline 
analysis. Initially, the origin of this delay was not clear; however, during real-time 
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acquisition, it was established to have arisen from post-processing by the INCA and was 
not a physiological delay between LV and aortic pressure. In order to perform accurate 
simultaneous analysis, the post-processing delay was determined in two phases 1) in-
vitro experimentation using a phantom aortic flow model followed by 2) in-vivo 
confirmation in the aortic root. 
 
Figure 44 Time-phase delay.  
The ECG gating of end-diastole for LVP (left ventricular pressure) occurs earlier than 
that of the aortic pressure transduced from the ComboMap. 
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3.2.2.1 IN-VITRO EXPERIMENTATION: 
The pulsatile aortic flow phantom was built to simulate a working ventricle with 
simplified pulmonary and systemic vessels. Its aortic equivalent is a silicon tube, 
1.2mm in thickness and 1200mm in length. A diagrammatic representation and the 
different parts forming the experimental rig are shown in Figure 45.  
Figure 45 Pulsatile Flow Phantom.  
Above: diagrammatic representation of the pulsatile flow phantom: 1) Ventricle piston; 
2) Ventricle and working fluid; 3) Arterial valve; 4) Suspension fluid; 5) Outer 
cylindrical case; 6) Venous reservoir; 7) Silicone vessel; 8) Venous channel; 9) Venous 
resistance screw; 10) Arterial resistance screw and catheter access; 11) Arterial 
compliance chamber; 12) Venous valve. Reproduced from200. Below: experimental set-
up for in-vitro determination of time-delay. 
This device is used in computational fluid dynamics to closely mimic the physiological 
system. The piston-pump ejects the fluid contained in a cylindrical chamber through a 
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tri-leaflet polyurethane valve into a straight silicone tube. At the opposite end, a 
Windkessel system consisting of an adjustable resistance screw and a compliance 
chamber provide the desired afterload if required. At the proximal end is a generator 
used to create pulsatile flow of up to 20L/minute. The in vitro set-up provides a range of 
physiological systolic pressures without adding confounding factors typical of the 
patient context, such as beat-to-beat variability and localised changes in wall stiffness. 
This allows close control of the fluid-dynamic conditions, which can be accurately 
modelled using computer simulations to provide a physical interpretation of the 
observed discrepancies. This has previously been validated as a model and further detail 
on the flow phantom is available and was performed with the help the aforementioned 
collaborators.200  
EXPERIMENTAL PROTOCOL 
The conductance catheter and ComboWire were aligned such that both pressure 
transducers were in the same location in the phantom aorta, the experimental set-up is 
shown in Figure 45. Pulses were generated initially by the piston pump; however due to 
the silicon nature of the tube, the distance between the input generator and receiver was 
shortened (1cm) to minimise wave reflection. A repetitive impulse, generated by 
tapping the aorta just proximal to the pressure transducers was performed and repeated 
three times, with varying degrees of pressure change. Simultaneous recordings were 
performed on the ComboMap and INCA console; electronic routing of the ComboMap 
recordings into the INCA enabled display of both tracings (conductance catheter and 
ComboWire) on the INCA tablet PC. Data were recorded and exported from the INCA. 
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3.2.2.2 IN-VIVO EXPERIMENTATION 
To determine if the signal misalignment persisted in-vivo and was not further 
influenced by patient factors (anatomy of aortic root, heart rate, temperature), the 
experiment was conducted in 3 healthy adult volunteers. 8Fr femoral access site was 
used to introduce an 8Fr 80cm guide catheter in three patients who had consented to the 
study protocol. A 4Fr PV loop conductance catheter (CC) and 0.014" ComboWire were 
aligned in the aortic root. The pressure sensors were aligned temporally and spatially. 
The pressure sensor on the CC has a radio-opaque marker; the pressure sensor on the 
ComboWire is immediately proximal to the radio-opaque region, thus enabling 
fluoroscopic alignment of the two. Simultaneous recordings were performed on the 
ComboMap and INCA console, with electronic routing of ComboWire signal into the 
INCA as described previously. Recordings were performed for one minute; this 
represented the average duration of recording performed in the clinical research setting.  
3.2.2.3 RESULTS 
The in-vitro and in-vivo measurements are depicted graphically in Figure 46. To 
increase accuracy, measurements were performed trough to trough in both the in-vitro 
and in-vivo experiments. The delay was found to be 88ms (4ms sampling time) in both. 
An adjustment feature was therefore incorporated into the SimpleWires software, 
enabling automatic alignment between the left ventricular signals and the coronary 
signals (auxiliary inputs) on data upload for analysis.  
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Figure 46 Time-phase misalignment.  
The pressure transduced from the INCA is seen in blue and from the combowire in red; 
impulse generation in-vivo is seen on the left and from the phantom aortic model on the 
right. The delay was measured from trough to trough.  
3.2.3 SIMPLEWIRES ANALYSIS SOFTWARE 
All data were recorded on and exported from Conduct NT software (CD Leycom). For 
analysis using the novel SimpleWires software, end-diastolic markers were ECG-gated 
(peak R-wave) and end-systolic markers were aligned to the maximum ratio of total LV 
volume to pressure prior to export and a low pass filter 25Hz was instituted. Combined 
coronary and LV data were exported from the INCA as comma separated value (csv) 
files onto a portable memory stick. Each dataset is exported as a separate file. Data were 
uploaded to the SimpleWires software analysis system, analysis at 10Hz for LV data 
Real-time measurement of  
post-processing delay 
Offline measurement of  
post-processing delay 
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and 25Hz for coronary data were performed using the matrix laboratory graphical 
programming language (Mat lab).  
3.2.3.1 DATA ANALYSIS  
On opening the SimpleWires programme, a graphical user interface (GUI) appears, 
Figure 47. To perform the analysis, the operator uploads the dataset of interest to the 
GUI from the csv files exported from Conduct NT (CD Leycom). The consecutive 
cardiac cycles of interest (beats) from the haemodynamic signals can then be accessed 
from the uploaded data file. The “beats” function enables the operator to select 
consecutive cycles from one of a range of parameters including left ventricular pressure 
(LVP), left ventricular volume (LVV), beat number (range of 1 to x where 1 is the first 
recorded cardiac cycle within that dataset and x is the last), ECG, coronary pressure, 
coronary flow velocity, aortic pressure, time (seconds). To select beats of interest, data 
are visualised as their respective recorded waveforms. 
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Figure 47 SimpleWires graphical user interface (GUI).  
The dataset of interest is selected and consecutive cardiac cycles are selected. 
Abbreviations: LVP left ventricular pressure. 
 
The software then plots the LV haemodynamic tracings over time (left ventricular 
pressure, LVP and volume, LVV); calculates and displays an ensemble average of LVP 
and LVV plotted over one cardiac cycle; and displays LVP as a function of LVV 
(pressure-volume loop) for each cardiac cycle and as an average of the selected cycles. 
The end-systolic pressure-volume relationship (ESPVR) and end-diastolic pressure 
volume relationship (EPDVR) relationship slope are calculated (based previously 
published and validated methodology, described in section 3.2.3.4) and depicted on the 
ensemble averaged PV loop as black lines intersecting the end-systolic and end-diastolic 
points on the loop respectively. The numerical values that accompany the left 
ventricular haemodynamic tracings are displayed at the bottom of the screen, Figure 48.   
 
The software performs temporal alignment of the acquired coronary and LV data by 
removal of the post-processing delay (determined from in-vitro and in-vivo 
MECHANICAL DETERMINANTS OF CORONARY BLOOD FLOW 
113		
experimentation, section 3.2.2) implemented by the INCA, allowing the observer to 
view LV and coronary haemodynamic variables over one cardiac cycle. Coronary 
pressure and flow velocity measurements are ensemble averaged over 5 beats and 
displayed graphically over one cardiac cycle. SimpleWires software is capable of 
converting the ConductNT voltages displayed for coronary pressure and velocity and 
therefore exported, to mmHg and cm/sec respectively.  
 
Figure 48 Left ventricular haemodynamics.  
The recorded measurements are displayed graphically in a number of formats and as 
numerical values. Abbreviations: LVP left ventricular pressure, LVV left ventricular 
volume, LV left ventricle. 
 
The observer can select coronary pressure or velocity signals displayed as a function of 
time to aid optimal selection of cardiac cycles prior to wave intensity analysis. The 
“align” function can be used to correct the 55ms delay implemented by the ComboMap 
pressure filters (previously established). The software enables visualisation of coronary 
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blood flow velocity or coronary pressure traces after smoothing with the option of 
Savitsky-Golay (S-G) filters or adaptive S-G filter, which can then be implemented to 
perform wave intensity analysis, Figure 49. 
 
Figure 49 Coronary haemodynamic signals. 
The observer can align the pressure and velocity signals, smooth the data and perform 
wave intensity analysis. 
 
3.2.3.2 STANDARDISED PV LOOP VARIABLES  
The left ventricular (LV) haemodynamic variables that are derived from the recorded 
LV haemodynamic traces are defined Table 2. In addition to instantaneous left 
ventricular pressure and volume, load-independent measures of ventricular function can 
be determined. 
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Contractility and cardiac work: The end-systolic PV relationship (ESPVR) represents 
the ratio of LV pressure to volume at the end of ventricular systole (left uppermost 
corner of the loop) and the slope (Ees) is calculated from single-beat estimation 
methods described below. The Starling contractile index (SCI) was calculated as the 
maximal rate of pressure change over time during isovolumic contraction (dP/dTmax) 
normalised to end-diastolic volume (EDV). The (external) stroke work (SW) was 
calculated as the area within the PV loop. Preload-recruitable stroke work (PRSW) was 
calculated as SW normalised to EDV.  
 
Diastolic Function: In addition to measured dP/dtmin, load-independent markers of 
relaxation were derived. Tau is a measure of active relaxation, and is the time in 
milliseconds (ms) for dP/dt min to be reduced by 1/e. The end-diastolic PV relationship 
(EDPVR) represents the ratio of LV pressure to volume at the end of ventricular 
diastole, measured at the peak of the R wave on the electrocardiogram. The slope of this 
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Haemodynamic Indices  Definition  
EDP, mmHg ECG-gated end-diastolic pressure 
ESP, mmHg Measured at left uppermost point of PV loop 
EDV, mL ECG gated end-diastolic volume 
ESV, mL Measured at left uppermost point of PV loop 
dP/dtmax, mmHg/sec Slope of peak maximum derivative of pressure change over time 
dP/dtmin, mmHg/sec Slope of peak minimum derivative of pressure change over time 
EDPVR, mmHg/mL ECG gated pressure to volume ratio 
ESPVR, mmHg/mL Left uppermost point of PV loop, pressure to volume ratio 
SV, mL EDV - ESV 
CO, L/min SV x HR 
EF, % SV/ESV x 100 
SW, mmHg.mL Area of PV loop 
PRSW, mmHg SW/EDV 
PVA, Joules PVA = SW+(0.5 xESP2/ ESPVR) 
SCI, mmHg/sec/mL dP/dTmax/EDV 
Tau, ms Time for dP/dt min to be reduced by 1/e  
Ea, mmHg/mL Ea = ESP/SV = (Heart Rate) Resistance = (HR) R. 
DTF, % Diastolic time/total time of cardiac cycle 
EDPVR beta Beta coefficient of EDPVR slope 
EDPVR alpha Alpha coefficient of EDPVR slope 
Ees Slope of the ESPVR line 
Table 2 The definitions and formulas of left ventricular (LV) haemodynamic variables 
Abbreviations: EDP End-Diastolic Pressure, ESP End-Systolic Pressure, EDV End-
Diastolic Volume, ESV End-Systolic Volume, EDPVR End-Diastolic Pressure-Volume 
Relationship, ESPVR End-Systolic Pressure Volume Relationship, SV Stroke Volume, 
CO Cardiac Output, EF Ejection Fraction, SW Stroke Work, PRSW Preload-
Recruitable Stroke Work, PVA Pressure Volume Area, SCI Starling Contractile Index, 
Ea Arterial Elastance, DTF Diastolic Time Fraction. 
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3.2.3.3 STANDARDISED CORONARY VARIABLES 
Coronary indices measured by SimpleWires: Simultaneous measurement of 
intracoronary pressure and blood flow velocities allows for the generation of multiple 
indices of haemodynamic assessment. Direct Measurements: Distal coronary pressure 
(Pd), proximal aortic (Pa) pressure, instantaneous peak velocity (IPV), mean coronary 
flow and the continuous ECG tracing are provided as direct inputs.  
Net coronary wave intensity (dI) and total wave intensity (dI+ and dI-) generation were 
also incorporated into SimpleWires software, the benefit of additional net wave 
intensity, defined as the product of incremental changes in local pressure and flow 
velocity, is that this is thought to more accurately reflect the impact of cardiac 
contraction and relaxation on coronary haemodynamics. The wave intensity analysis 
feature on SimpleWires, enables the observer to generate data on the six main coronary 
wave energies previously identified during the cardiac cycle.96 Calculation of wave 
energies has been previously described, in brief, the software provides the observer with 
wave areas, peaks and percentage. 
 
3.2.3.4 NOVEL SOFTWARE FEATURES 
A number of additional features not currently available to clinical researchers have been 
incorporated into the SimpleWires analysis software. These are broadly divided below 
into coronary wave intensity analysis and LV haemodynamic analysis tools. 
MECHANICAL DETERMINANTS OF CORONARY BLOOD FLOW 
118		
CWIA INCORPORATED FEATURES 
Pulse Wave Speed: 
This is a fundamental factor in cWIA determination as is calculated using the sum of 
squares method (SPc), which has been previously validated.97,201 However, this method 
has limitations in the context of hyperaemic intervention: the SPc underestimates wave 
speed under these conditions, thus overestimating magnitudes of the forward travelling 
compression wave and backward compression wave energies that arise during systole, 
potentially invalidating results.104 Cardiac therapeutic interventions frequently involve 
induction of vasodilatation and hyperaemia, thus require accurate estimation of pulse 
wave speed.101,202 The novel capability of this software is that it enables the wave speed 
value calculated at baseline to be applied to derivation of cWIA during hyperaemia, 
which is acceptable given that wave speed is not influenced by vasodilatation.  
Adaptive Savitzky-Golay Filter: 
 Differencing data results in noise in the signal, as cWIA is the product of two 
differences, this greatly increases signal noise; therefore the use of a Savitzky-Golay (S-
G) filter is crucial to cWIA.203 The acquired pressure and velocity signals are ensemble-
averaged over a few cardiac cycles and then smoothed using the Savitzky-Golay (S-G) 
filter to remove the acquisition noise and estimate the pressure and velocity time 
derivatives prior to WIA.97,204 S-G is a digital filter that can smooth datasets by 
increasing the signal-to-noise ratio without distorting the signal. The S-G filter 
calculates the least squares fit to a polynomial of order N to the data of frame-size F 
centered on a particular sample time t.203 Operator selection of such filters (a feature of 
all currently available cWIA analysis programmes) introduces marked inter- and intra-
observer variability. Recently, Rivolo et al. showed, using in-vivo human and animal 
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data that the pressure and velocity time derivatives are strongly sensitive to the S-G 
parameters chosen, which in turn markedly effects the areas and peaks of the main 
waves generated. The main reason for the variability observed in wave generation is the 
incapability of the S-G filter to deal with the different timescale features present in the 
velocity waveform, spanning from the relatively flat systolic plateau to the sharp early-
diastolic rise. An adaptive S-G filter algorithm automatically selects the optimal S-G 
filter parameters, smoothing the acquired pressure and velocity waveforms; the 
percentage error in the cWIA derived metrics post ensemble-averaging using the 
adaptive filter was found to be ≤ 10% for all levels of noise tested within physiological 
range. On validation in human and animal datasets, this technique improved robustness 
by a 60% reduction in variability in outcome in wave peak and area.196,197 Thus the 
adaptive S-G algorithm was integrated into the SimpleWires software as it removes 
operator bias, providing an accurate and standardised method to perform coronary WIA.  
LV PV INCORPORATED FEATURES 
In addition to instantaneous LV pressure and volume measurements, novel analytical 
tools were incorporated in the software to calculate additional parameters that do not 
currently feature on the CE marked software system that is commercially available. 
Single beat estimations of ESPVR and EDPVR curves:  
It is not easy to change loading conditions without provoking reflex changes in 
contractility of the heart in human subjects, therefore estimating contractility from a 
single beat is of prime importance.26 The novel software system incorporates single beat 
assessment of the end-diastolic pressure volume relationship (EDPVR) and end-systolic 
pressure volume relationship (ESPVR) curves (load independent measures of contractile 
function and passive diastolic properties), without the need for inferior vena cava 
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occlusion. Single beat estimation of the ESPVR slope (Ees) has been shown to be very 
accurate when compared to actual measured Ees in human and animal studies.205-207 The 
model applied in this software is that described by Shishido et al.206 The advantages of 
this model over others is that the time-varying elastance is approximated linearly using 
two functions, one for isovolumic contraction and one for the ejection phase; 
quantitatively correlating with contractility and loading conditions (r=0.9); generating 
an accurate estimation of Ees.206,207 
 
The end-diastolic pressure-volume relationship (EDPVR) can also be estimated from a 
single end-diastolic Pressure and Volume point. This method is based on the premise 
that overall EDPVRs share a common underlying shape; when a wide range of EDPVR 
slopes were normalised with scaling of LV volumes, all EDPVR slopes were identical 
and described by a common non-linear analytical expression with coefficient values that 
were reasonably well linked with the size of the heart such that: 
Equation 19       !"# = !! · !"#!" 
Where An = 282 mmHg and Bn = 2.79.208,209 This model was found to be applicable to 
normal and diseased hearts in humans; furthermore, the predicted error measured over a 
range 0-40mmHg EDP was <3mmHg.208 
 
Single beat estimation was performed from an ensemble average cardiac cycle (5 beats). 
 
Myocardial energetics: The time varying elastance was calculated as the instantaneous 
pressure-volume relationship through one cardiac cycle. The measurement of pressure 
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volume area (PVA) or total mechanical energy facilitates an understanding of the left 
ventricle in terms of myocardial energetics and efficiency. Pressure-Volume Area 
(PVA), the measure of total mechanical energy generated by ventricular contraction, 
was calculated as the sum of SW and elastic potential energy according to the following 
equation:193 
Equation 20 !"# = !"+ (!.!× !"#!!"#$%) 
 
The incorporation of arterial elastance (Ea) to this analysis software enables the 
observer to appreciate the ventricular-arterial interaction. This is calculated as the ratio 
of ESP to stroke volume. 
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3.3 RESULTS 
3.3.1 SIMULTANEOUS LV AND CORONARY MEASUREMENT IN-VIVO 
Subjects:  
Fifteen volunteers were selected to undergo baseline, simultaneous resting 
measurements. The measurements were performed in the cardiac catheter laboratory. 
Patients were included in the study if there were on the waiting list for outpatient 
coronary angiography. Subjects were excluded if they had LV impairment; significant 
comorbidities; arrhythmia; valvular heart disease; unstable angina or recent myocardial 
infarction. Patients provided written and informed consent for the study, which had 
local ethical approval.  
Protocol:  
8Fr femoral access site was used to introduce an 8Fr 80cm guide catheter to the aortic 
root, followed by intra-arterial heparin (70IU/kg). The hardware was set-up as described 
above and calibrated. The ComboWire was placed in the coronary artery and the 
pressure-volume loop catheter was placed in the left ventricle; recordings were 
performed for one minute at rest and on administration of intravenous adenosine 
(140mcg/kg/min) on commencement of infusion, for at least 90 seconds.  
3.3.2 SOFTWARE VALIDATION 
To assess the accuracy and reproducibility of the quantitative data generated by 
SimpleWire software analysis system it was compared against the commercially 
available CE marked software system ConductNT that was used as the gold standard.  
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Datasets:  
Data were acquired as per the above in-vivo protocol, on ConductNT software using the 
INCA. All fifteen datasets were analysed on both ConductNT and SimpleWires 
software analysis system (as described above). Datasets were considered acceptable if 
they: 1) had a steady baseline recording 2) more than 5 consecutive cardiac cycles were 
recorded at baseline with no ventricular ectopic beats identified. The exact same cardiac 
cycles were used for analysis of LV haemodynamic indices on both software 
programmes. PV loop variables were generated from the ensemble average of the five 
consecutive cardiac cycles.  
Statistical Analysis:  
Statistical analysis was performed using GraphPad Prism v7.0 (GraphPad Software Inc., 
CA). Quantitative data are expressed as mean±SD; data were assessed for normality of 
(Gaussian) distribution both graphically and by use of the Shapiro Wilk’s test. Paired t-
tests were used to establish the level of significance of differences between the two 
analytical software.  The Bland Altman test was used as a measure of statistical 
agreement between the matched data generated by the software analysis programmes; 
the difference of the paired measurements was compared against the mean of the 
measurements; P < 0.05 was considered statistically significant.  
Results:  
Table 3 summarises all the haemodynamic output variables from fifteen patients 
generated, the bias and 95% level of agreement. There was clinically acceptable 
agreement between the two software programmes; no statistically significant difference 
was demonstrated. Figure 50 demonstrates the Bland-Altman plots generated, there 
MECHANICAL DETERMINANTS OF CORONARY BLOOD FLOW 
124		
were no relationships identified between the differences and magnitudes of the 




Indices SimpleWires ConductNT P Value Bias  95% Limit of 
Agreement 
HR, bpm 67.5±14.3 67.3±14.1 0.7 0.2 -0.6 to 0.9 
EDP, mmHg 14.9±5.7 15.7±6.1 0.4 -0.8 -8.2 to 6.6 
ESP, mmHg 131.3±24.4 133.7±24.3 0.3 -2.4 -17.6 to 12 
EDV, mL 105.8±20.5 106.4±20.0 0.9 -0.6 -23.6 to 22.4 
ESV, mL 48.0±17.5 47.8±16.8 0.4 0.2 -3.4 to3.8 
dP/dtmax, mmHg/s 1307±272 1351±278 0.7 -44 -71 to -17 
dP/dtmin mmHg/s -1391±277 -1426±286 0.8 34.9 13.6 to 56.1 
EDPVR, mmHg/mL 0.155±0.08 0.143±0.081 0.5 0.01 -0.03 to 0.05 
ESPVR, mmHg/mL 3.2±1.3 3.2±1.3 0.6 -0.08 -0.025 to 0.8 
SV, mL 60.1±13.5 58.8±15.6 0.5 1.2 -21.3 to 23.7 
EF, % 61±12.5 64±9.4 0.4 -3.7 -24.0 to 16.5 
SW, mmHg.mL 7212±1931 7193±2191 0.5 18.8 -955 to 952 
SCI, mmHg/sec/mL 13.0±4.5 13.5±4.6 0.8 -0.5 -3.0 to 2.0 
PRSW, mmHg 69.2±21.2 69.2±20.4 0.5 -0.02 -7.0 to 7.0 
Table 3 Haemodynamic variables derived from the two software systems.  
Abbreviations: EDP End-Diastolic Pressure, ESP End-Systolic Pressure, EDV End-
Diastolic Volume, ESV End-Systolic Volume, EDPVR End-Diastolic Pressure-Volume 
Relationship, ESPVR End-Systolic Pressure Volume Relationship, SV Stroke Volume, 
EF Ejection Fraction, SW (External) Stroke Work, SCI Starling Contractile Index, 
PRSW Preload-Recruitable Stroke Work. 
 




Figure 50 Bland-Altman plots.  
Difference from the mean of major haemodynamic variables. 
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3.3.3 MECHANICAL DETERMINANTS OF CORONARY HAEMODYNAMICS 
This was an exploratory study examining the impact of myocardial properties on 
coronary haemodynamics. As wave intensity analysis has the ability to discriminate 
between forward and backward travelling waves in the coronary circulation, thus those 
arising proximally or distally respectively, the aim was firstly to determine the timings 
of coronary wave energies and ascertain their origin by investigating the temporal 
relationship between coronary wave energies and LV mechanical change through one 
cardiac cycle; furthermore as waves arising distally are believed to originate from 
change in myocardial properties, the second aim was to delineate the myocardial 
contribution to changes in coronary blood flow morphology. Following work by Krams 
et al, myocardial properties have been suggested as a mechanism behind the phasic 
nature of coronary blood flow and coronary systolic flow impediment. The theory 
behind this is that left ventricle can be seen as a continuum with LV elastance being 
transferred to the microvasculature.188 Thus increasing elastance would decrease 
systolic flow. Time varying elastance, Equation 4, first described by Suga et al, is 
discussed in detail in section 1.2.3.1 and used to describe the contractile properties of 
the ventricle by relating instantaneous LV pressure to volume through one cardiac 
cycle. 8 Although coronary blood flow has been examined as a function of E(t) in open 
chested dogs, this has never before been examined in humans. 190 Simultaneous 
coronary and instantaneous LV pressure and volume measurements allow this 
mechanism to be revisited and examined in more detail. 
Datasets:  
Data were acquired as per the above in-vivo protocol, datasets were considered 
acceptable if they were 1) simultaneous 2) high quality LV and coronary 
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haemodynamic tracings 3) absence of ectopic beats and 4) steady state recordings. 
Coronary wave energies and PV loop variables were generated from an ensemble 
average of 5 consecutive cardiac cycles. 
Statistical analysis:  
Due to heart rate variability between subjects, timings were non-dimensionalised. 
Statistical analysis was performed using GraphPad Prism v7.0 (GraphPad Software Inc., 
CA). Quantitative data are expressed as mean±SD; statistical comparison of quantitative 
data were performed using Student’s t-test. Simple linear regression analysis was used 
to evaluate the association between coronary wave energy timings with LV cardiac 
cycle events times; the results from different measurements were correlated using 
Pearson’s correlation coefficient. 
Results:  
A representative example of a 1-minute recording of simultaneous LV and 
intracoronary haemodynamic data at baseline is displayed in Figure 51. A typical 
example of the visual display of systemic and intra-coronary haemodynamic 
waveforms, mechanical events during one cardiac cycle defined as: end-diastole, 
dP/dtmax, end-systole, dP/dtmin and the accompanying coronary wave intensity 
analysis including net wave intensity, generated from the ensemble averaging of 5 
consecutive cardiac cycles, is shown in Figure 52. The timing of the cardiac cycle 
events and the initiation, peak and end of the four main coronary wave energies are 
shown in Table 4, and depicted graphically in Figure 53; end-diastole was defined as 
Time 0.  
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Figure 51. Simultaneous acquisition of coronary and left ventricular haemodynamics. 
This is a representative dataset; tracings show continuous ECG recordings, left 
ventricular pressure (LVP), left ventricular volume (LVV), distal coronary pressure 
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Figure 52. A representative example of ensemble averaged tracings. 
In the top panel, left ventricular (LV) pressure and volume in addition to distal coronary 
pressure and flow velocity are described over one cardiac cycle; time 0 is end-diastole, 
the first broken line denotes dP/dtmax, the solid line denotes end-systole and the second 
broken line is dP/dtmin. The middle panel shows the main backward and forward wave 
energies generate from the above coronary tracings. The bottom panel depicts net wave 
intensity (black).   
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Cardiac Cycle Event Time (ms) 
End-Diastole 6±8 
dP/dt max 76±26 
Start BCW 36±25 
Peak BCW 105±43 
End BCW 202±53 
Start FCW 69±29 
Peak FCW 117±34 
End FCW 158±41 
End-Systole 382±54 
dP/dt min 448±60 
Start BEW 376±61 
Peak BEW 464±113 
End BEW 581±71 
Start FEW 337±60 
Peak FEW 409±63 
End FEW 442±62 
Table 4 Timings of waves and cardiac cycle events. 
Abbreviations: BCW backward compression wave, FCW, forward compression wave, 
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Figure 53 Wave generation during the cardiac cycle. 
The black broken line represents end-systole, with standard deviation (red broken line) 
Abbreviations: Abbreviations: ED end-diastole, BCW backward compression wave, 
FCW, forward compression wave, BEW backward expansion wave, ES end-systole, 
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3.3.4 CORONARY WAVE ENERGIES AND EVENTS IN THE CARDIAC CYCLE 
Compression waves were seen to occur in what is traditionally known as systole and the 
expansion waves seen to occur in diastole. The backward travelling compression or 
pushing wave (BCW) drives an increase in coronary pressure but a decrease in coronary 
flow velocity, arising distally. This is the first wave seen and is initiated soon after end-
diastole (while the aortic valve is still closed) during the start of cardiac contraction; the 
BCW overlaps with dP/dtmax and reaches its peak immediately after dP/dtmax, the 
BCW ends soon after the aortic valve opens and LV ejection commences. The 
maximum rate of pressure increase in the ventricle (dP/dtmax) coincides with aortic 
valve opening, at the onset of aortic pressure rise the forward travelling compression 
wave (FCW) commences. The FCW is a forward travelling wave that increases pressure 
and velocity, arising proximally in the coronary artery; this peaks at mid-systole, ending 
at end-systole. The forward expansion wave, or suction wave, reduces pressure and 
reduces velocity in the coronary artery arising proximally. The onset of the FEW occurs 
just before end-systole, after peak LV and aortic pressure; although the myocardium is 
still contracting, the FEW coincides with the drop in aortic pressure; the FEW peaks 
then troughs following aortic valve closure.  Interestingly the forward travelling waves, 
believed to originate from the aorta only start once LV pressure has exceeded diastolic 
pressure (FCW) and end once LVP falls below diastolic aortic pressure (FEW), even 
though the aortic valve has closed, this is clearly seen in Figure 54 where the wave 
durations are described relative to the PV loop, the forward waves start and stop at 
exactly the same LV pressure. The backward travelling expansion wave (BEW), arising 
distally, reduces pressure but increases coronary velocity; the initiation of the BEW 
coincides with end-systole, the point of maximal LV activation, following which, cross-
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bridge uncoupling occurs and LV relaxation commences. The BEW continues beyond 
the FEW reaching a peak at the maximum rate of pressure decay in the LV (dP/dtmin). 
The BEW tends to follow LV pressure drop, and terminates when LV pressure is at 
equipoise, this occurs after mitral valve opening, because although the ventricle is 
filling, the LV pressure continues to drop. Interestingly, the backward waves appear to 
be delimited by aortic valve opening and closure. Interestingly, we note for the first 
time that forward travelling waves are delimited by diastolic blood pressure and the 
backward travelling waves are delimited by the aortic valve; overall, the wave energies 
closely follow the mechanical events described in the cardiac cycle. This is depicted 
graphically in Figure 53 through one cardiac cycle and in Figure 54 as a pressure 
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Figure 54 Cardiac cycle events and wave energies described on the PV loop. 
Abbreviations: LVP left ventricular pressure, LVV left ventricular volume, ED end-
diastole, ES end-systole, BCW backward compression wave, FCW, forward 
compression wave, BEW backward expansion wave, FEW forward expansion wave. 
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3.3.5 CORRELATIONS BETWEEN TIMINGS OF WAVE GENERATION AND 
MECHANICAL EVENTS 
Data from the fifteen patients were analysed. Cardiac cycles were normalised to adjust 
for heart rate variability between patients such that the duration of each cycle became 
one second (cardiac cycle duration multiplied by 60, divided by the heart rate). The 
timing of the initiation of the FCW correlated with dP/dtmax time (69±29 versus 76±26 
milliseconds; r = 0.8, P <0.001). The timing of the initiation of the BEW correlated with 
end-systolic time (382±54 versus 376±61 milliseconds; r = 0.9; P <0.001). The time of 
peak BEW correlated with dP/dtmin (464±113 versus 448±60 milliseconds; r = 0.8, P 
<0.001), Figure 55. 
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Figure 55. Correlations between cardiac cycle events and wave energy.  
Abbreviations: FCW, forward compression wave, BEW backward expansion wave. 
Initiation FCW-dP/dtmax Time 
Initiation BEW-End-systolic Time 
Peak BEW-dP/dtmin Time 
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3.3.6 MECHANICAL DETERMINANTS OF CORONARY BLOOD FLOW 
In Figure 56, a representative example of the time-varying elastance curve is 
demonstrated; and the relationship between coronary pressure and coronary blood flow 
velocity and instantaneous elastance both at rest and during steady-state hyperaemia. As 
expected time varying elastance rises and falls and reaches a peak E(max); graphical 
evaluation of mean coronary blood flow velocity plotted against LV elastance 
demonstrate maximum systolic flow impediment at two points during systole, the first 
is just prior to aortic valve opening, and the second is at peak LV elastance; when 
elastance is at its maximum and minimum, coronary blood flow velocity appears 
uniquely related to elastance. Graphical evaluation of mean coronary pressure plotted 
against elastance demonstrates an inverse relationship to that of coronary blood flow 
velocity. On abolition of microvascular resistance, on administration of adenosine, 
further graphical evaluation was performed during hyperaemia. The time varying 
elastance curve peaks at the same point, but the E(max) is greater; mean coronary blood 
flow velocity plotted against LV elastance demonstrates that the course of coronary 
blood flow in systole is almost identical to that in diastole in the absence of 
autoregulatory processes, suggesting in the absence of autoregulation, the myocardium 
acts as a continuum, with the coronary microvasculature vulnerable to transmission of 
myocardial contractile properties; as expected, peak coronary blood flow velocity 
increases. Mean coronary pressure plotted against elastance, demonstrates a similar 
relationship to that at rest; however, as expected peak and trough pressures are lower 
than at baseline. 
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3.4 DISCUSSION  
This study utilises novel analytical software to assess simultaneous coronary and 
haemodynamic waveforms in human subjects. This is the first time that simultaneous 
LV pressure-volume data and coronary haemodynamic signals have been acquired in-
vivo, in human subjects, and analysed to this degree of accuracy. This study 
demonstrates that it is possible to measure simultaneous LV and coronary 
haemodynamics at high resolution in the cardiac catheter laboratory setting. The main 
findings of this study can be summarised as follows: 1) Forward travelling coronary 
wave energies arise only when LV pressure exceeds aortic diastolic pressure; 2) 
backward travelling coronary wave energies are generated in the presence of aortic 
valve closure; 3) the maximum rate of change in intra-cavity pressure only occurs 
during the isovolumic phases of the cardiac cycle 4) the timing of wave energies closely 
follow cardiac cycle events; 5) LV elastance is related to coronary blood flow velocity 
when LV elastance is at its maximum and minimum 6) in the absence of autoregulation, 
coronary blood flow velocity is directly, inversely related to LV elastance.  
 
One of the major aims of this study was to describe the temporal relationship between 
coronary wave energy timings (derived from wave intensity analysis) and the 
mechanical events that occur throughout one cardiac cycle from end-diastole to end-
systole. Previous studies have attempted to describe cWIA in term of LV mechanical 
changes; the measurement of instantaneous LV pressure and volume however are 
fundamental parameters when describing myocardial properties, the absence of which, 
limits conclusions that may be drawn from the cardiac-coronary interaction. The unique 
ability of this work to simultaneous measure myocardial properties and coronary 
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haemodynamics has enabled demonstration of the relationship between the two, 
building on prior work performed in this area. 
 
The relationship between coronary wave energies and the cardiac cycle 
Performing simultaneous measurements not only allows temporal alignment of 
coronary with LV haemodynamics, but also enables visualisation of coronary wave 
energies as part of the pressure-volume loop, from which a number of physiological 
derivations can be made. Conceptually forward travelling waves are believed to arise 
from the aorta, proximal to the coronary artery. This study demonstrates that the origin 
of these waves is likely to be far more complex; they are a result of the interaction 
between the left ventricle and the aorta, our study shows that a minimum ventricular 
pressure is required to generate the forward travelling compression wave; this is a flow-
accelerating wave, generated on aortic valve opening, the start of which coincides with 
and has shown to correlate with dP/dtmax, it continues until aortic and LV pressure 
reach a peak in systole, this coincides with the ejection phase and aortic valve opening. 
We’ve shown this to initiate when LV pressure is equal to and exceeds diastolic aortic 
pressure. Following ejection, LV and aortic pressure decline, there follows a period of 
isovolumic relaxation accompanied by a forward travelling expansion (suction wave), 
this wave decelerates flow, arising immediately after peak LV and aortic pressure, 
continues beyond aortic valve closure until the minimum cut-off of diastolic pressure is 
reached, which is just prior to dP/dtmin. Diastolic aortic pressure represents the limit at 
which the LV can induce changes in aortic blood flow and therefore drive transmission 
of forward travelling wave energies.  
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The backward travelling waves have been shown in this study to be delimited by aortic 
valve closure; suggesting the generation of these waves are also as a result of LV-aortic 
interaction, not purely distal microcirculatory events. The backward travelling waves 
follow the pattern of LV pressure rise and fall, and are absent in the presence of zero 
LV pressure. The backward compression wave (BCW) arises soon after LV 
depolarisation, the generation of which overlaps with dP/dtmax, however, this wave 
terminates on aortic valve opening. The initiation of the backward expansion wave 
(BEW) coincides with end-systole, unlike the forward expansion wave, which occurs 
once LV and aortic pressure has peaked, the BEW occurs at the point of maximal LV 
activation, following which, cross-bridge uncoupling and LV relaxation occurs, 
suggesting that backward expansion wave is more related to transmission of myocardial 
properties than intra-cavity LV or aortic pressure alone. The BEW peak coincides with 
dP/dtmin, then continues through diastole, beyond mitral valve opening, although the 
ventricle is filling, the myocardium is continuing to relax and the LV pressure continues 
to drop; the BEW continues until the LV is in equipoise, and LVP is at a minimum. 
 
This study is in agreement with investigations previously performed in humans by 
Davies et al, they examined the origin of coronary wave energies and their relationship 
to LV mechanical events, furthermore, the findings in relationship to temporal 
alignment of events is consistent with animal work in this area.96,107 The addition of 
simultaneous LV PV loop measurements places this study in a unique position, PV loop 
measurements enable accurate determination of cardiac cycle events: end-systole, end-
diastole, dP/dtmax and dP/dtmin, enabling validation of hypotheses and an increased 
understanding of the origin of coronary wave energies, building on work performed by 
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Rolandi et al.100 The current knowledge is based on the premise that backward waves 
originate from the distal microcirculation and forward waves originate from the 
aorta;96,100,101 this study demonstrates for the first time, that although coronary wave 
energies have proximal and distal origins, their generation is dependent on the 
ventricular-arterial interaction, suggesting the mechanisms behind wave generation may 
be far more complex than initially understood. 
 
LV elastance describes myocardial properties through one cardiac cycle, coronary 
pressure increases as LV elastance increases; conversely, coronary blood flow velocity 
decreases as LV elastance decreases. We demonstrate that at rest coronary blood flow 
velocity is not solely dependent on LV elastance, consistent with previous animal work 
performed in open chested dogs;190 however peak LV elastance coincides with maximal 
systolic flow impediment, this is the basis behind work performed by Sun et al., they 
related systolic flow impediment to the contractile properties of the ventricle.107 The 
unique relationship between the two is maintained during hyperaemic states; the benefit 
of this technology means that we have demonstrated for the first time, that in the 
absence of autoregulation, coronary blood flow is closely dependent on LV elastance; 
the pattern of systolic flow and diastolic flow through one cardiac cycle become similar 
suggesting that on abolition of microvascular resistance, the myocardium acts as a 
continuum thus transmitting forces to the microvasculature; this is consistent with 
previous work performed by Krams et al.188 
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3.5 LIMITATIONS 
The data were analysed offline and acquired using PV loop analytical software, the 
major limitations of this method of acquiring coronary data is the absence of direct 
recording, with electronic routing of coronary haemodynamics into the INCA; this 
imposed a post-processing delay on the data, however, this was calculated and adjusted 
for. The next step in this software development involve developing SimpleWires into an 
online tool, capable of real-time acquisition; the aims are to integrate the software into 
the INCA, although currently limited by the hardware, which requires further 
development. LV elastance was calculated on the premise that V0 was zero, in the 
absence of changes in LV contractility and relaxation however, this was 
inconsequential. This was an exploratory physiological to enhance our understanding of 
the myocardial-coronary interaction. 
3.6 CONCLUSIONS 
Novel analytical software was developed to enhance understanding of the interaction 
between coronary haemodynamics and mechanical changes during the cardiac cycle. 
The technology used enabled temporal alignment of coronary wave energies with 
cardiac cycle events and facilitated an understanding of the impact of instantaneous 









4 THE EFFECTS OF DYNAMIC EXERCISE ON 
MYOCARDIAL SYSTOLIC AND DIASTOLIC 
FUNCTION: EXERCISE-INDUCED 
ISCHAEMIA VERSUS CONTROL GROUP 
COMPARATOR 
INTRODUCTION 
Stable angina, often referred to as angina of effort, has been recognised for over two 
centuries. Induction of ischaemia leads to a cascade of left ventricular haemodynamic 
effects; these however depend on the technique used to provoke it. The effect of 
exercise-induced ischaemia on left ventricular haemodynamics has not been extensively 
studied. As most episodes of ischaemia in patients with coronary artery disease are 
provoked by exercise, the aim of this work was to identify the precise haemodynamic 
changes incurred by exercise-induced ischaemia by studying the interaction between the 
myocardium, coronary arteries and systemic vasculature and comparing these to 
patients without ischaemia. 
 
METHODS 
Sixteen patients (6 control, 10 ischaemia) underwent invasive cardiac catheterisation 
with left ventricular pressure volume loop and invasive coronary assessment using dual-
sensor pressure-flow wire. Patients exercised using a supine cycle ergometer.  
 
MYOCARDIAL SYSTOLIC AND DIASTOLIC FUNCTION ON EXERCISE 
145		
RESULTS 
At low impact, exercise demonstrated a beneficial effect in both groups, but adversely 
affected haemodynamic variables in patients with coronary artery disease at the onset of 
ischaemia: end-diastolic (90±28 versus 109±31 mL; P<0.05) and end-systolic volumes 
(39±14 versus 71±31 mL; P<0.001) significantly increased, with overall decrease in 
ejection fraction (57±19 versus 36±15%; P<0.001) and cardiac output compared to 
control group (7±2.3 versus 4.5±1.9; P<0.05). Demand ischaemia led to a rightward 
shift in end-systolic and end-diastolic pressure volume relations. The ventricular-arterial 
interaction was adversely affected with an increase in systemic vascular resistance seen 




This study delineates the changes that occur with demand ischaemia during dynamic 
exercise in humans. A biphasic response to exercise was seen in patients with 
significant coronary artery disease: low impact exercise exhibiting a beneficial effect on 
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4.1 INTRODUCTION 
Stable angina, often referred to as angina of effort, has been recognised for over two 
centuries. 134 The principal cause of which is luminal narrowing of the epicardial 
coronary arteries. During effort angina, adaptations in coronary microvascular 
resistance are exhausted in the presence of a coronary stenosis, limiting the necessary 
increase in coronary blood flow in the face of increased oxygen consumption.121,210 
Induction of ischaemia leads to a cascade of left ventricular haemodynamic effects; this 
complex cardiac-coronary interaction is poorly understood.211 Diastolic pressures 
frequently increase dramatically during ischaemia and have attracted much 
attention.145,149,155,212 Changes in left ventricular diastolic function have been shown to 
be of clinical importance; experimental studies have demonstrated that ischaemia 
induced diastolic abnormalities often precede the development of systolic abnormalities 
and resolve more slowly on resolution of the ischaemia.213,214 Late and early diastolic 
changes suggest a number of factors are in operation, including changes in compliance 
reflective of the late diastolic phase, and early diastolic pressure change reflecting 
pressure decay from preceding systole. The left ventricular diastolic pressure-volume 
relationship changes when the heart is made ischaemic; the particular response of the 
left ventricular diastolic pressure volume relation has been thought to depend on how 
ischaemia is induced. When induced by rapid pacing in the presence of critical coronary 
stenosis (demand ischaemia), the diastolic pressure-volume relationship shifts 
upwards.125,155,215 When ischaemia is induced by coronary occlusion, (supply 
ischaemia), the relationship shifts rightwards or downward.125,153 However, recent 
studies in humans and earlier preclinical work have shown that an upward shift can also 
occur with coronary occlusion.149,150 Furthermore, a rightward shift has also been 
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demonstrated with demand ischaemia, although the direction of the shift may be more 
dependent on left ventricular contractility than the mechanism of ischaemia.155 However 
the haemodynamic accompaniments of ischaemia are variable, and depend on the 
technique used to provoke it; as most episodes of ischaemia in patients with coronary 
artery disease are provoked by exercise, they may be accompanied by different 
haemodynamic changes to those provoked by pacing. The effect of exercise-induced 
ischaemia on left ventricular haemodynamics has not been extensively studied. The 
limitation of previous work examining left ventricular pump properties and the coronary 
vasculature is the inability to convey the interaction between the components of the 
system. To identify the precise haemodynamic changes incurred by exercise-induced 
ischaemia, we applied left ventricular pressure-volume loop assessment with invasive 
measurement of distal coronary pressure and flow velocity in patients with ischaemic 
heart disease causing angina and in a group of patients without ischaemia; the aim was 
to explain the pathophysiological response of ischaemia by way of the interaction 






MYOCARDIAL SYSTOLIC AND DIASTOLIC FUNCTION ON EXERCISE 
148		
4.2 METHODS 
4.2.1 STUDY POPULATION 
We included consecutive patients scheduled for routine coronary angiography ± 
proceed to angioplasty at St Thomas’ Hospital, London, United Kingdom. Patients were 
selected for the study if they had symptoms of exertional angina; angiographic criteria 
for inclusion was one or more epicardial coronary artery with > 50% diameter stenosis. 
Exclusion criteria were unstable symptoms, previous myocardial infarction, coronary 
artery bypass graft surgery, impaired left ventricular function, severe co-morbidities, 
valvular heart disease, atrial fibrillation, or the inability to undertake exercise. Patients 
with a left main stem stenosis, severe multi-vessel coronary disease or chronic total 
occlusions were not included. Oral nitrate preparations, calcium channel blockers and 
beta-blockers were stopped at least 48 hours before the procedure. All patients 
underwent written, informed consent prior to partaking in the study. This study received 
approval from the National Research Ethics Committee (09/H0802/39). 
 
4.2.2 CATHETER LABORATORY PROTOCOL AND INSTRUMENTATION 
A specially adapted supine cycle ergometer (Ergosana, Germany) was attached to the 
catheter laboratory table. Cardiac catheterisation was performed via the right radial 
artery using a standard 5Fr arterial sheath. Weight adjusted heparin was administered 
(70IU/kg) intra-arterially. Right and left coronary angiograms were then taken using 
standard diagnostic catheters. Intracoronary nitrates were not used. The 5Fr arterial 
sheath was exchanged over a long wire for a 7.5Fr shortened sheathless guide (Asahi, 
Vascular Perspectives), which was introduced into the aortic root; see section 2.6.1.1 for 
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details on guide catheter alteration. A dual-sensor pressure velocity 0.014” coronary 
guide wire (Combowire, Volcano Corp, San Diego, CA) was then connected to the 
Combomap console (Volcano Corp) and was delivered through the sheathless guide; 
auxillary inputs were electronically routed to the Inca (CD Leycom) to enable for 
simultaneous acquisition. The Combowire pressure signal was normalised against the 
fluid filled catheter signal at the tip of the guide.80,101 The guide catheter was then 
inserted into the coronary ostium and the Combowire advanced distal to the stenosis in 
the target coronary artery (Figure 57), full details regarding ComboWire calibration are 
in section 2.3.2. The guide catheter was then disengaged and left ventricular pressure 
and volume measurements were assessed with a 4Fr conductance catheter (CC) system 
(CD Leycom, The Netherlands). This flexible pigtail catheter has a solid-state pressure 
sensor and electrodes situated at regular intervals; continuous left ventricular volumes 
are calculated by measuring time-varying elastance; this technique has been previously 
validated and applied in the study of cardiac disease states.184,185,193,194 The CC is 
connected to a signal processor (Inca, CD Leycom, The Netherlands) and delivered to 
the ventricular cavity across the aortic valve via the sheathless guide. Correct 
positioning was confirmed by fluoroscopy and conductance signals. Volume calibration 
was performed by left ventricular (LV) volume measurements obtained from 
transthoracic three-dimensional echocardiography.193 Full details regarding calibration 
can be found in section 2.2.3.2. Optimisation of the coronary Doppler velocity traces 
and LV pressure-volume measurements was performed.  
4.2.3 EXERCISE PROTOCOL 
Baseline measurements were taken before the patients underwent one period of 
exercise. This protocol was a standardised incremental programme, starting at 30 W and 
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increasing incrementally by 20 W per minute at a cadence of 60 revolutions per minute. 
Exercise was continued until any of the following occurred: 1) ST segment depression 
>3mm; (2) maximal age-related heart rate; (3) severe chest pain; (4) physical exhaustion 
and (5) arrhythmia. Continuous surface ECG recordings, left ventricular haemodynamic 
tracings, and coronary pressure and flow velocity signals were recorded throughout the 
intervention. After the exercise protocol, the patients underwent physiological 
assessment of the coronary stenosis with intravenous adenosine and underwent 
angioplasty where necessary.216 
 
Figure 57 Conductance catheter and ComboWire position (fluoroscopy)  
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4.2.4 DATA ACQUISITION AND ANALYSIS 
Coronary pressure and flow velocity signals were sampled at 200Hz and acquired 
online on the Combomap system (Volcano Corp); the coronary signals were 
electronically routed to the Inca (CD Leycom) to facilitate real-time simultaneous 
acquisition and visualisation of all haemodynamic variables.198,199 CC measurements 
were acquired online using the dedicated data acquisition and analysis software 
(Conduct NT, version 3.18.1 CD Leycom); recording was continuous throughout the 
exercise protocol. Coronary and LV data were imported into the custom made 
SimpleWires programme (King’s College London, United Kingdom) for offline 
analysis.  Ten consecutive cardiac cycles were selected from baseline and each minute 
of exercise and into recovery. Peak exercise was determined by maximal power output; 
ischaemia was identified by ST segment depression. Ensemble averages of the cardiac 
cycles were used in further analysis and presented as baseline, 50% peak and peak. 
 
Mean coronary blood flow velocity (U) and distal coronary pressure (Pd) were 
determined from the Doppler signal and high-fidelity pressure signal respectively, distal 
to the coronary stenosis. Wave intensity analysis (WIA) explains phasic flow in terms 
of a series of wave fronts that underlie the changes in coronary pressure and flow 
velocity in the coronary arteries.97 WIA enables separation of the local net waveform in 
the coronary artery into forward (arising proximally) and backward (arising distally) 
travelling components; thus WIA is a powerful tool for investigating cardiac-coronary 
interactions and has been used previously to interpret clinical data.96,101,202 Adjustment 
for the non-physiological time-delay between the digitally archived signals (coronary 
pressure and velocity, 55ms; coronary and left ventricular pressure; 88ms) was 
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performed, see section for 3.2.2 details.101,198 Time derivatives were obtained after 
smoothing the raw signals using an adaptive Savitzky-Golay filter; the adaptive filter 
algorithm has been shown to improve WIA robustness, thus providing an accurate 
standardised approach to coronary WIA.192,196 Net wave intensity was performed and 
normalised to the sampling rate and separation into forward and backward components 
was performed using the single–point technique.97,201 Because coronary blood flow was 
being examined during exercise hyperaemia, baseline pulse wave velocity was 
implemented for WIA determination during exercise to account for limitations in the 
single-point technique during hyperaemia.104 
 
CC measurement allows for acquisition of instantaneous LV volumes and pressure. Left 
ventricular conductance volumes (EDV, ESV) were calculated at the maximum rate of 
LV pressure rise (dP/dTmax) and pressure decay (dP/dTmin); stroke volume was 
calculated as the difference in these volumes. In addition to instantaneous LV volumes 
and pressure, the software calculates load-independent parameters of LV 
contractility.217 The end-systolic PV relationship (ESPVR) represents the ratio of LV 
pressure to LV volume at the end of ventricular systole (uppermost left corner of the PV 
loop). The Starling contractile index (SCI) is calculated as the maximal rate of pressure 
change over time during isovolumetric contraction (dP/dTmax) normalised to end-
diastolic volume (EDV). LV stroke work (SW) was calculated as the area of the PV 
loop; preload-recruitable stroke work (PRSW) was calculated by normalising the SW to 
EDV. LV stroke work was calculated as the product of peak LV peak systolic pressure 
and stroke volume.193,218 Pressure volume are (PVA) a measure of total mechanical 
energy generated by ventricular contraction, was calculated as the sum of stroke work 
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and elastic potential energy see Equation 20. Systemic vascular resistance was 
calculated as the ratio between the pressure drop across the vascular bed and the cardiac 
output and decribed as Wood units (mmHg.min/L). End-diastolic pressure volume 
relations (EDPVR) were performed from single-beat estimations, previously validated 
in humans.208 The slope of ESPVR was calculated using the single beat method (Ees), 
shown to accurately reflect acute inotropic change, with minimal influence from loading 
conditions.205 Arterial elastance (Ea) was calculated as the ratio of end-systolic pressure 
(ESP) to stroke volume (SV) to assess the impact of arterial load on the ventricle. 37 The 
ventricular-arterial interaction was described as the ratio of Ea: Ees where Ea is a 
measure of net arterial load and Ees is a load-independent measure of LV contractility, 
ESPVR was used as a surrogate for Ees. Optimal efficiency is achieved when the ratio 
of Ea: Ees=1, in failing hearts this has been shown to be elevated.37,40,128 
4.2.5 STATISTICAL ANALYSIS 
Statistical analysis was performed using GraphPad Prism v7.0 (GraphPad Software Inc., 
CA). Quantitative data are expressed as mean ± SD; categorical variables are described 
as proportions and percentages. Data were assessed for normality of (Gaussian) 
distribution both graphically and by use of the Shapiro-Wilk normality test. Baseline 
characteristics were compared using unpaired t-test for normally distributed data and 
Mann-Whitney U for those without normal distribution; categorical data (two nominal 
variables) were compared by use of the Fisher exact test. Statistical comparison of serial 
haemodynamic measurements (quantitative data) of normal distribution were performed 
using a repeated measures two-way ANOVA with comparison to baseline and the 
previous step, adjustment for multiple comparisons were performed using the 
Bonferroni correction to generate adjusted P values. A P value < 0.05 was considered 
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statistically significant for all tests. Results from different measurements of normal 
distribution were correlated using the Pearson correlation coefficient.219 
4.3 RESULTS 
Between April 2014 and May 2016, thirty patients were screened and twenty-nine 
consented into the study. Figure 58 demonstrates the flow of patients in the study. 
Sixteen patients successfully completed the study protocol. Reasons for exclusion were 
as follows: no significant coronary disease (4), three-vessel coronary disease requiring 
coronary artery bypass graft surgery (2) inability to deliver the conductance catheter 
into the LV (4); technical inability to perform pressure-volume measurements (1); guide 
catheter-related complication prior to taking research measurements (1); access site 
crossover to right femoral approach (1). Full background demographics and procedural 
details in patients with and without exercise-induced ischaemia are shown in Table 5. 
There were no significant differences in baseline characteristics between the two groups.  
Invasive pressure-volume loop acquisition was performed in all patients; coronary 
physiology measurements were performed in thirteen patients and wave intensity 
analysis was performed in twelve patients; of the thirteen patients, simultaneous data 
were obtained in eight, and sequential coronary and LV physiological measurements 
were obtained in five, Figure 58.  
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Figure 58 Patient flow diagram.  
Abbreviations: 3VD three-vessel disease, LV left ventricle, Pd distal coronary pressure, 
PV pressure-volume loop, cWIA coronary wave intensity analysis. 
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Table 5. Baseline demographics and procedural details of study participants.  
Categorical data are expressed as counts and percentages (n/N). Quantitative data that is 
normally distributed is described as mean +/- standard deviation; quantitative data that 
is not normally distributed is described as median and interquartile range (IQR). 
Abbreviations see xvi. 
 
Patient Demographics Total (16) Control (6) Ischaemia (10) P 
Male sex 13/16 (81%) 6/6 (100%) 7/10 (70%) 0.25 
Age, years 66.9±10.6 65.5±9.2 67.7±11.7 0.70 
Height, cm 167.9±8.5 168.5±3.9 167.6±10.4 0.84 
BMI kg/m2 29.1±4.4 31.6±4.6 27.5±3.7 0.07 
Previous PCI 8/16 (50%) 4/6 (67%) 4/10 (40%) 0.61 
Previous MI 3/16 (19%) 1/6 (33%) 2/10 (20%) >0.99 
LVEF, % 57±8 58±6 56±9 0.64 
Diabetes mellitus 9/16 (56%) 4/6 (67%) 5/10 (50%) 0.63 
Hypertension 13/16 (81%) 5/6 (83%) 8/10 (80%) >0.99 
Dyslipidemia 14/16 (88%) 6/6 (100%) 8/10 (80%) 0.50 
Family History 10/16 (63%) 4/6 (67%) 6/10 (60%) >0.99 
Smoking history 11/16 (69%) 4/6 (67%) 7/10 (70%) >0.99 
Current Medications     
Βeta-blockers 10/16 (63%) 4/6 (67%) 6/10 (70%) >0.99 
Nitrates 4/16 (25%) 2/6 (33%) 2/10 (20%) 0.60 
Statins 13/16 (81%) 6/6 (100%) 7/10 (70%) 0.25 
ACEi 10/16 (63%) 3/6 (50%) 7/10 (70%) 0.61 
Aspirin 14/16 (88%) 5/6 (83%) 9/10 (90%) >0.99 
Clopidogrel 11/16 (69%) 4/6 (67%) 7/10 (70%) >0.99 
Procedural details     
Diseased vessels  2 (1 to 2) 1 (1 to 1) 2 (2 to 3) <0.01 
Hyperaemic Pd/Pa 0.77 (0.62 to 0.88) 0.92 (0.87 to 0.97) 0.62 (0.6 to 0.75) <0.01 
LAD/Cx/RCA* 8/2/6 3/1/2 5/1/4 - 
Duration (mins) 97 (84 to 111) 97 (88 to 102) 97.5 (84 to 117) 0.72 
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4.3.1 EFFECT OF EXERCISE ON HAEMODYNAMICS AT THE ONSET OF 
ISCHAEMIA 
The haemodynamic effects of exercise in patients with preserved left ventricular 
function with and without functionally significant coronary artery disease are shown in 
Table 6. Functional significance of coronary artery disease was determined at the end of 
the study protocol following adenosine administration with an FFR<0.8; coronary artery 
disease with a resting Pd/Pa measurement of <0.8 and angiographically >70% stenosis 
was considered functionally significant and intravenous adenosine was not 
administered.216 At low impact, exercise demonstrated a beneficial effect in both 
groups, but adversely affected haemodynamic variables in patients with coronary artery 
disease at the onset of ischaemia. In both groups, exercise significantly increased heart 
rate, end-diastolic and end-systolic pressure, dP/dtmax and dP/dtmin (Figure 59). 
Compared with baseline values, end-diastolic (90±28 versus 109±31 mL; P<0.05) and 
end-systolic volumes (39±14 versus 71±31 mL; P<0.001) were significantly increased 
in the group with ischaemia at peak exercise, this resulted in a decrease in ejection 
fraction (57±19 versus 36±15%; P<0.001); this did not occur group without ischaemia. 
Furthermore, at peak exercise, cardiac output dropped in the ischaemia group but 
continued to increase and was significantly higher in the control group (7±2.3 versus 
4.5±1.9; P<0.05), Figure 60.  
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Figure 59 Percentage change in haemodynamic variables. 
In the control and ischaemia groups at peak exertion compared to baseline; *P< 0.05 
compared to baseline. 
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The maximum cardiac power output, measured in watts, increased in both groups, and 
did not significantly differ between the groups. Compared to baseline, stroke work (the 
external work performed by the heart) significantly increased in the control group 
(7453±2794 versus 9074±3294 mmHg.mL; P<0.05) but not in the ischaemia group. 
Compared to baseline, pressure volume area (the sum of external stroke work and 
potential energy) significantly increased in both the control group (1.4±0.4 versus 
1.6±0.5 Joules; P<0.05) and the ischaemia group (1.2±0.4 versus 1.4±0.4 Joules; 
P<0.001). The ratio of stroke work to pressure volume area (a marker of ventricular 
efficiency) remained unchanged in the control group but significantly decreased at the 
onset of ischaemia in the group with significant coronary artery disease (71±15 versus 
51±16%; P<0.001) and at peak exercise was significantly lower than the control group 
(51±16% versus 75±10%; P<0.05). 
 
At 50% maximal workload, contractility (PRSW) increased in both groups compared to 
baseline (control group 82±20 versus 70±20 mmHg, P<0.05; ischaemia group 83±23 
versus 68±15 mmHg, P<0.05), Figure 60; but at maximal workload, contractility 
decreased in the group with significant coronary artery disease at the onset of ischaemia 
(59±24 versus 83±23 mmHg; P<0.001). At 50% maximal workload, passive diastolic 
function (beta coefficient of end-diastolic pressure volume relationship), improved in 
both groups (control: 5.9±0.3 versus 5.5±0.5, P<0.001; ischaemia: 5.9±0.1 versus 
5.1±0.2, P<0.001) compared to baseline, this continued to improve in the control group 
at peak exercise (5.5±0.5 versus 5.1±0.2; P<0.05) but not in the ischaemia group. 
Active diastolic relaxation, measured by Tau, showed a numerical reduction in both 
groups but this did not reach significance. 
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During exercise in the control group of patients, without functionally significant 
coronary artery disease and preserved left ventricular function, a rightward shift was of 
the PV loop was seen, accompanied by an upward shift in the end-systolic pressure 
volume relation (ESPVR), Figure 61. In patients with significant coronary artery 
disease, on initiation of exercise, an upward shift of the EDPVR was demonstrated with 
a leftward shift of the ESPVR. On continued exercise, at the onset of ischaemia, a 
profound rightward shift was demonstrated of both the EDPVR and ESPVR (relative to 
both initial exercise and baseline), accompanied by a reduction in the area of the 
pressure-volume loop (Figure 61). 
4.3.2 THE VENTRICULAR-ARTERIAL INTERACTION IN THE PRESENCE OF 
SIGNIFICANT CORONARY ARTERY DISEASE 
An increase in vascular stiffness was demonstrated at peak exercise in the cohort of 
patients with ischaemia compared to the control group. Arterial elastance (Ea), which is 
a component of lumped mean and pulsatile load to the left ventricle increased at peak 
exercise compared to baseline in the ischaemia group (2.9±1.0 versus 5.5±2.9 
mmHg/mL; P<0.001), driven by the increase in end-systolic pressure and a reduction in 
stroke volume in the former, Figure 60. Systemic vascular resistance (SVR) was 
significantly higher at peak exercise in the ischaemia group compared to the control 
group (44±18 versus 24±17 mmHg.min/L; P<0.05). These changes in the ischaemia 
group adversely affected the ventricular-arterial interaction; the ratio of Ea to end-
systolic elastance increased in the ischaemia group (0.8±0.3 versus 2.6±0.8; P<0.05) 
and was significantly higher than the control group at peak exercise (2.6±0.8 versus 
0.7±0.4; P<0.05). 
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Figure 61 Representative examples of changes in the pressure-volume loop. 
At the onset of exercise in patients with and without significant coronary artery disease. 
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4.3.3 RELATIONSHIP BETWEEN CORONARY BLOOD FLOW VELOCITY 
AND DIASTOLIC TIME FRACTION IN ISCHAEMIA 
Coronary haemodynamic changes are summarised in Table 7. Representative examples 
of haemodynamic signals and associated wave intensity are depicted in Figure 62. In the 
overall cohort of patients, compared to baseline values, coronary blood flow velocity 
significantly increased at peak exercise (12.3±5.4 versus 17.6±7.8; P<0.005); this was 
driven by a significant increase in coronary blood flow velocity in the control group 
(10.8±3.0 versus 17.1±6.4; P<0.05), and a trend toward an increase in coronary blood 
flow velocity in the ischaemia group (13.3±6.7 versus 17.8±9.2; P= 0.06). A trend 
toward a decrease in microvascular resistance was observed overall at peak exercise 
compared to baseline but this did not reach significance. Compared to baseline values, 
distal coronary pressure significantly increased in the control group (103±15 versus 
119±12; P<0.05) but not in the ischaemia group, driven by the increase in mean aortic 
pressure (Figure 63). The pressure gradient across the stenosis could not be calculated 
in patients with simultaneous pressure-volume loop measurements and ComboWire 
measurements through a single guide catheter, due to the impact of the equipment on 
the fluid filled manometer pressure tracing. In patients with sequential coronary 
haemodynamic measurements, compared to baseline, the pressure gradient significantly 
increased at peak exercise (ischaemia) in patients with significant coronary artery 
disease (15±10 versus 24±17; P<0.05) but not in those without significant coronary 
artery disease. Diastolic time fraction significantly decreased in the control group on 
peak exercise compared to baseline values (53±4 versus 61±5; P<0.05) but did not 
decrease in the group with significant coronary artery disease despite a significant 
increase in heart rate (Figure 63). 
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Figure 62 Representative example of haemodynamics: baseline versus peak exercise. 
Haemodynamic tracings (above) and wave intensity (Jm-2s-2x105) (below). 
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4.3.4 CORONARY WAVE INTENSITY ANALYSIS AND CARDIAC 
MECHANICS 
In reference to the coronary wave energies arising distally, coronary wave intensity 
analysis demonstrated a significant increase in the net energy of the backward travelling 
suction wave (during diastole), this increased compared to baseline in both the control 
group (-10±3.7 versus -3.0±1.4x103 J/m2/sec2; P<0.001) and the ischaemia group (-
11±2.8 versus -4.7±0.9 x103 J/m2/sec2; P<0.001). There was also an increase in the net 
energy of the backward travelling compression or pushing wave (during early systole) 
in both the control group (-8.6±3.8 versus -4.5±3.5 x103 J/m2/sec2; P<0.05) and 
ischaemia group (-11±4.6 versus -5.1±3.1 x103 J/m2/sec2; P<0.001) at peak exercise 
compared to baseline values. In reference to the wave energies arriving proximally in 
the aorta, there was no significant increase in the net energy of forward travelling 
compression wave; however, the peak of the forward compression wave (arising in 
systole) was significantly increased at peak exercise compared to baseline values in the 
control group (12.5±8.3x104 versus 22±15x104 J/m/sec2; P<0.05) but not in the 
ischaemia group. The forward travelling suction wave (arising in early diastole) 
increased significantly on exercise compared to baseline in the both the control group 
(10.8±6.0 versus 3.1±1.7 x103 J/m2/sec2; P<0.001) and the ischaemia group (6.8±2.4 
versus 3.6±1.3 x103 J/m2/sec2; P<0.05) (Figure 64). 
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Analysis of seven patients with simultaneous coronary and LV haemodynamic 
measurements revealed a correlation with the coronary wave energies and cardiac 
mechanics during exercise both in the presence and absence of significant coronary 
artery disease. The peak of the forward travelling compression wave (arising in systole) 
correlated with dP/dtmax (r = 0.5; P<0.001); the net wave energy of the backward 
travelling compression wave (arising in early systole) also correlated with dP/dtmax (r = 
-0.6; P<0.0001); the net wave energy of the backward travelling suction wave (arising 
in diastole) correlated with dP/dtmin (r = 0.6; P<0.0001) (Figure 65). 
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4.4 DISCUSSION 
This is the first time to our knowledge, coronary and left ventricular haemodynamics 
have been measured simultaneously in humans, both at rest and during exercise and to 
this degree of accuracy. The main findings of this study can be summarised as follows: 
1) At low impact, exercise exhibits a beneficial haemodynamic effect on the 
cardiovascular system, but adversely affects stroke volume and cardiac output at the 
onset of ischaemia; 2) demand ischaemia initially drives the PV loop upward followed 
by a rightward shift after a specific duration and intensity of ischaemia, with a reduction 
of the external (useful) work performed by the heart; 3) in the presence of significant 
coronary artery disease, the ventricular-arterial interaction is impaired on peak exercise; 
4) coronary blood flow velocity is maintained through preservation of the diastolic time 
fraction in the presence of significant coronary artery disease when autoregulatory 




In the absence of significant coronary artery disease, dynamic exercise improves 
haemodynamic variables. An increase in heart rate and stroke volume drives an increase 
in cardiac output. Stroke work and total mechanical energy expenditure increases with 
an increase in ventricular efficiency. Contractility increases, as demonstrated by an 
increase in the ESPVR slope; these findings are consistent with pre-clinical work 
performed by Nozawa et al in this area, they demonstrated an increase in the area of the 
pressure-volume loop (stroke work) accompanied by an increase in the ESPVR slope in 
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conscious dogs.32 As contractility increases, basal energy consumption of the 
myocardium increases, thus shifting the pressure-volume area-myocardial oxygen 
consumption ratio upward; in the absence direct measurement of MVO2 in the study, 
we were unable to demonstrate an increase in mechanical efficiency as was performed 
in the instrumented dogs.8,32 
 
The systemic response to exercise in this cohort was manifest as a decrease in systemic 
vascular resistance and a decrease in arterial elastance, which represents lumped mean 
and pulsatile load to the left ventricle. Changes in systemic vascular resistance enhance 
stroke volume, thus facilitating the increased cardiac output necessary for sustained 
exercise. This theory was supported by the improvement seen in ventricular-arterial 
coupling (Ea:Ees ratio) during exercise. 
 
The increased in total mechanical energy was accompanied by a significant increase in 
coronary blood flow velocity and an increase in distal coronary pressure, which 
followed the rise in mean aortic pressure. The increase in coronary blood flow velocity, 
(and therefore increased oxygen supply) has been previously studied and is a recognised 
consequence of increase myocardial oxygen demand (consumption).110,121 Similarly 
distal coronary pressure rise has been shown to follow a rise in mean aortic pressure.101 
During peak exercise, there was no increase in the pressure gradient across the coronary 
lesion; exercise represents true physiological hyperaemia, this is less than can be 
achieved pharmacologically, thus would be consistent with a negative fractional flow 
reserve measurement in this patient cohort.67,92 
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Significant coronary artery disease:  
This is the first time that end-systolic and end-diastolic pressure volume relations have 
been studied simultaneously in humans with angina pectoris. The advantage of this is 
that the sequence of events during the onset of ischaemia with regard to systolic and 
diastolic function can be described. Importantly, this study benefitted from direct 
measurement of coronary pressure and flow velocity to demonstrate functional 
significance of coronary artery disease, which has not been previously performed. We 
hypothesised that diastolic properties are a function of systolic properties and that 
changes are not manifest in isolation. 
 
Myocardial work and Contractility  
In patients with significant coronary artery disease, on initiation of dynamic exercise, 
there was an initial improvement in haemodynamic variables: the initial increase in 
stroke volume and therefore cardiac output enabled the body to sustain physical 
activity; this was accompanied by an initial increase in contractility, the slope of the 
ESPVR curve became steeper, with an increase in the area of the pressure volume (PV) 
loop, the latter representing an increase in external stroke work. However, continued 
exercise, lead to a decrease in cardiac output, with a rightward shift of the ESPVR 
slope. The striking rightward shift of the PV loop is representative of decreased 
contractility and acute LV dilatation, with higher end-diastolic and end-systolic 
volumes. These findings are consistent with pre-clinical work performed by Steendijk et 
al in canines; they delivered increasing doses of dobutamine after inducing coronary 
stenosis, an initial increase in cardiac output and increase in the gradient of the ESPVR 
slope was seen; however, at the highest doses of dobutamine, a drop in cardiac output 
MYOCARDIAL SYSTOLIC AND DIASTOLIC FUNCTION ON EXERCISE 
175		
occurred, followed by a rightward downward shift of the ESPVR curve.156 During 
ischaemia, a rightward shift and reduction in the area of the pressure-volume loop 
corresponds to an increased in total mechanical energy expenditure but a decrease 
external stroke work, and therefore a decrease in ventricular efficiency (conversion of 
metabolic energy to external work). These findings were also demonstrated by 
Steendijk et al.156 Importantly, we found in the presence of single vessel coronary 
disease: left anterior descending (5), dominant right coronary artery (4), dominant left 
circumflex (1), inducing regional ischaemia effect the total PV loop.  
 
Diastolic function 
In patients with significant coronary artery disease, the early stages of exercise were 
accompanied by the physiological response expected in healthy individuals: an increase 
in contractility, stroke work and cardiac output. However, on observation of the 
pressure volume loop, an upward shift of the end-diastolic pressure-volume relationship 
can be seen early on, prior to the clinical manifestation of ischaemia (ECG changes and 
chest pain). This upward shift demonstrated on exercise is consistent with the 
previously recognised increase in diastolic pressure relative to volume with demand 
ischaemia in patients with coronary artery disease.145,149,212 Previous studies of pacing 
induced ischaemia have shown similar findings.125 Importantly we demonstrated an 
upward then rightward shift of both the ESPVR and EDPVR relations; these latter 
changes have been shown to occur with coronary occlusion in humans but not with 
demand ischaemia. Paulus et al induced two different types of ischaemia in in dogs 
(pacing and coronary occlusion): pacing induced an upward shift and occlusion drove a 
rightward shift of the EDPVR. As both changes were seen in this patient cohort, the 
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theory that the technique used to provoke ischaemia dictates the direction of the 
EDPVR is brought into question. The findings of this study clearly demonstrated that 
systolic and diastolic function are closely linked, initially, contractility is preserved or 
improved, thus driving the end-diastolic pressure-volume relationship upward; there 
then follows impairment of contractile function, that occurs after continued supply-
demand mismatch that may be related to a specific duration or intensity of ischaemia; 
impaired systolic function is then accompanied by a rightward shift of the EDPVR 
relation; these findings reflect work by Takano et al: they found that on inducing 
ischaemia by pacing in dogs that the EDPVR response was dictated by the change in 
left ventricular contractility; as pacing is not true physiological ischaemia, there were 
not able to demonstrate the continuum shown in this study.155 We have therefore shown 
that systolic and diastolic function are closely related, with ischaemic changes acting as 
a continuum, of which the end-stage is a rightward shift of the EDPVR. 
 
Ventricular-Arterial Interaction 
The dynamic interaction between the heart and the systemic vasculature is fundamental 
to the heart providing adequate cardiac output and the arterial pressures necessary for 
distal organ perfusion; in the case of exercise, the increased perfusion necessitated by 
skeletal muscle.109,114 We showed this normal physiological response of the peripheral 
vasculature to be adversely affected in the presence of significant coronary artery 
disease. In this study, an initial decrease in systemic vascular resistance was seen, 
followed by a steep rise. Arterial elastance significantly increased on exercise in the 
presence of significant coronary artery disease; arterial elastance is inversely related to 
compliance. Ventriculo-arterial coupling (Ea:Ees ratio) correlates inversely to pump 
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efficiency such that the heart is optimally efficient at a ratio of 0.7 and an Ea:Ees>1.0 is 
seen in failing hearts.37,40,128 In this cohort of patients with preserved left ventricular 
function, the Ea:Ees ratio was within normal limits at rest; however, on exercise this 
increased dramatically, driven by initially by the increase in Ea, followed by a reduction 
in contractile function (Ees). This acute increase in afterload is likely to play a key role 
in LV dysfunction during ischaemia, and is likely to contribute to the acute LV 
dilatation and global systolic impairment that was observed. Thus cardiac efficiency 
becomes impaired and VA uncoupling occurs. The VA uncoupling seen in exercise-
induced ischaemia is similar to those in acute heart failure.38 Therefore demonstrating 
the systemic effects of ischaemia. 
 
Coronary haemodynamics 
In the presence of significant coronary artery disease, the pressure gradient across the 
coronary stenosis increased on exercise; thus the increase in myocardial demand in 
patients with ischaemic heart disease could not be sustained by an increase in coronary 
flow velocity. This is due to the exhaustion of autoregulatory mechanisms in the 
presence of a flow limiting stenosis.67,220 Despite the increase in heart rate, diastolic 
time fraction was seen to be preserved in this cohort of patients, which has previously 
been suggested as a mechanism for maintaining coronary perfusion in the presence of 
coronary artery disease.65 
 
Interestingly, coronary wave energies increased in both groups on exercise; 
simultaneous LV and coronary measurements demonstrated that these wave energies 
follow dP/dTmax and dP/dtmin. These findings would suggest that cWIA could be used 
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as a potential surrogate for cardiac mechanical changes; these support findings of 
previous preclinical and human work.100,107 The importance of this is the potential 
application of cWIA in assessment of LV haemodynamics, when LV invasive 
measurements may not be practical. 
4.5 LIMITATIONS 
This was a small single centre observational study; however, this is the first time to our 
knowledge, coronary and left ventricular haemodynamics have been measured 
simultaneously in humans, both at rest and during exercise and to this degree of 
accuracy. Pressure-volume loop and coronary wave intensity analysis during exercise 
introduces noise despite the use of filters and ensemble averaging of consecutive 
cardiac cycles to reduce this. The impact of a stenosis proximal to the measurement of 
wave intensity analysis on the single point method of calculation is not known; 
however, there is no known alternative to this. In the presence of single vessel coronary 
disease, the left ventricular changes incurred were due to regional ischaemia; however 
the manifestation of ischaemia affected the entire left ventricle. Total myocardial blood 
flow was not measured, thus the contributions of collateral flow to ischaemic regions 
and redistribution of blood flow were not measured. 
4.6 CONCLUSIONS 
This study delineates the changes occurring with demand ischaemia during dynamic 
exercise in humans, and the interaction of the heart with the systemic circulation. 
Importantly there is a biphasic response in patients with ischaemia, with low impact 
exercise exhibiting a beneficial effect on acute haemodynamics. Coronary wave 
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intensity analysis, accurately reflects the cardiac mechanical change occurring during 
exercise, thus has potential future application in the measurement of contractile function 


















	5 THE ROLE OF NITRATES IN ANGINA 
PECTORIS REVISITED 
INTRODUCTION  
Nitrates are the most effective drug for instant relief of acute ischaemia. A number of 
concepts have been used to describe how they work, including a reduction in 
myocardial oxygen consumption and beneficial effects on coronary blood flow. 
However, the precise and unique anti-ischaemic mechanism remains unclear. The 
importance of understanding these mechanisms, may facilitate the development of 
improved therapeutic agents without the setbacks of nitrate tolerance. The gold standard 
in-vivo measure of myocardial energy expenditure, cardiac performance and the 
interaction with the arterial system is by way of left ventricular (LV) pressure-volume 
(PV) loop analysis; the aim of this study was to examine the effect of nitrates on 
humans with the novel capability of measuring simultaneous LV pressure-volume 
relations and invasive measures of coronary blood flow, using a dual sensor pressure-
flow coronary guide wire, in the cardiac catheter laboratory to perform real-time 
continuous assessment of the cardiovascular response to nitrates. 
METHODS  
Fifteen patients with significant coronary artery disease underwent cardiac 
catheterisation followed by intra-arterial administration of 1mg isosorbide dinitrate; 
continuous recording of invasive LV PV and coronary haemodynamic measurements 
were performed for the duration of administration and for 2 minutes after; changes 
induced by nitrates were compared to baseline; serial haemodynamic measurements 
were compared using one-way analysis of variance. 
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RESULTS  
ISDN administration resulted in a reduction in preload and afterload, as evidenced by a 
reduction in end-diastolic pressure (13 ±5 versus 9±4mmHg; P<0.001) and arterial 
elastance (1.7±0.8 versus 2.2±1.1 mmHg/mL; P <0.05), with an overall decrease in total 
mechanical energy expenditure (1.2±0.4 versus 1.5±0.5 Joules; P <0.001) and therefore 
myocardial oxygen consumption. Consequently a leftward, downward shift of the 
pressure-volume loop was effected, increasing the efficiency of energy conversion to 
external work (68±10 versus 74±9%; P <0.05). Early coronary vasodilatation with a 
temporary increase in coronary blood flow velocity (20±11 versus 13±5 cm/sec; 
P<0.05) was followed by a reduction in the pressure gradient (4.8±3.7 versus 7.2±3.8 
mmHg/cm/sec; P<0.05) and stenosis resistance (2.7±3.6 versus 4.4±3.3 mmHg/cm/sec; 
P<0.01) suggestive of stenosis dilatation. ISDN administration did not have a 




The anti-anginal mechanism of nitrates in patients with ischaemic heart disease is 
mediated by its vasodilatory effects on the systemic vasculature and the coronary 
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5.1 INTRODUCTION 
Nitrates are the most effective drug for instant relief of acute myocardial ischaemia; 
they may also be administered as a preventative agent or in combination with other anti-
anginals221. A number of concepts of how nitrates work at both a macroscopic and 
cellular level have been proposed, including clinically important anti-thrombotic 
activity; endothelin-derived relaxing factor activity enhancing endothelial dysfunction 
and positive remodelling following myocardial infarction.159,222,223 Perhaps of most 
interest however, is how nitrates relieve acute ischaemia. The major action of nitrates is 
on vascular smooth muscle relaxation. The initial belief that the advantageous effect of 
nitrates was due to dilatation of the coronary circulation has since been discarded for 
two reasons: firstly, intracoronary vasodilators did not predictably relieve ischaemia and 
secondly, nitrates appear beneficial only in the presence of peripheral 
vasodilatation.224,225 Thus the theory arose that the predominant action of nitrates was 
through a reduction in myocardial oxygen consumption by increasing peripheral 
vasodilatation and therefore reducing preload and afterload.226-228 The preload reduction 
is demonstrated by decreased right heart pressure, chamber size and a decrease in 
cardiac output (although a modest increase in ejection fraction has been seen). This 
decline in systemic arterial pressure also triggers sympathetic nervous system activation 
with reflex increase in heart rate, thus driving a biphasic response: initial vasodilatation 
followed by reflex vasoconstriction.229 Interestingly, nitrates improve ischaemia in areas 
receiving inadequate blood flow, although total myocardial blood flow may remain the 
same or decrease due to decreased oxygen consumption; it is presumed that decreased 
systolic wall tension redistributes myocardial blood flow.230,231 Proposed coronary 
effects include stenosis dilatation (and therefore reduction in stenosis resistance), 
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enhanced collateral flow, and the reversal of coronary vasoconstriction. However, it is 
likely that a combination of myocardial, coronary and systemic effects contribute to the 
anti-anginal effect.169,232 The precise and unique anti-ischaemic mechanism of action of 
nitrates remains much debated; importantly following repeated episodes of ischaemia, 
nitrate tolerance can develop and the effect is attenuated, with some suggestion of later 
harmful effects.233 Thus by understanding the mechanism of nitrates, newer anti-anginal 
therapies could be developed. The gold standard for assessing cardiac performance and 
its interaction with the arterial system is pressure-volume (PV) analysis; simultaneous 
in-vivo pressure-volume measurements with a conductance catheter (CC) placed in the 
LV allow real-time assessment of the cardiac performance and its interaction with 
arterial load. 183 The combination of PV loop assessment and real-time invasive 
measures of coronary blood flow enables us to more precisely examine the 
cardiovascular changes that occur with nitrate administration.38,195,234 Studies on the 
action of nitrates have examined the myocardial, systemic and coronary effects in 
isolation. Thus the aim of this study was to ascertain the cardiovascular response to 
nitrates by simultaneously assessing myocardial blood flow velocity, energetics and 
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5.2 METHODS 
5.2.1 STUDY POPULATION 
Patients were identified from routine waiting lists for coronary angiography ± proceed 
to angioplasty at St Thomas’ Hospital, London, United Kingdom. Patients were selected 
for the study if they were symptomatic with Canadian Cardiovascular Society 
functional angina class II-III; angiographic criteria for inclusion was one or more 
epicardial coronary artery with > 50% diameter stenosis. Exclusion criteria were the 
presence of unstable angina, previous myocardial infarction, coronary artery bypass 
graft surgery, impaired left ventricular function, severe co-morbidities, valvular heart 
disease and atrial fibrillation. Patients with a left main stem stenosis, severe multi-vessel 
coronary disease or chronic total occlusions were also excluded. Oral nitrate 
preparations, calcium channel blockers and beta-blockers were stopped at least 48 hours 
before the procedure. All patients underwent written, informed consent prior to 
partaking in the study. This study received approval from the National Research Ethics 
Committee (09/H0802/39). 
5.2.2 CATHETER LABORATORY INSTRUMENTATION AND PROTOCOL 
Left heart catheterisation was performed via the right femoral artery using a standard 
8Fr femoral sheath. Weight adjusted heparin was administered (70IU/kg) intra-
arterially. Right and left coronary angiograms were then taken using standard diagnostic 
catheters. Intracoronary nitrates were not used. An 8Fr 80cm Launcher guide catheter 
(Medtronic Vascular, MN, USA) was introduced into the aortic root. A dual-sensor 
pressure velocity 0.014” coronary guide wire (ComboWire, Volcano Corp, San Diego, 
CA) was then connected to the ComboMap console (Volcano Corp) and was delivered 
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through the guide; auxiliary inputs were electronically routed to the Inca (CD Leycom) 
to enable for simultaneous acquisition, a further description is provided in section 2.3.2 
and 3.2.1. The ComboWire pressure signal was normalised against the fluid filled 
catheter signal at the tip of the guide.80,101 The guide catheter was then inserted into the 
coronary ostium and the ComboWire advanced distal to the stenosis in the target 
coronary artery (Figure 66). The guide catheter was then disengaged and left ventricular 
pressure and volume measurements were assessed with a 4Fr conductance catheter (CC) 
system (CD Leycom, The Netherlands). This flexible pigtail catheter has a solid-state 
pressure sensor and electrodes situated at regular intervals; continuous left ventricular 
volumes are calculated by measuring conductance; this technique has been previously 
validated and applied in the study of cardiac disease states.184,185,193,194 The CC is 
connected to a signal processor (Inca, CD Leycom, Netherlands) and delivered to the 
ventricular cavity across the aortic valve via the guide. Correct positioning was 
confirmed by fluoroscopy and conductance signals, Figure 66. Volume calibration was 
performed by left ventricular (LV) volume measurements obtained from transthoracic 
three-dimensional echocardiography, further details regarding set-up and calibration can 
be found in section 2.2.3.2.193 Optimisation of the coronary Doppler velocity traces and 
LV pressure-volume measurements was then performed.  
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Figure 66. Instrumentation during ISDN (fluoroscopy). 
 
Baseline measurements were taken before the patients received isosorbide dinitrate 
(ISDN). This was a standardised protocol: 2mL of sterile 0.1% ISDN solution was 
diluted 1:5 in 10ml 0.9% Saline, with a resulting drug concentration of 2mg/10mL. 1mg 
of ISDN was injected manually via the manifold over 5 seconds and deliver to the aortic 
root via the guide catheter. Continuous surface ECG recordings, left ventricular 
haemodynamic tracings, and coronary pressure and flow velocity signals were recorded 
throughout. 
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5.2.3 DATA ACQUISITION AND ANALYSIS 
Coronary pressure and flow velocity signals were sampled at 200Hz and acquired 
online on the Combomap system (Volcano Corp); the coronary signals were 
electronically routed to the Inca (CD Leycom) to facilitate real-time simultaneous 
acquisition and visualisation of all  (coronary and LV) haemodynamic variables. 198,199 
CC measurements were acquired online using the dedicated data acquisition and 
analysis software (Conduct NT, version 3.18.1 CD Leycom); recording was continuous 
during the intervention. From the continuous recordings, at least three consecutive 
cardiac cycles were selected. For the purposes of analysis, the findings were separated 
into three stages: stage 1 at baseline, stage 2 following administration of ISDN at peak 
fall in LV systolic pressure (coinciding with peak fall in distal coronary pressure) and 
stage 3 the peak rise in LV pressure following the fall; these changes and the 
corresponding numbering are depicted graphically on a typical haemodynamic tracing 
in Figure 67. Coronary and LV data were imported into the in-house custom-made 
programme (King’s College London, United Kingdom) for offline analysis, further 
details regarding the software programme and validation can be found in section 3.198,199 
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Figure 67 Simultaneous systemic and intracoronary recording.  
From top to bottom panel: intra-cardiac electrocardiogram (ECG), left ventricular (LV) 
intra-cavity pressure, total left ventricular (LV) volume, distal coronary pressure (Pd), 
mean coronary blood flow velocity (U). Time points defined as baseline (1), following 
administration of ISDN, peak fall in LV systolic pressure (2) (coincides with peak fall 
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Mean coronary blood flow velocity (U) and distal coronary pressure (Pd) were 
determined from the Doppler signal and high-fidelity pressure signal respectively, distal 
to the coronary stenosis. Pressure gradient ∆!  across the stenosis was determined by: 
Equation 21 !"#$$%"# !"#$%&'( ∆! = !"!" 
Where end-systolic pressure was used as a surrogate for mean aortic pressure.  
 
Stenosis resistance was determined by: 
Equation 22 !"#$%&'& !"#$#%&'(" (!") = !"− !"!"#$ !"#"$%#& !"##$ !"#$ (!) 
Wave intensity analysis (WIA) explains phasic flow in terms of a series of wave fronts 
that underlie the changes in coronary pressure and flow velocity in the coronary 
arteries.97 WIA enables separation of the local net waveform in the coronary artery into 
forward (arising proximally) and backward (arising distally) travelling components; 
thus WIA is a powerful tool for investigating cardiac-coronary interactions and has been 
used previously to interpret clinical data.96,101,202 Adjustment for the non-physiological 
time-delay between the digitally archived signals (coronary pressure and velocity, 
55ms; coronary and left ventricular pressure; 88ms) was performed101,198 Time 
derivatives were obtained after smoothing the raw signals using an adaptive Savitzky-
Golay filter; the adaptive filter algorithm has been shown to improve WIA robustness, 
thus providing an accurate standardised approach to coronary WIA.192,196 Net wave 
intensity was performed and normalised to the sampling rate and separation into 
forward and backward components was performed using the single–point technique. 
97,201 Administration of nitrates does not affect pulse wave velocity, thus baseline pulse 
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wave velocity measurements were implemented for WIA determination during ISDN 
administration to account for the limitations of the single-point technique used in 
determination of coronary WIA.104 
 
CC measurement allows for acquisition of instantaneous LV volumes and pressure. Left 
ventricular conductance volumes (EDV, ESV) were calculated at the maximum rate of 
LV pressure rise (dP/dTmax) and pressure decay (dP/dTmin); stroke volume (SV) was 
calculated as the difference in these volumes, and cardiac output (CO) as the product of 
SV and heart rate. In addition to instantaneous LV volumes and pressure, the software 
calculates load-independent parameters of LV contractility.217 The end-systolic PV 
relationship (ESPVR) represents the ratio of LV pressure to LV volume at the end of 
ventricular systole (uppermost left corner of the PV loop). The Starling contractile index 
(SCI) is calculated as the maximal rate of pressure change over time during 
isovolumetric contraction (dP/dTmax) normalised to end-diastolic volume (EDV). LV 
stroke work (SW) was calculated as the area of the PV loop; preload-recruitable stroke 
work (PRSW) was calculated by normalising the SW to EDV. LV stroke work was 
calculated as the product of peak LV peak systolic pressure and stroke volume.193,218 
Pressure volume are (PVA) a measure of total mechanical energy generated by 
ventricular contraction, was calculated as the sum of stroke work and elastic potential 
energy according to Equation 20. Systemic vascular resistance was calculated as the 
ratio between the pressure drop across the vascular bed and the cardiac output and 
decribed as Wood units (mmHg.min/L). End-diastolic pressure volume relations 
(EDPVR) were performed from single-beat estimations, previously validated in 
humans.208 The slope of ESPVR was calculated using the single beat method (Ees), 
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shown to accurately reflect acute inotropic change, with minimal influence from loading 
conditions.205 Arterial elastance (Ea) was calculated as the ratio of end-systolic pressure 
(ESP) to stroke volume (SV) to assess the impact of arterial load on the ventricle.37 The 
efficiency of conversion of metabolic energy to mechanical energy was calculated as 
the ratio of stroke work to pressure-volume area and described as a percentage.31 
5.2.4 STATISTICAL ANALYSIS 
Statistical analysis was performed using GraphPad Prism v7.0 (GraphPad Software Inc., 
CA). Quantitative data are expressed as mean ± SD; categorical variables are described 
as proportions and percentages. Data were assessed for normality of (Gaussian) 
distribution both graphically and by use of the Shapiro-Wilk normality test. Statistical 
comparison of serial haemodynamic measurements (quantitative data) of normal 
distribution were performed using a repeated measures one-way analysis of variance 
with comparison to baseline and the previous step; repeated measures two-way analysis 
of variance was performed to assess for the interaction of functionally significant 
coronary disease within the serial haemodynamic measurements; adjustment for 
multiple comparisons were performed using the Bonferroni correction to generate 
adjusted P values. A P value < 0.05 was considered statistically significant for all tests. 
Results from different measurements of normal distribution were correlated using the 
Pearson correlation coefficient. 219 
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5.3 RESULTS 
Between December 2013 and April 2016, twenty patients were consented into the study. 
Figure 68 demonstrates the flow of patients in the study. Fifteen patients successfully 
completed the study protocol. Reasons for exclusion were as follows: no significant 
coronary disease (1), three-vessel coronary disease requiring coronary artery bypass 
graft surgery (1), coronary artery disease requiring rotational atherectomy (1), frailty 
(1); technical inability to perform pressure-volume measurements (1). Full background 
demographics and procedural details are shown in Table 8. 
 
Figure 68 Patient flow diagram. 
Abbreviations: 3VD three-vessel disease, PV pressure-volume loop. 
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Patient Demographics Total (n=15) 
Male sex 12/15 (80%) 
Age, years 66±14 
Height, cm 169.6±7.2 
BMI kg/m2 28.4±4.4 
Previous PCI 9/15 (60%) 
Previous MI 5/15 (33%) 
LVEF, % 55±16 
Diabetes mellitus 5/15 (33%) 
Hypertension 10/15 (67%) 
Dyslipidemia 5/15 (88%) 
Family History 7/15 (47%) 
Smoking history 2/15 (13%) 
Current Medications  
Βeta-blockers 10/15 (67%) 
Nitrates 6/15 (40%) 
Statins 12/15 (80%) 
ACEi 10/15 (67%) 
Aspirin 14/15 (93%) 
Clopidogrel 14/15 (93%) 
Procedural details  
Number of diseased vessels  1 (1 to 2) 
> 50% stenosis of target lesion 15/15 (100%) 
Target vessel (LAD/Cx/RCA) 13/1/2 
FFR <0.8 12/15 (80%) 
Duration of procedure (minutes) 76 (65 to 91) 
Table 8 Baseline demographics and procedural details of study participants. 
Categorical data are expressed as counts and percentages. Quantitative data that is 
normally distributed is described as mean +/- standard deviation; quantitative data that 
is not normally distributed is described as median and interquartile range (IQR). For 
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Of fifteen patients, fourteen were administered intra-aortic isosorbide dinitrate and one 
patient received sublingual glyceryl trinitrate, therefore was not included in the final 
analysis. Invasive pressure-volume loop acquisition was performed in all patients; 
coronary physiology measurements were performed in thirteen patients (wave intensity 
analysis performed in eleven), simultaneous data were obtained in eleven patients; 
sequential coronary and LV physiological measurements were obtained in one patient.  
Haemodynamic effects of Isosorbide Dinitrate 
The haemodynamic effects of isosorbide dinitrate (ISDN) are summarised in Table 9. 
The functional significance of coronary artery disease was determined at the end of the 
study protocol following adenosine administration with an FFR<0.8; coronary artery 
disease with a resting Pd/Pa measurement of <0.8 and angiographically >70% stenosis 
was considered functionally significant and intravenous adenosine was not 
administered.216 Of the fourteen patients who underwent final analysis, there were no 
significant differences in left ventricular, systemic or coronary response to nitrates 
between the patients who had functionally significant coronary artery disease (11) 
versus those who did not (3). Figure 67 shows a representative example of the signals 
recorded on ISDN administration. Following ISDN administration all pressures fell 
significantly (Figure 69). Compared to baseline (stage 1) at minimal left ventricular 
systolic pressure (stage 2), ISDN caused an early significant reduction in end-systolic 
pressure (ESP), end-diastolic and end-systolic volumes and dP/dt min (P < 0.05); there 
followed a late (stage 3) reduction in end-diastolic pressure (EDP), a sustained 
reduction in ESP, LV volumes, dP/dtmin and an increase in heart rate (P < 0.05). 
Overall stroke volume remained unchanged; however an early, marginal, but 
statistically significant, increase in cardiac output was seen compared to baseline 
NITRATES IN ANGINA PECTORIS REVISITED 
195		
(4.5±1.7 versus 4.0±1.7 L/min; P < 0.05), predominantly driven by an increased heart 
rate (Figure 69). Systemic vascular resistance decreased at stage 2 compared to baseline 
(26±13 versus 39±22 mmHg.min/L; P < 0.05) and remained low. Arterial elastance, 
which is a component of lumped mean and pulsatile load on the left ventricle also 
decreased at stage 2 compared to baseline (1.7±0.8 versus 2.2±1.1 mmHg/mL; P 
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 ISDN administration (n=14) P value  
 1 2 3 1vs2 1vs3 2vs3 
HR bpm 63±11 69±14 68±11 0.14 <0.05* >0.99 
EDP mmHg 13±5 10±4 9±4 0.08 <0.001* 0.62 
ESP mmHg 126±23 99±21 108±26 <0.001* <0.05* 0.07 
EDV mL 124±38 114±38 111±39 <0.05* <0.05* >0.99 
ESV mL 56±24 46±22 49±24 <0.001* <0.05* 0.66 
EF % 55±12 59±14 55±12 0.08 >0.99 0.25 
SV† mL 63±22 66±23 62±21 >0.99 0.37 0.31 
CO† L/min 4.0±1.7 4.5±1.7 4.2±1.6 <0.05* 0.33 0.11 
dP/dtmax 1282±240 1265±224 1333±228 >0.99 0.38 0.32 
dP/dtmin -1275±171 -1039±182 -1135±187 <0.001*  <0.05* <0.05* 
Load-independent markers of contractility 
SCI mmHg/mL/s 11±3 12±3 13±4 0.53 <0.05* 0.13 
ESPVR mmHg/mL 2.6±1.2 2.5±1.1 2.5±0.9 >0.99 0.76 >0.99 
PRSW mmHg 60±12 58±9 61±10 0.82 >0.99 0.35 
Load independent markers of relaxation 
Tau ms 37±4 36±4 37±4 0.56 >0.99 >0.99 
EDPVR Beta 5.9±0.2 5.9±0.2 5.8±0.2 >0.99 >0.99 0.06 
EDPVR mmHg/mL 0.11±0.06 0.10±0.06 0.09±0.05 0.22 <0.05* 0.14 
LV myocardial energetics 
SW mmHg.mL 7405±2567 6638±2491 6766±2464 <0.05* <0.05* >0.99 
PVA (Joules) 1.5±0.5 1.2±0.4 1.3±0.5 <0.001* <0.001* 0.26 
SW: PVA % 68±10 74±9 72±10 <0.05* <0.05* 0.43 
Ventricular-arterial interaction 
SVR mmHg.min/L 39±22 26±13 31±20 <0.05* <0.05* 0.12 
Ea mmHg/mL 2.2±1.1 1.7±0.8 2.0±0.9 <0.05* >0.99 0.13 
Table 9 Haemodynamic variables following ISDN.  
Data are expressed as mean±SD. List of Abbreviations see xvi. Stage 1 corresponds to 
baseline, stage 2 to peak LV pressure fall, stage 3 to peak LV pressure rise post fall. 
†Stroke volume and cardiac output calculated from the EDV at dP/dtmin and the ESV at 
dP/dtmax; *P<0.05 compared to baseline. 
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Figure 69 Graphical representation of haemodynamic change with ISDN 
Heart rate (HR, beats per minute), end-diastolic pressure (EDP), end-systolic volume 
(ESV), the maximum rate of left ventricular pressure decay (dP/dtmin) and cardiac 
output (CO). Stage 1 corresponds to baseline, stage 2 to peak LV pressure fall, stage 3 
to peak LV pressure rise post fall.  
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Figure 70. Percentage change from baseline following ISDN. 
From left to right: Starling contractile index (SCI), stroke work: pressure volume area 
ratio (SW:PVA), stroke work (SW), pressure-volume area (PVA), arterial elastance 
(Ea), systemic vascular resistance (SVR) 
 
Myocardial contractility, compliance and energetics 
The starling contractile index (dP/dtmax normalised to end-diastolic volume), which is 
a load independent marker of contractility, increased at stage 3 compared to baseline 
(13±4 versus 11±3 mmHg/mL/s; P <0.05). However, other load independent markers of 
contractility (preload recruitable stroke work and ESPVR) did not. Compared to 
baseline, the external work performed by the heart (stroke work, SW) decreased (stages 
1 and 2) (7405±2567 versus 6638±2491 mmHg.mL; P <0.05). The total mechanical 
energy expended by the heart (pressure volume area, PVA) also decreased compared to 
baseline (1.2±0.4 versus 1.5±0.5 Joules; P <0.001). Despite this, the efficiency of 
conversion of metabolic energy to mechanical energy (SW: PVA ratio) increased 
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following ISDN administration (68±10 versus 74±9 %; P <0.05), Figure 70. There were 
no significant changes in compliance (reflective of the late diastolic phase), a significant 
reduction in the end-diastolic pressure-volume relationship point was seen (0.11±0.06 
versus 0.09±0.05 mmHg/mL; P <0.05); however, the slope of the EDPVR relationship 
remained unchanged. The changes in the pressure volume loop on administration of 
ISDN can be seen in Figure 71. A leftward, downward shift of the pressure-volume loop 
occurs, this is accompanied by a reduction in the total area of the pressure-volume loop. 
 
Figure 71 A representative example the pressure-volume loop following ISDN.  
Stage 1 corresponds to baseline, stage 2 to peak LV pressure fall, stage 3 to peak LV 
pressure rise post fall. 
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The impact of ISDN on coronary artery disease and coronary wave energies 
The coronary haemodynamic changes on administration of ISDN are summarised in 
Table 10. Typical examples of the haemodynamic signals obtained and the associated 
coronary wave intensity are depicted in Figure 72. Following administration of 1mg 
ISDN, an early increase in mean coronary blood velocity was seen compared to baseline 
(20±11 versus 13±5 cm/sec; P<0.05), this was accompanied by a decrease in mean 
distal coronary pressure (71±21 versus 83±21 mmHg; P<0.001); this resulted in an early 
decrease in microvascular resistance compared to baseline (35±29 versus 55±35 mmHg; 
P<0.01) with a reduction in pressure gradient across the stenosis (4.8±3.7 versus 
7.2±3.8 mmHg/cm/sec; P<0.05) and stenosis resistance (2.7±3.6 versus 4.4±3.3 
mmHg/cm/sec; P<0.01) (Figure 73). The increase in coronary blood velocity was not 
sustained, although the drop in pressure gradient and stenosis resistance persisted into 
stage 2. The main coronary wave energies are depicted in Figure 74 and summarised in. 
In all patients, the four main coronary wave energies were seen, which were in turn 
generated by the coronary pressure and velocity signals. At the onset of cardiac 
contraction, a backward compression wave or pushing wave was generated followed by 
a forward travelling compression or pushing wave in the coronary artery. At the onset of 
relaxation a forward travelling expansion wave can be seen, soon followed by a 
backward travelling expansion or suction wave. All the wave energies decreased 
following administration of ISDN (P<0.05). Interestingly, the energy of forward 
travelling compression wave, which is believed to be generated by left ventricular 
ejection, and is thought to accelerate flow, correlated with the ventricular-arterial 
interaction (r = -0.5; P<0.05), Figure 74. 
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 ISDN administration (n=14) P value  Multiple comparison 
 1 2 3  1vs2 1vs3 2vs3 
U cm/sec 13±5 20±11 18±15 0.1    
Pd mmHg 83±21 71±21 77±23 <0.05 <0.001* 0.10 0.13 
ΔP mmHg 55±35 35±29 42±30 <0.05 <0.01* <0.01* 0.07 
SR mmHg/cm/sec 4.4±3.3 2.7±3.6 3.2±3.2 <0.05 <0.01* <0.01* 0.20 
MR 
mmHg/cm/sec 
7.2±3.8 4.8±3.7 6.0±3.8 <0.001 <0.001* <0.01* 0.06 
DTF % 66±3 65±5 64±3 0.1    
Coronary Wave Energies†  
BCW 
J/m2/sec2x103 
-6.0±3.6 -4.0±2.9 -4.5±3.3 0.08    
BEW 
J/m2/sec2x103 
-8.3±5.1 -5.1±4.0 -4.0±2.4 <0.05 0.07 <0.05* 0.47 
FCW 
J/m2/sec2x103 
5.9±3.5 3.8±3.0 3.4±2.4 <0.05 <0.01* <0.05* >0.99 
FEW 
J/m2/sec2x103 
3.9±2.9 3.3±2.7 2.8±2.0 0.2    
Table 10 Coronary haemodynamics and wave energies  
P values calculated by repeated measures ANOVA followed by bonferroni correction 
for multiple comparisons. *P<0.05 compared to baseline; †Total number of patients 11. 
Stage 1 corresponds to baseline, stage 2 to peak LV pressure fall, stage 3 to peak LV 
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Figure 72 Typical haemodynamic tracings and wave intensity analysis. 
Changes in coronary wave intensity at stage 2 of ISDN administration (lower frame) 
compared to baseline (upper frame). The cardiac cycles have been ensemble-averaged 
(above) and corresponding wave intensity generated (Jm-2s-2x105) (below). 
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Figure 73 Changes in coronary haemodynamics. 
Stage 1 corresponds to baseline, stage 2 to peak LV pressure fall, stage 3 to peak LV 
pressure rise post fall; mean coronary blood flow velocity (U; top left); distal coronary 
pressure (Pd; top right); microvascular resistance (MR; bottom left) and stenosis 
resistance (SR; bottom right); *P<0.05 compared to baseline. 
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Figure 74 Changes in the coronary wave energies. 
Stage 1 corresponds to baseline, stage 2 to peak LV pressure fall, stage 3 to peak LV 
pressure rise post fall; backward expansion wave (BEW, top left), backward 
compression wave (BCW, top right); forward compression wave (FCW, bottom left); 
*P<0.05 compared to baseline; Correlation of forward compression wave with cardiac 
mechanics: the ratio of arterial elastance (Ea) to contractile function (Ees) (bottom 
right). 
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5.4 DISCUSSION 
This study shows that in patients with coronary artery disease, the beneficial effects of 
nitrates in preventing or reducing ischaemia is due to a complex interplay of cardiac, 
coronary and systemic changes. The main findings can be summarised as follows: 1) 
ISDN administration drives a reduction in preload and afterload, decreasing total 
mechanical energy expenditure and therefore myocardial oxygen consumption; 2) a 
leftward downward shift of the pressure-volume loop has favourable effects on left 
ventricular energetics, increasing the efficiency of energy conversion to external work 
3) early coronary vasodilatation with a temporary increase in coronary blood flow 
velocity is followed by a reduction in the pressure gradient and stenosis resistance 
suggestive of stenosis dilatation. ISDN administration did not have a demonstrable 
effect on intrinsic myocardial properties, with no change in compliance or contractility 
seen.  
LV preload, afterload and myocardial oxygen consumption 
Isosorbide dintrate is known to be a potent vasodilator of smooth muscle; with 
differential effects on the venous and arterial circulation; Imhof et al demonstrated that 
at relatively low doses of nitroglycerin, venodilatation was maximal; however, higher 
doses were required to induce systemic arterial vasodilatation, the latter increasing 
progressively with increasing doses of nitroglycerin.235,236 In this study, the 
administration of 1mg intra-arterial ISDN resulted in both a preload and afterload 
reduction; these findings are consistent with both venodilatation and arterial 
vasodilatation. Following ISDN administration all pressures fell significantly, as 
venodilatation has been shown to maximal at low doses of ISDN and not dose 
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dependent, it can be concluded that the preload reduction was a result of venous 
pooling.235 We also demonstrated a significant reduction in invasive, accurate measures 
of afterload: an early and sustained decrease in systemic vascular resistance was 
demonstrated, and a measured reduction in arterial elastance. Acute reductions in LV 
loading conditions have been previously shown to reduce myocardial oxygen demand;38 
these findings are consistent with the changes in the pressure-volume loop demonstrated 
in this study: a decrease in total mechanical energy expenditure (or pressure-volume 
area, PVA) was effected by nitrates, and PVA is linearly related to myocardial oxygen 
consumption (MV02).8 The intrinsic myocardial properties were not affected; although 
no change in myocardial compliance was demonstrated, the end-diastolic pressure to 
volume ratio decreased, this can be seen clearly consistent with a left shift of the 
pressure volume loop. These findings consistently support that one of the major 
mechanisms of nitrates, at this plasma concentration, is driven by both a preload and 
afterload reduction, reducing demand. Following the peak fall in LV pressure post-
ISDN administration, an increase in heart rate and immediate increase in LV systolic 
pressure occurred. This may well be explained by ISDN-induced vasodilatation 
triggering baroreceptor activity in these patients, with a reflex sympathetic response.  
De Coster et al noted similar findings following administration of intracoronary ISDN. 
225 
Coronary haemodynamic effects and wave intensity analysis 
The results of this study demonstrate that the anti-ischaemic effects of nitrates are at 
least partially mediated by coronary vasodilatation. We directly measured coronary 
blood flow velocity and distal coronary pressure. The administration of ISDN was 
associated with an immediate sudden increase in coronary blood flow velocity, a 
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decrease in distal coronary pressure and therefore an overall reduction in microvascular 
resistance; this was not sustained, however, despite a reduction in aortic perfusion 
pressure, the pressure gradient across the coronary lesions decreased with an 
accompanied decrease in stenosis resistance, this reduction was in the region of 30 to 
40%. These findings are consistent with earlier work performed by Brown et al. They 
measured luminal area in diseased and normal portions of coronary arteries using 
coronary angiographic data. They demonstrated a 38% reduction in stenosis resistance 
in severely diseased vessel, the greater the stenosis, the more marked the percentage 
gain in luminal area.169 De Coster et al also concluded shat the anti-ischaemic effect of 
nitrates was due to stenosis dilatation and increased perfusion, although they did not 
measure coronary artery diameter or blood flow directly.225 Interestingly, this study has 
demonstrated in cohort of patients with ischaemic heart disease a very similar pattern of 
systemic, cardiac and coronary effects, whereas previous studies have shown marked 
inter-patient variability. Furthermore, the beneficial coronary effects were demonstrated 
in the absence of exercise-induced angina, bringing into question the early theory that 
nitrates only exhibit a beneficial effect in the presence of peripheral vasodilatation.169,224 
 
All the wave energies decreased following administration of ISDN, this was despite the 
observed decrease in microvascular and stenosis resistance. The reduction in wave 
energies mirrored the drop in left ventricular and systemic pressure. As shown in 
section 3.3.4, the forward travelling waves are more dependent on the ventricular-
arterial interaction than initially thought; we have previously shown that these waves 
are delimited by diastolic blood pressure. Interestingly, and consistent with these 
findings, the energy of forward travelling compression wave that is believed to 
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accelerate flow correlated with ventricular-arterial coupling (Ea:Ees ratio). These 
findings would support the hypothesis generated in section 3.3.4.  
5.5 LIMITATIONS 
The coronary findings were suggestive of stenosis dilatation, which may not be 
angiographically detectable; total myocardial blood flow was not measured, therefore 
redistribution of myocardial blood flow and collateral blood flow was not assessed. The 
action of ISDN on coronary artery stenosis is not clear in the absence of 
vasoconstriction, and at the site of a severe stenosis there may be a degree of ischaemia 
at rest. However, the main advantage of this current body of work is the use of very 
accurate measures of coronary and left ventricular haemodynamics enabling definitive 
observations and description of the cardiovascular response as a whole. 
5.6 CONCLUSION 
In this study the anti-anginal mechanism of nitrates in patients with ischaemic heart 
disease has been shown to be mediated by its vasodilatory effects on the systemic 
vasculature and the coronary circulation; both a reduction in demand and an increase in 
blood supply were seen.  
	6 THREE-DIMENSIONAL MYOCARDIAL 
DEFORMATION IMAGING: A NOVEL NON-
INVASIVE MEASURE OF CONTRACTILITY  
INTRODUCTION 
Subclinical systolic and diastolic left ventricular (LV) dysfunction have been shown to 
be independently related to atherosclerosis. 3D speckle tracking echocardiography 
(3DSTE) is a relatively new technique that provides a more comprehensive evaluation 
of LV mechanics than has previously been possible. Deformation imaging has been 
shown to detect subclinical myocardial dysfunction earlier than biomarkers or 
conventional echocardiographic indices. Identifying non-invasive parameters that 
closely reflect contractility and relaxation is of high importance (ideally during resting 
conditions); there is a need for validation of parameters of mechanical dyssynchrony 
with myocardial properties. The aim of this study was to correlate non-invasive 
parameters of strain obtained by 3DSTE with invasive load-independent measures of 
LV function. 
METHODS 
16 patients with ischaemic heart disease and preserved LV function underwent invasive 
simultaneous left ventricular pressure-volume loop assessment in the cardiac catheter 
laboratory under resting conditions followed by 3DSTE data acquisition. Global LV 
longitudinal (GLS), circumferential (GCS), and radial strain was compared with left 
ventricular haemodynamic assessment. Quantitative data were compared by use of 
Student t-test; ategorical data were compared by use of the Fisher exact test; results 
from different measurements were correlated with Pearson’s correlation coefficient; 
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receiver-operating characteristics (ROC) curves were generated for echocardiographic 
measures of LV function 
RESULTS 
GCS correlated with end-systolic pressure volume relationship (ESPVR: r = −0.8; P < 
0.001), pre-load recruitable stroke work (PRSW: r = −0.6, P = 0.002) and the starling 
contractile index (SCI: r = -0.7; P < 0.01) more than GLS. However GLS generated the 
greatest area-under the curve for the ROC curves (AUC = 0.7, SE=0.1), compared to 
GCS (0.5, SE=0.1).  
CONCLUSIONS 
The use of 3DSTE for prediction of contractile function is feasible in a cohort of 
patients with ischaemic heart disease. Close correlation with PV loop analysis suggests 



















Among patients with suspected coronary artery disease (CAD), risk categorisation 
based on clinical characteristics is traditionally used to identify patients who would 
benefit from diagnostic testing.237,238 Identification of left ventricular (LV) systolic or 
diastolic dysfunction significantly increases the likelihood of significant CAD and 
therefore need for further investigation.239,240 In those without overt dysfunction, stress 
echocardiography has traditionally been used as a widely available low-cost approach to 
detection of ischaemia and contractile reserve; however, its assessment remains 
subjective requiring adequate training of the observer.241 Importantly, the presence of 
subclinical LV dysfunction has also been suggested as a marker of CAD; both 
subclinical systolic and diastolic dysfunction have been shown to be independently 
related to CAD, providing incremental value over traditional risk stratification.49,242 
Several studies have demonstrated that progressive subclinical LV diastolic dysfunction 
is related to the degree of atherosclerosis; the effect of repeated subclinical ischaemia 
either leading to impaired relaxation or remodelling of the myocardium.243,244 
Myocardial deformation imaging enables frame-by-frame tracking of speckle patterns 
on grey-scale images to calculate the variation of the segment length from 
baseline.245,246 3D speckle tracking echocardiography (3DSTE) is a relatively new 
technique that provides a more comprehensive evaluation of left ventricular mechanics 
from 3D datasets than has previously been possible, with lower rates if inter- and intra-
observer variability.247 Detection of impaired myocardial mechanics by deformation 
imaging has been shown to detect subclinical myocardial dysfunction earlier than 
biomarkers or conventional echocardiographic indices of ventricular function; in 
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clinical studies of cardiotoxic agents and thyroid carcinomas, early left ventricular 
systolic and diastolic dysfunction demonstrated by impaired longitudinal and 
circumferential strain were seen relative to baseline.248,249 Deformation imaging as an 
adjunct to stress echocardiocardiography has been shown to increase its predictive 
value.51 Global measures of strain have been shown to have superior prognostic 
properties over left ventricular ejection fraction alone. The validity of which has been 
extensively studied in pre-clinical and clinical non-invasive studies.245,250 The gold 
standard for assessing left ventricular chamber properties is using invasive LV pressure-
volume analysis and invasive measures of coronary blood flow velocity and pressure 
respectively. Invasive LV haemodynamic assessment enables derivation of load-
independent markers of both contractility and relaxation, accurately reflecting systolic 
and diastolic function respectively.195 There is a need for a more specific validation of 
parameters of strain that correlate with contraction and relaxation.53,251 Only one animal 
study and no human studies have investigated the relationship between strain and with 
invasive measures of systolic function, identifying non-invasive parameters that closely 
reflect contractility and relaxation is of high importance (ideally during resting 
conditions); serial assessment of systolic and diastolic dysfunction with non-invasive 
testing for prognostication and risk stratification purposes in patients with a known 
history of coronary artery disease could be an important issue for clinical investigation 
and may be a feasible alternative to stress echocardiography in certain cohorts of 
patients.53 The aim of this study was to examine patients with preserved LV ejection 
fraction with a history of coronary artery disease but in the absence of significant 
atherosclerosis, to correlate non-invasive parameters of strain obtained by 3DSTE with 
invasive load-independent measures of LV function. 




6.2.1 STUDY POPULATION 
Patients were considered suitable if they had a left ventricular ejection fraction (LVEF) 
>50% on two-dimensional echocardiography with non-obstructive coronary artery 
disease on coronary angiography. Patients were between 18 and 90 years of age. 
Patients were excluded from the study if it was not possible to obtain adequate 2D 
(parasternal or any of the 3 apical views) or 3D datasets for analysis (>2 segments not 
be visualised or visible translational artefacts). Patients were excluded if they had LV 
regional wall motional abnormalities, functionally significant coronary artery disease, a 
history of cardiomyopathy, the presence of significant valvular heart disease (moderate 
or severe), or had undergone previous coronary artery bypass grafting. The study was 
approved by the National Research Ethics Committee to be performed at St Thomas’ 
Hospital, London, UK. All patients gave written informed consent prior to undertaking 
the study. All patients underwent LV PV measurements in the cardiac catheter 
laboratory followed by 3D echocardiography.  
 
6.2.2 HAEMODYNAMIC MEASUREMENTS 
Patients underwent cardiac catheterisation via the right femoral artery using a 6Fr 
femoral sheath (Terumo). Left and right coronary angiograms were performed as per 
standard protocol to assess for coronary artery disease. On identification of atheroma, a 
standard 6Fr guide catheter was used to engage the coronary ostium of the target vessel 
with introduction of dual-sensor pressure flow wire to the target vessel; intravenous 
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adenosine was administered to identify functionally significant coronary artery disease 
(FFR<0.8), patients underwent angioplasty if necessary.92 Access via the right femoral 
arterial sheath was then used to perform baseline simultaneous LV pressure volume 
(PV) measurements, three sequential recordings of 30 seconds to 1 minute, with the 
patient in a supine position. This was performed using a 4Fr conductance catheter CD 
Leycom, Zoetermeer, Netherlands). The specifications of the conductance catheter (CC) 
are described in section 2.2.1, and the set-up and calibration techniques are described in 
section 2.2.3.2. In brief, this flexible pigtail catheter (no inner lumen) is introduced into 
the LV using guide catheter (commercially available 6 Fr 80cm Judkins Right 4.0 
Launcher; Medtronic). The CC has 10 equally spaced electrodes with a solid-state 
pressure sensor and is connected to a PV signal processor (Inca, CD Leycom); 
continuous LV volume tracings are calculated by measuring parallel electric 
conductance between adjacent ventricular blood segments delineated by selected 
catheter electrodes; this technique has been shown to reflect LV segmental volumes in 
pre-clinical and clinical studies and has been utilised in the assessment of heart failure 
device therapies.183,193,195 Accurate CC positioning is confirmed by fluoroscopy and on 
inspection of the segmental PV loop signals. Measurements were performed during 
steady-state conditions, avoiding excessive arrhythmia from premature beats. Recorded 
variables were averaged from 10 cardiac cycles to minimise inaccuracies from beat-to-
beat variation and change in venous return from respiration; repeat baseline recordings 
ensured reproducibility of CC measurements. 
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6.2.3 2D ECHOCARDIOGRAPHY 
2D echocardiography was performed by Dr Kapetenakis using a commercially available 
system: Sonos 7500 (Philips) with an S5-1 transducer. LV dimensions and fractional 
shortening were obtained with M-mode from the parasternal long axis view. Apical 2- 
and 4-chamber views were acquired for calculation of LVEF with biplane method of 
disks. Pulsed Doppler was used to calculate the myocardial performance index. 
Analyses were subsequently performed offline with EchoPac. 
 
6.2.4 3D REAL-TIME TRANSTHORACIC ECHOCARDIOGRAPHY 
3DRTE uses the X4 matrix array transducer to obtain pyramidal volume in real-time. 
This has previously been described, in summary, full volume acquisition (FVA) is 
necessary to visualise the entire LV, and thus 4 smaller real-time volumes are acquired 
from alternate cardiac cycles and are combined to provide a larger pyramidal volume 
(Figure 75). FVA is performed during breath hold and requires a relatively stable R-R 
interval to minimise translation artefacts between the 4 acquired sub-volumes. Apical 
FVAs of the LV were obtained in all patients. To optimise the frame rate of acquisition, 
depth was minimised to include mitral and aortic valves only, required for spatial 
orientation in subsequent analyses. The endocardial border was semi-automatically 
detected and traced with an LV cast created (Figure 75B) that provides LV time-volume 
data for one cardiac cycle. This is then subdivided into pyramidal sub-volumes to obtain 
time-volume data for each of the 16-myocardial segments. All acquisitions were 
digitally stored for offline analysis by TomTec software (TomTec Imaging Systems, 
Unterschleissheim, Germany). LVEF was determined as follows: 
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Equation 23 !"#$ = !"#$"− !"#$"!"#$" ! !"" 
 
Total LVEF was automatically generated by the software volume changes during the 
cardiac cycle. The LV mass was calculated as: 
Equation 24 !" !"#$%&'#%( !"#$%&− !" !"#$%&'#(&) !"#$%& ! !.!"(!/!") 
 
Figure 75 Full volume analysis  
Full volume analysis (A); LV cast produced by quantitative analysis (B); regional 
volume curves in normal systolic function (C); global volume curves in normal systolic 
function (D) 
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6.2.5 SPECKLE-TRACKING ECHOCARDIOGRAPHY 
As mentioned previously, relative deformation imaging enables characterisation of 
regional and global myocardial function. 3D strain describes the tangential deformation 
of the longitudinal and circumferential strain components. 3D strain measurements of 
the LV were performed using 3DSTE, following import of 3D full volume datasets 
analysed by a highly experienced investigator using vendor-independent 3D speckle 
tracking software (4D LV analysis, version 3.1.2. TomTec Imaging Systems). 
Automatic reconstruction of the 3D endocardial surface was performed on identification 
of the apex and mitral annular line within the largest LV long-axis dimensions, 
performed in both end-diastolic and end-systolic frames. Manual adjustment of the 
endocardial border was performed when necessary. For strain analysis, the LV was 
divided into 16 myocardial segments (described above); the software provided averaged 
longitudinal, circumferential, radial and 3D strain time curves from each segmental 
strain-time curve, from which peak global strain was determined. Systolic timing 
dispersion index (SDII), defined as the difference between the earliest (#1) and the most 
delayed (#2) peak systolic phase (%) among the 16 cardiac segments. Second was the 
systolic dyssynchrony index (SDI) described by Kapetanakis et al., defined as the 
systolic dyssynchrony of peak systolic phases in the 16 cardiac segments, which is a 
simple reproducible method of quantifying global LV dyssynchrony. 251,252 
6.2.6 DATA ANALYSIS 
CC data analysis was performed with dedicated data acquisition and analysis software 
(Conduct NT, version 3.18.1, CD Leycom). Conductance volumes (EDV, ESV) were 
calculated at the maximum rate of LV pressure rise (dP/dt+) and pressure decay (dP/dt-), 
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stroke volume was calculated as the difference in these volumes. In addition to 
instantaneous LV volumes and pressure, this software calculates load-independent 
parameters of LV contractility.217 The end-systolic PV relationship (ESPVR) represents 
the ratio of LV pressure to LV volume at the end of ventricular systole (uppermost left 
corner of the PV loop). The Starling contractile index (SCI) is calculated as the maximal 
rate of pressure change over time during isovolumetric contraction (dP/dTmax) 
normalised to end-diastolic volume (EDV). LV stroke work (SW) was calculated as the 
area of the PV loop; preload-recruitable stroke work (PRSW) was calculated by 
normalising the SW to EDV. LV stroke work was calculated as the product of peak LV 
peak systolic pressure and stroke volume.193,218 Pressure volume area (PVA) was 
calculated as according to Equation 20. 
6.2.7 STATISTICAL ANALYSIS 
Statistical analysis was performed using GraphPad Prism v7.0 (GraphPad Software Inc., 
CA). Quantitative data are expressed as mean±SD, categorical variables are described 
as proportions and percentages. Data were assessed for normality of (Gaussian) 
distribution both graphically and by use of the Shapiro Wilk’s test. Statistical 
comparison of categorical data was performed using paired student t-tests were 
performed. Statistical comparison of quantitative data not falling within a normal 
distribution was performed using the Friedman test. Categorical data were compared by 
use of the Fisher exact test. Results from different measurements were correlated with 
Pearson’s correlation coefficient. A P value of <0.05 was considered statistically 
significant for all tests. 




Between March 2014 and November 2015, 21 patients were recruited into the study. 16 
patients successfully completed the protocol. Reasons for exclusion were as follows: 
inability to obtain adequate echocardiographic datasets (4) procedure related 
complication during angioplasty leading to type 2 myocardial infarction (1). Full 
background characteristics, cardiac risk factors and current anti-anginal therapy of the 
patient cohort are shown in Table 11. The patients’ clinical characteristics were 
representative of a cohort of patients with ischaemic heart disease. Invasive left 
ventricular pressure volume loops assessment and myocardial deformation imaging was 
performed in all patients and the data are presented in Table 12; myocardial deformation 




















Table 11 Baseline demographics. 
The baseline characteristics, cardiovascular risk factors and current medications of 
study participants is described. Categorical data are expressed as counts and 
percentages. Quantitative data that is normally distributed is described as mean +/- 
standard deviation 
Demographic Total (n=17) 
Age (years) 65±12 
Male sex 13/17 (76%) 
Height (cm) 168±7 
Body Mass Index (kg/m2) 28.8±3.3 
Cardiac Risk Factors  
Hypertension 14/17 (82%) 
Diabetes Mellitus 9/17 (53%) 
Hypercholesterolaemia 14/17 (82%) 
Smoking History 11/17 (65%) 
Previous Myocardial Infarction 3/17 (18%) 
Previous Percutaneous Coronary Intervention 10/17 (59%) 
Family History 8/17 (47%) 
Medications  
Beta-Blocker 14/17 (82%) 
Statin 2/17 (12%) 
Nitrate 1/17 (6%) 
ACEi/AIIRB 13/17 (76%) 
Calcium Channel Antagonist 5/17 (29%) 
Nicorandil 2/17 (12%) 
Aspirin 15/17 (88%) 
Clopidogrel 15/17 (88%) 
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Table 12 Echocardiographic parameters and LV PV loop assessment. 
Categorical data are expressed as counts and percentages. Quantitative data that is 








3D Echocardiographic Parameters 
LV Mass, grams 137.4±10.2 
Global Longitudinal Strain %  -16.7±9.3 
Global Circumferential Strain %  -26.3±16.0 
Twist degrees/sec 12.5±8.1 
Torsion degrees/cm 1.5±1.0 
Systolic Dyssynchrony Index %  5.2±1.9 
Systolic Timing Dispersion Index %  9.3±5.3 
Pressure-Volume Loop Assessment 
Markers of Contractility  
dP/dT max, mmHg/sec 1376±61 
End-Systolic Pressure Volume Relationship, mmHg/mL 4.0±0.8 
Starling Contractile Index, mmHg/mL/s 14±1 
Preload Recruitable Stroke Work, mmHg 70±6 
Markers of Relaxation   
dP/dT min, mmHg/sec -1404±62 
End-Diastolic Pressure Volume Relationship, mmHg/mL 0.16±0.07 
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Correlations between PV measurements and 3DSTE parameters 
In the cohort of patients with ischaemic heart disease, myocardial deformation imaging 
accurately reflected left ventricular myocardial mechanical properties. As would be 
expected, left ventricular mass correlated with stroke work (the external work 
performed by the heart for contraction) (SW: r=0.6; P < 0.05) and the pressure volume 
area (total mechanical energy expenditure of the heart) (PVA: r= 0.8; P < 0.01). The 
measure of global circumferential strain (GCS) correlated with load-independent 
markers of contractility: the end-systolic pressure volume relationship (ESPVR: r = 
−0.8; P < 0.001), pre-load recruitable stroke work (stroke work normalised to end-
diastolic volume) (PRSW: r = −0.6, P = 0.002) and the starling contractile index (dP/dt 
max normalised to end-diastolic volume) (SCI); GCS also correlated with the maximum 
rate of pressure increase in the left ventricle (dP/dt max: r = −0.5, P = 0.02), Figure 76. 
Global longitudinal strain was not shown to correlate with ESPVR, PRSW, SCI or dP/dt 
max. Interestingly, GCS also correlated with the maximum rate of pressure decay in the 
left ventricle (dP/dt min: r = -0.7; P < 0.05).  
Comparison of echocardiographic techniques for prediction of contractility 
Receiver-operating characteristics (ROC) curves were generated for both 
echocardiographic global measures of contractility. This was performed by 
dichotomising the variable for strain, to represent good LV function (GCS<-20, GLS<-
15) or poor LV function. The greatest area-under the curve (AUC) for the ROC curves 
was generated by GLS (AUC = 0.678, SE=0.1112), this was greater than the AUC for 
GCS (0.500, SE=0.112). These were compared using GraphPad Prism using the 
following equation: 
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Equation 25 ! = (!"#$ 1− !"#$ 2)!" (!"#$ 1)! + !" (!"#$ 2)! 
 These are demonstrated in Figure 77.  
 
 
Figure 76 Correlation of global circumferential strain (GCS) with contractility 
End-systolic pressure volume relationship (ESPVR, top left); pre-load recruitable stroke 
work (PRSW, top right); starling contractile index (SCI, bottom left); maximum rate of 
pressure increase in the left ventricle (dP/dt max, bottom right). 
ESPVR and GCS PRSW and GCS 
SCI and GCS dP/dtmax and GCS 































































































































































The results of this study show that in cohort of patients with known ischaemic heart 
disease, myocardial deformation imaging: 1) correlates with load-independent 
contractility indices derived from invasive PV loop assessment, 2) is predictive of 
contractile function at rest. This is the first study of its kind to have been performed in 
humans correlating invasive with non-invasive measures of left ventricular function. 
The importance of these findings is that strain parameters are able to closely reflect 
invasive markers of contractility and therefore may enable us to estimate contractility 
non-invasively in a consecutive manner and even during resting conditions in humans. 
In agreement with a previous rat model, we demonstrated that GCS correlated with 
ESPVR, PRSW, SCI and dP/dt max.53 We also demonstrated that GCS is a very poor 
predictor of contractility, this has implications in taking this measure forward. The 
additional value of myocardial deformation imaging in this cohort of patients with 
preserved left ventricular function on 2D echocardiography can be seen from the 
identification of patients with sub-clinical left ventricular dysfunction and the ability of 
GLS to predict contractile function. Although strain has previously been validated 
against gold-standard non-invasive techniques, to our knowledge, this has not been 
performed against the invasive gold-standard. The search for powerful non-invasive 
systolic parameters is important not only for research purposes, but also in the clinical 
arena. Superiority of speckle tracking derived parameters to predict subtle myocardial 
injury has been previously shown in pre-clinical and clinical data, moreover the reduced 
inter- and intra-observer variability provided by 3D echocardiographic techniques has 
made this an even better tool. We therefore propose myocardial deformation imaged 
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using 3DSTE may be a valuable tool in the determination of contractile function at rest.  
6.5 LIMITATIONS 
This study was performed in a cohort of patients with ischaemic heart disease, therefore 
the findings cannot be transferable to all patient cohorts without a wider validation 
study; however, they accurately reflect findings in animal studies previously performed 
in both normal and diseased hearts. 
6.6 CONCLUSIONS 
The use of 3DSTE for prediction of contractile function is feasible in a cohort of 
patients with ischaemic heart disease. Close correlation with PV loop analysis suggests 












7 PERCUTANEOUS VENTRICULAR 
RESTORATION USING THE PARACHUTE 
DEVICE: THE PARACHUTE III PRESSURE-
VOLUME LOOP SUB-STUDY 
INTRODUCTION 
Left ventricular dilatation and remodelling following acute myocardial infarction 
increases wall stress, ventricular volumes and leads to heart failure (HF), which is 
associated with a high mortality. Percutaneous ventricular restoration (PVR) therapy 
reduces LV volumes leading to a more effective ejection without the increased 
morbidity and mortality associated with surgery. This study investigated the 
haemodynamic effects of LV volume reduction from PVR on LV performance and its 
interaction with the arterial system. 
METHODS 
Ten patients with symptomatic ischemic HF of New York Heart Association (NYHA) 
classes II to IV with LV antero-apical wall akinesia underwent Parachute implantation. 
Pressure-volume loops were recorded immediately pre- and post PVR implantation and 
at 6 month follow up. 
RESULTS 
PVR significantly reduced end-diastolic volume (228±76 versus 294±69; P<0.05), with 
a greater relative reduction (average 33% versus 21%) in end-systolic volume (139±74 
versus 99±53; P<0.05) with overall 6% increase in ejection fraction (40±13 versus 
46±14; P<0.05). Furthermore, a reduction in dyssynchrony was evident on the 
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segmental loops; this was found to be statistically significant as measured by a 
reduction in the dyssynchrony index by 5% (19±4 versus 15±5 %; P < 0.05) 
immediately post-procedure, sustained at 6-months. A marked improvement in 
ventricular-arterial coupling was seen (reduction in Ea:Ees ratio  from 1.8±1.0 to 
1.1±0.6; mean ±SD; P<0.05) and all load-independent indices of contractility: end-
systolic pressure-volume relationship, starling contractile index,and preload recruitable 
stroke work (P<0.54) 
CONCLUSION  
This present study assessed both the immediate haemodynamic effects of LV volume 
reduction using the Parachute percutaneous ventricular restoration device. The 
Parachute device improved synchronous contraction, reduced wall stress and was 
associated with LV reverse remodelling.  
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7.1 INTRODUCTION 
Left ventricular dilatation and remodelling following acute myocardial infarction (AMI) 
are most commonly associated with anterior AMI and have been well documented in 
both experimental and clinical investigations.173-175 One third of patients enrolled in the 
GISSI-3 trial (n=13,679) demonstrated evidence of this progressive LV dilatation and 
remodelling following AMI.163 Treatment advances have led to increased survival from 
AMI; however this may have led to a larger population at risk of congestive heart 
failure (CHF).177 Despite huge advances in pharmacological and device therapies, the 
onset of CHF is associated with a 32% 1-year mortality.177 LV remodelling following 
AMI leads to scar formation, distorted geometry, increased wall stress and eventual 
dilatation; thus LV volume assessment in CHF can be used as an independent predictor 
of clinical outcomes.178 An important measure of therapeutic efficacy is the 
demonstrable improvement in LV volume and geometry. The aim of percutaneous 
ventricular restoration (PVR) therapy in this cohort of CHF patients is to reduce LV 
volumes and thus reduce wall stress; remodelling of the LV thus increasing 
synchronicity can lead to a more effective ejection without the increased morbidity and 
mortality associated with surgery.179 PVR is a catheter-based approach to delivery of a 
compliant partitioning (PARACHUTE) device to the LV apex, thus partitioning the 
akinetic myocardium; the conical nitinol frame with ePTFE membrane enables device 
compression and therefore percutaneous implantation. Initial studies demonstrated 
safety and feasibility with improved NYHA functional status, LV end-systolic volume 
index (LVESVI), LV end-diastolic volume index (LVEDVi), ejection fraction (EF) and 
LV end-diastolic pressure (EDP); improved survival compared to historical cohorts was 
shown.180,181 Device safety and feasibility has demonstrated to 3 years following the 
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first-in-human studies.253 More recently, an observational registry of 100 subjects 
supports PVR safety and efficacy at 1-year follow up in a real-world setting.254 
However data on the haemodynamic consequences are lacking, importantly, the effect 
of the device on LV preload, afterload, dyssynchrony indices and contractility. Accurate 
assessment of cardiac performance is critical in CHF to gauge prognosis and assess 
therapeutic response. Although ejection fraction is the most commonly used measure of 
cardiac function, the gold standard for assessing cardiac performance and its interaction 
with the arterial system is pressure-volume (PV) analysis. In CHF ventricular-arterial 
uncoupling occurs, this can accurately be measured by PV analysis as the ratio of 
Ea:Ees where Ea is a measure of net arterial load and Ees is a load-independent measure 
of LV contractility. Optimal efficiency is achieved when the ratio of Ea:Ees=1, in 
failing hearts this has been shown to be elevated.37,40,128 Simultaneous in-vivo pressure-
volume measurements with a conductance catheter (CC) placed in the LV allow real-
time assessment of the cardiac performance and its interaction with arterial load.183 PVR 
provides a unique model for assessing both the immediate haemodynamic effects of LV 
volume reduction and geometrical restoration and reverse remodelling on LV 
performance and its interaction with the arterial system; this percutaneous technique 
eliminates the confounding effects of cardio-pulmonary bypass.  
7.2 METHODS 
7.2.1 STUDY DESIGN 
The PARACHUTE III (PercutAneous Ventricular RestorAtion in Chronic Heart 
FailUre due to Ischaemic HearT DiseasE) PV Loop sub-study was a prospective, single 
arm study conducted in 2 centres in Europe. The study was designed to assess safety, 
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feasibility and efficacy of the PARACHUTE device through investigation of immediate 
changes in LV PV relationships during PVR using a CC and to relate these findings to 
acute haemodynamic changes and 6-month haemodynamic and clinical outcomes. 
7.2.2 PATIENT SELECTION 
Participants with symptomatic ischaemic HF of New York Heart Association (NYHA) 
classes II to IV were included in this study. Participants were between 18 and 79 years 
of age (inclusive) with LV antero-apical wall motion abnormality (akinesis or 
dyskinesis) secondary to myocardial infarction; LV ejection fraction between 15% and 
40%, and managed with stable doses of standard HF medical therapy for at least 3 
months, as determined by the site investigator. Subjects with myocardial ischaemia 
requiring revascularisation or cardiac resynchronisation therapy within 60 days, and 
those with significant valve disease were excluded from the study. All sites obtained 
approval from an institutional review board or ethics committee before study 
commencement, and written informed consent was obtained from all subjects at the 
appropriate time before involvement in the study.  
7.2.3 STUDY DEVICE AND PROCEDURE 
The Parachute system includes the Parachute device, the pre-shaped delivery catheter 
and dilator, and the balloon delivery system that facilitates expansion of the device, 
Figure 30.The Parachute device is composed of a self-expanding nitinol frame (16 
struts; radio-opaque), an ePTFE impermeable membrane, and an atraumatic polymer 
foot available in 4 sizes (65, 75, 85 and 95mm) with two different “foot” heights. The 
tips of the struts anchor the device on the myocardium and the atraumatic foot provides 
contact between the LV apex and the device, orientating it toward the LV outflow tract.  
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As per protocol, subjects were enrolled based on the following criteria: 1) written, 
informed consent form; 2) baseline evaluation for anatomical suitability and device 
compatibility; performed using echocardiography, multi-slice computed tomography 
(CT) and cardiac magnetic resonance imaging (Figure 41); and 3) successful placement 
of a 14F or 16F sheath in the femoral artery and pulmonary artery catheter in the 
femoral vein. Multi-modality imaging was also used to provide accurate measurements 
and to exclude LV thrombus and severe calcification. The procedure is described in 
Figure 78 and was performed under conscious sedation in the catheterisation laboratory. 
253,254 All subjects were required to receive 12 months of aspirin and anticoagulation 
with warfarin post–device implant.  
 
Figure 78 Parachute Study Procedure.  
LV angiography is performed with a pigtail catheter in the LV (A), the delivery catheter 
is positioned in the apex (B), the Parachute foot is then exposed and contact is made 
with the antero-apical wall, confirmed in left anterior oblique, LAO (C) and right 
anterior oblique, RAO (D) views. Device delivery is facilitated by 20cc balloon 
expansion (E), retraction of the delivery system, followed by fluoroscopic confirmation 
of position in LAO (F) and RAO (G) views. LV angiogram confirms partitioning of 
akinetic myocardium (H). 
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7.2.4 INSTRUMENTATION 
Simultaneous LV PV measurements were performed immediately prior to and 
following the Parachute implant and where possible at 6-months post implantation. 
Measurements were performed during steady-state conditions, avoiding excessive 
arrhythmia from premature beats. Recorded variables were averaged from 10 cardiac 
cycles to minimise inaccuracies from beat-to-beat variation and change in venous return 
from respiration; repeat baseline recordings ensured reproducibility of CC 
measurements. These were performed using a 7Fr CC (CD Leycom, Zoetermeer, the 
Netherlands); this flexible over-the-wire pigtail catheter is introduced into the LV using 
a super-stiff 0.025” J-wire. The catheter has 12 equally spaced electrodes with a central 
high fidelity, solid-state pressure sensor and is connected to a PV signal processor (Inca, 
CD Leycom), this device is described in more detail in section 2.2.1. The conductance 
method calculates continuous LV volume tracings by measuring parallel electric 
conductance between adjacent ventricular blood segments delineated by selected 
catheter electrodes; this technique has been shown to reflect LV segmental volumes in 
pre-clinical and clinical studies and has been utilised in the assessment of heart failure 
device therapies. 184,185,193 Accurate CC positioning is confirmed by fluoroscopy and on 
inspection of the segmental PV loop signals. LV Volume calibration was performed via 
right-heart catheterisation: a 6Fr single-lumen, balloon tipped Swan-Ganz catheter 
(Arrow International, USA) was positioned in the pulmonary artery to perform 
thermodilution and subtraction of calculated parallel conductance was performed by 
injection of 10mL boluses of 6% hypertonic saline through the distal port of the Swan-
Ganz catheter, further detail with regard to invasive calibration methods can be found in 
section 2.2.3.4. 255 
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7.2.5 DATA ANALYSIS 
CC data analysis was performed with dedicated data acquisition and analysis software 
(Conduct NT, version 3.18.1, CD Leycom). Conductance volumes (EDV, ESV) were 
calculated at the maiximum rate of LV pressure rise (dP/dt+) and pressure decay (dP/dt), 
stroke volume was calculated as the difference in these volumes. In addition to 
instantaneous LV volumes and pressure, this software calculates load-independent 
parameters of LV contractility. 217 The end-systolic PV relationship (ESPVR) represents 
the ratio of LV pressure to LV volume at the end of ventricular systole (uppermost left 
corner of the PV loop). The Starling contractile index (SCI) is calculated as the maximal 
rate of pressure change over time during isovolumetric contraction (dP/dTmax) 
normalised to end-diastolic volume (EDV). LV stroke work (SW) was calculated as the 
area of the PV loop; preload-recruitable stroke work (PRSW) was calculated by 
normalising the SW to EDV. LV stroke work was calculated as the product of peak LV 
peak systolic pressure and stroke volume. 193,218 Cardiac output and cardiac index (CI) 
for volume calibration were calculated using the Fick method.256 Participant follow up 
at 6-months was performed with elective admission for repeat invasive haemodynamic 
assessment, this included clinical follow up and assessment of functional status, 
transthoracic echocardiography and multi-slice CT. Clinical endpoints were: death, 
recurrent hospitalisation, emergency surgery, NYHA functional class and 6-minute 
walk test (6-MWT). The haemodynamic endpoints for the PV loop sub-study were a 
measurable change in LV volumes, assessment of LV contractility and mid-term 
improvement in ventricular-arterial coupling. 
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7.2.6 STATISTICAL ANALYSIS 
Statistical analysis was performed using GraphPad Prism v7.0 (GraphPad Software Inc., 
CA). The study was not powered to show a significant difference in haemodynamic 
endpoints due to the absence of previous invasive haemodynamic data. Quantitative 
data are expressed as mean±SD, categorical variables are described as proportions and 
percentages. Data were assessed for normality of (Gaussian) distribution both 
graphically and by use of the D’Agostino-Pearson omnibus test. Statistical comparison 
of serial haemodynamic measurements (quantitative data) of normal distribution was 
performed using a repeated measures one-way ANOVA, adjustment for multiple 
comparisons was performed using the Bonferroni correction to explain significant 
differences; in the presence of only pre and post (absence of 6 month) data, paired t-
tests were performed. Statistical comparison of quantitative data not falling within a 
normal distribution was performed using the Friedman test for repeated haemodynamic 
measurements and a 2-tailed Wilcoxon signed-rank test for paired samples. Categorical 
data were compared by use of the Fisher exact test. A two-sided alpha of 0.05 was 













Between December 2013 and May 2015, eleven subjects were enrolled at 2 sites in 
Europe: Onze-Lieve-Vrouwziekenhuis, Aalst, Belgium and St Thomas’ Hospital, 
London, UK. Of the eleven patients consented, no attempt to deliver the device was 
made in one subject because of anatomical reasons. Ten patients underwent successful 
Parachute implantation (baseline characteristics in Table 13) and haemodynamic data 
were obtained in all patients prior to implantation and nine patients post implantation: 
one patient had a major vascular complication requiring surgical repair, therefore the 
CC could not be reinserted immediately post procedure or at 6-month follow up. 
Immediate surgical explant (within 72 hours) was performed in two patients for non-
optimal positioning of the device and therefore seven patients were discharged with 
device in-situ. There were no aortic valve complications. These seven patients 
underwent 6-month outpatient clinical follow-up, and a total of six patients underwent 
6-month invasive repeat haemodynamic assessment with simultaneous LV PV loop 
analysis; one patient died from traumatic subdural haematoma during repeat admission 
prior to catheter laboratory measurements. Disposition of patients enrolled is described 
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Baseline Characteristic Total 
Device Success 8/10 (80%) 
Age, years 61.0±10.4 
Gender, male 9/10 (90%) 
Weight, kg 94.0±21.9 
Height, cm 169.4±10.0 
BMI kg/m2 32.3±4.1 
Ischaemic heart failure 10/10 (100%) 
NYHA II 6/10 (60%) 
NYHA III 4/10 (40%) 
NYHA IV (ambulatory) 0/10 (0%) 
6-MWT, metres 327±131* 
Smoking history 8/10 (80%) 
History of stroke 1/10 (10%) 
History of hypertension 4/10 (40%) 
History of diabetes mellitus 4/10 (40%) 
History of dyslipidemia 8/10 (80%) 
Prior ICD implantation 5/10 (50%) 
Prior CRT device  4/10 (40%) 
Previous PCI 10/10 (100%) 
Previous CABG 1/10 (10%) 
Table 13 Baseline characteristics  
Data are presented as counts (n/N) and percentages (%) or as mean ± SD. * Data 
available in only nine patients. Abbreviations: BMI body mass index, NYHA New York 
Heart Association Functional Class, 6-MWT 6-minute walk test, ICD implantable 
cardioverter defibrillator, CRT (±D) cardiac resynchronisation therapy ± defibrillator, 
PCI percutaneous coronary intervention, CABG coronary artery bypass graft surgery, 
HF congestive heart failure 
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Figure 79 Disposition of patients enrolled.  
LV PV (pressure-volume) measurements were performed in 9 patients pre- and post-
procedure and in 6 patients pre-, post- and 6 months.  
 
Haemodynamic, Functional Outcomes and Dyssynchrony Index 
Figure 80 shows the New York Heart Association class distribution for 12 months post-
procedure. Symptomatic improvements were evident in 50%, with no change in 37.5% 
and worsening in 12.5%, consistent with previous studies.253,257 The median NHYA 
class, however, remained unchanged between baseline, 6 and 12 months (P= 0.5) due to 
the small sample size. All haemodynamic variables are summarised in, Table 14. 
Haemodynamic measurements were performed before and after Parachute implantation 
under conscious sedation. Haemodynamic measurements at 6-month follow up were 
performed under local anaesthetic. At 6-month haemodynamic follow-up, the parachute 
device significantly reduced both end-diastolic and end-systolic volumes by a mean of 
44 (95% CI -69 to -20) and 40 ml (95% CI -63 to -16) respectively (Figure 81); there 
was an overall increase in ejection fraction by 5% [median 39% (IQR 27-51) to 44% 
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(IQR 35-59)] (Figure 82). A significant reduction in the measured dyssynchrony index 
[median 20% (IQR 14-22) to 14% (IQR 11-21); P < 0.05] was seen immediately post 
procedure and sustained to 6-months (Figure 83). End-systolic pressure increased 
significantly by mean 28mmHg (95% CI 12-45), end-diastolic pressure did not 
significantly change immediately post implantation, but was elevated at 6-month follow 
up. Percentage changes of major haemodynamic variables are summarised in (Figure 
84). 
 
Figure 80 Clinical outcomes. 
 n=10, according to New York Heart Association classes I to IV.  
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Figure 81 End-Diastolic Volume (EDV) and End-Systolic Volume (ESV).  
Change in EDV and ESV from baseline. ** Indicates statistically significant difference 
baseline versus 6 months and post procedure versus 6 months. 
 
Figure 82 Ejection Fraction.  
Change in ejection fraction from baseline. ** Indicates statistically significant 
difference baseline versus 6 months and post procedure versus 6 months. 
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Figure 83 Dyssychrony Index.  
Change in dyssynchrony from baseline. * Indicates statistically significant difference 
baseline versus post procedure. 
 
Figure 84 Percentage change in haemodynamic variables.  
Baseline to 6 months post procedure; * indicates statistically significant change. Box 
and whisker plots demonstrate mean with maximum and minimum values. 
Abbreviations see xvi. 
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LV Contractility, Ventricular-Vascular Coupling and Myocardial Energetics 
The reversal of LV dyssynchrony was accompanied by a leftward PV loop shift, and 
therefore leftward shift of the ESPVR curve and an increase in stroke work The 
maximum rate of LV pressure increase (dP/dt+), a load-dependent marker of LV 
contractility showed a trend toward increase (P=0.06). Load-independent markers of 
contractility: ESPVR (P=0.03), SCI (P=0.02) and PRSW (P=0.04) all significantly 
increased at 6 months post-procedure in line with the increase ejection fraction 
(described above) (Figure 86).  
 
The interaction between the heart and the vascular loading system determines the 
external work and metabolic efficiency of the heart.40 Therefore the elevation of end-
systolic pressure (ESP) and relief of dyssynchrony in this cohort was associated with a 
significant increase in external stroke work. Despite the increase in ESP, the net arterial 
load, as measured by effective arterial elastance (Ea), remained unchanged. Furthermore, 
at 6-month follow up, a marked improvement in ventricular-arterial coupling was seen 
(reduction in Ea:Ees ratio  from 1.8±1.0 to 1.1±0.6; mean ±SD; P<0.05) (Figure 87). 
Although total ventricular work increased, the ratio of external stroke work (SW) to 
total work (PVA), the efficiency of energy transfer, increased significantly, from 54.7% 
to 59.8% (P<0.05) (Figure 88).  
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Figure 85 Pressure volume loops performed in 7 patients prior to implant (black) and 
post implant (blue). The total PV loop prior to implant demonstrates a leftward shift in 
response to a decrease in dyssynchrony. 




























































































Figure 86 Percentage change in indices of contractility.  
Baseline to 6 months post procedure. *Indicates statistically significant change. Box and 
whisker plots demonstrate mean, maximum and minimum value. Abbreviations see xvi. 
Figure 87 Ratio of Ea:Ees.  
This demonstrates the interaction of the left ventricle with the arterial system at baseline 
compared to 6 months post procedure. 
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 Figure 88 Ratio of SW:PVA expressed as a percentage.  
This demonstrates the efficiency of conversion of metabolic energy to external stroke 
work at baseline compared to 6 months post procedure.  
 
 
Figure 89 Percentage change in markers of LV relaxation and efficiency.  
From baseline to 6 months post procedure. * Indicates statistically significant change. 
Box and whisker plots demonstrate mean with maximum and minimum values. 
Abbreviations: SW:PVA stroke work to pressure volume area ratio, Ea:Ees arterial 
elastance to end-systolic elastance ratio. 
Indices of LV Relaxation 
A significant improvement in active LV relaxation as measured by the maximum 
derivative of LV pressure decay  (dP/dt-) (-679±244 to -962±189mmHg/s; P<0.05) was 
demonstrated with a trend toward reduction in Tau (P=0.09) ( ). An improvement in LV 
compliance as measured by LV end-diastolic pressure and EDPVR (End-Diastolic 
Pressure Volume Relationship) could not be demonstrated at 6-month follow up, this is 
likely due to the effect of heavy sedation on a reduction in diastolic stiffness in heart 
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failure patients during peri-procedural measurements that was absent on 6-month 
follow-up; the large volume reduction and the small patient cohort.258   
7.4 DISCUSSION 
The Parachute device partitions and isolates the apical region of the LV from the rest of 
the chamber.  The goal is to exclude infarcted, dyskinetic regions of myocardium to 
optimize the use of contractile energy produced by remaining myocardium for 
generating forward cardiac output and blood pressure.  Pressure-volume analysis 
showed that both immediately after and 6 months following implant, the Parachute 
device reduced chamber volume, and enhanced pressure generation with trends towards 
increased stroke volume in most of the patients studied.  These were the result of 
leftward/upward shifts of the ESPVRs and EDPVRs.  Along with these, we also saw 
increased SW/PVA ratio indicating a greater proportion of ventricular work expressed 
externally.  Initial studies demonstrated safety and feasibility with improved NYHA 
functional status and improved survival compared to historical cohorts.180,181 Device 
safety and feasibility has been demonstrated to 3 years following the first-in-human 
studies 253 and in over 100 subjects at 1-year follow up in a real-world setting.254 
However there were significant complications with this device implantation thus it was 
associated with significant (40%) morbidity. Left ventricular dilatation and remodelling 
following acute myocardial infarction (AMI) is most commonly associated with anterior 
AMI and has been well documented in both experimental and clinical investigations;173-
175 One third of patients demonstrate evidence of progressive LV dilatation and 
remodelling.163 Treatment advances have led to increased survival from AMI; 177  
however the onset of CHF is associated with a 32% 1-year mortality. 177 The assessment 
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of cardiac performance is critical in CHF to gauge prognosis and assess therapeutic 
response. This study examined the immediate and mid-term haemodynamic effects of 
percutaneous ventricular restoration (Parachute) device implantation on cardiac 
performance and ventricular-arterial interaction and their relationship to clinical 
outcomes in a cohort of patients with akinetic aneurysmal apices secondary to acute 
myocardial infarction.  It was not able to demonstrate that every patient responded as 
intended haemodynamically, which would be consistent with the clinical response that 
is seen in approximately half of patients. 
Left ventricular dyssynchrony is frequently observed in congestive heart failure, it leads 
to inefficient left ventricular contraction and decreased cardiac output. This places 
patients at increased risk of cardiac events and is an important predictor of outcome. 259 
In congestive heart failure, LV function is disturbed by a combination of factors: 
reduced contractile function, abnormal loading conditions and dyssynchronous 
contraction. The conductance catheter method is an alternative and invasive measure of 
LV dyssynchrony, traditionally used to measure global systolic and diastolic volumes; 
the segmental conductance signals are able to describe temporal and spacial indices and 
have been previously described and validated.260 Ventricular dyssynchrony is associated 
with a rightward shift of the PV loop (and therefore ESPVR) with a reduction in stroke 
work (PV loop area) and stroke volume, with an accompanied decline in dP/dt+. 
259,261,262 In the patients that responded (4 out of 7) implantation of the Parachute device, 
through partitioning of the dyskinetic left ventricular apex, increased synchronicity of 
contraction, with observed increases in contractility and ventricular efficiency. 
Continuous assessment of instantaneous LV pressure and volume enabled real-time 
display of the reversal of dyssynchrony in this study through normalization of 
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segmental PV loops. This was further supported by a leftward shift in the total pressure-
volume loop in the responders, a leftward shift of ESPVR and an increase in stroke 
work, accompanied by an improvement in load-independent markers of contractility. 
An improvement in dP/dt-, representative of the early diastolic phase, is likely to be 
related to preceding systole, thus reflecting enhanced contraction, rather than passive 
diastolic properties. The ability to measure EDV by the conductance method enables a 
direct measure of the preload imposed on the heart, partitioning of the ventricle lead to 
reduced end-systolic and diastolic volumes, thus reducing the abnormal excessive 
loading conditions that predominate in CHF.  A reduction in wall stress and improved 
contractile function at 6 months is suggestive of LV reverse remodelling. 
The dynamic interaction between the heart and the systemic vasculature is fundamental 
to the heart providing adequate cardiac output and the arterial pressures necessary for 
distal organ perfusion.109,114 Ventriculo-arterial coupling correlates inversely to pump 
efficiency, this can accurately be measured by PV analysis as the ratio of Ea:Ees where 
Ea is a measure of net arterial load and Ees is a load-independent measure of LV 
contractility. Ea:Ees is an important parameter that measures the interaction between the 
left ventricle and the arterial system and is a determinant of net ventricular performance 
and cardiac energetics.37,38 The heart is optimally efficient at a ratio of 0.7; in CHF 
ventricular-arterial uncoupling occurs and an Ea:Ees>1.0 is seen.37,40,128. Following 
Parachute implantation we observed enhanced ventricular-arterial coupling, this was 
seen to be mediated by the increase in contractility observed from the relief of 
dyssynchrony. We therefore conclude that the immediate beneficial effects of the 
Parachute device are predominantly mediated by its ability to reduce LV dyssynchrony, 
with long term reduction in wall stress and likely reverse remodelling. Although 
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medical therapy remains the mainstay of treatment in CHF, mortality remains 
significantly high in this cohort. 177,263,264 Other than CRT, there are no known 
percutaneous interventional therapies that aim to restore mechanical synchrony.218 
Several hypotheses underlie the failure of surgical ventricular restoration in the STITCH 
trial including the absence of dyskinetic wall motion in 50% of patients, with only a 
modest degree of volume reduction, depite immediate acute decrease in mechanical 
synchrony observed froollowing ventricular restoration.255,265-267 Thus a percutaneous 
approach with the Parachute device may achieve a more reproducible volume reduction 
without the increased risk of surgery in appropriately selected patients, although it is not 
without risk, and as yet we are unable to determine which patients will respond 
haemodynamically and clinically to the device. Thus this is the first demonstration of 
the therapeutic efficacy of the parachute through restoration of mechanical synchrony, 
in a cohort of patients with apical dyskinesis.  
7.5 LIMITATIONS 
This study has limitations due to the small sample size and the unblinded single arm 
nature of the study. Absolute conclusions cannot be drawn in the absence of a control 
group to demonstrate efficacy and superiority of the device when compared to optimal 
HF therapies alone. Due to study design, bias cannot be ruled out in the adjudication 
process. This study was associated with 40% complication rate, thus it should be 
recommended that the device be used with caution in the appropriate patient group. 
7.6 CONCLUSIONS 
This present study assessed both the immediate haemodynamic effects of LV volume 
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reduction and geometrical restoration and reverse remodelling on LV performance and 
its interaction with the arterial system. Percutaneous ventricular restoration was 
associated with a reduction in end-diastolic and end-systolic volumes and LV reverse 
remodelling in the mid-term. The on-going large-scale Parachute IV study will establish 
the role of this novel therapeutic approach in ischaemic heart failure.268 
 
Potential Impoact 
The Parachute device provides a novel therapeutic approach for patients with systolic 
heart failure; this haemodynamic study validates and supports the previously observed 
favorable clinical outcomes thereby supporting the adoption of this device in a specific 














In this chapter, the main findings of the thesis are discussed. The aim of this synthesis is 
to review the studies performed, the addition of knowledge to the existing literature, the 
implications of this work and future directions of study. 
 
Origins and design 
Fundamental to advancing our understanding of cardiovascular pathophysiology and 
therapeutics is the examination of the components of the cardiovascular system and the 
coordinated response to physiological and non-physiological changes. For the purposes 
of addressing the aims of this research, this can be separated into the ventricular-arterial 
(VA) interaction, how the pump interacts with the system and the cardiac-coronary 
interaction. Instinctively, we know this to be an artificial divide; however, the 
interactions within the system are likely to be far more complex than initially 
appreciated. 
 
Coronary blood flow is known to be phasic in nature, increasing in systole and 
decreasing in diastole. The mechanism of coronary systolic flow impediment has 
generated great interest and extensive work in this area over the past 4 decades.72,187,188 
The close proximity of the coronary vasculature to the myocardium means a two-way 
interaction exists; and coronary blood flow morphology is not merely a function of 
aortic pressure. Recent work has centred around examining the product of simultaneous 
changes in the coronary pressure and flow velocity signals to describe these in terms of 
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successive wavefronts or wave intensity analysis. 96,97As WIA can differentiate between 
proximally arising waves from the aorta and distally arising waves from the 
microcirculation, this has enabled a greater understanding of the aortic and myocardial 
components driving (and impeding) coronary blood flow. More recently it was 
proposed that WIA was more closely related to cardiac mechanics than initially 
understood; attempts to further delineate this focussed on independent measurement of 
left ventricular pressure and coronary pressure and flow velocity.  
 
The instantaneous ventricular pressure-volume (PV) relationship is crucial to describing 
intrinsic myocardial properties; thus to understand cardiac mechanics, it is necessary to 
appreciate that PV relationships represent force-length relations at the ventricular level, 
thus is the most accurate means of measuring chamber geometry, compliance and 
contractile function in humans. Progression of technology and validation of the 




The study of coronary physiology and left ventricular (LV) pump properties are two 
separate fields of work. The aim of this thesis was to bring together these research 
interests to enable a greater understanding of the interaction between the components of 
the cardiovascular system, which is poorly understood. 
 





Chapter 3: The Development Of A Novel Analytical Software System 
In this results chapter the development of a novel software system was described. The 
configuration of existing commercially available hardware enabled creation of a tool 
capable of simultaneous online assessment of LV properties, and therefore the VA 
interaction and coronary haemodynamics. An analytical software programme 
incorporating automated algorithms to measure the simultaneous tracings was validated 
and used to describe 1) the influence of cardiac mechanics on coronary waves and 2) the 
mechanical determinants of coronary blood flow. The following work has not been 
previously performed, and would not have been possible without the generation of this 
software. The origins of coronary wave energies are incompletely understood. Here we 
demonstrated that forward travelling wave arising from the aorta were the product of the 
ventricular-arterial interaction, the generation of these waves is dependent on peak LV 
pressure exceeding diastolic aortic pressure. This suggests that a complex interplay 
comprising, preload, afterload (lumped mean and pulsatile) and contractile force is 
involved in wave generation in the coronary artery. Furthermore backward travelling 
waves were found to mirror the ventricular pressure-volume relationship very closely, 
the backward travelling suction wave commences immediately after the ventricle has 
reached its state of maximal contraction and continues until cross-bridge uncoupling is 
complete. Coronary blood flow velocity was found to be uniquely linked to LV 
elastance on abolition of autoregulation, suggesting the unique morphology of coronary 
flow is as a result of a combination of transmural compressive forces and intra-vascular 
forces generated by the resistance vessels. 
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The development of the above tools facilitated examination of the cardiovascular 
response to exercise and the pathophysiological mechanism of exercise-induced 
ischaemia. 
 
Chapter 4: Myocardial Systolic And Diastolic Function During Exercise-Induced 
Ischaemia 
The cardiovascular response to exercise is the most important circulatory adjustment the 
body has to make; this is therefore the most important means of understanding how the 
components of the system interact. Survival of the Homo Sapien species was dependent 
on the procurement of food, hence gene selection in the Late Paleolithic era was 
influenced by physical activity. Convincing evidence shows that this genome has 
remained essentially unchanged over the past 10,000 years. The findings of this study 
demonstrate that in the presence of significant coronary artery disease, a biphasic LV 
response to exercise occurs. Although early diastolic abnormalities are demonstrated, in 
an attempt to increase circulating blood flow to exercising muscles, contractile function 
and cardiac output increase; a threshold is then reached, believed to be a certain 
duration and intensity of ischaemia (inability of supply to meet demand), beyond which 
impairment of contractile function and ventricular-arterial coupling occurs. Interestingly 
in an attempt to ameliorate these stressors, the system firstly maintains diastolic time 
fraction to maintain coronary blood flow and secondly, reduces external work. 
Variations in dP/dt closely correlated with generated wave energies suggesting that 
wave intensity analysis may well be a potential surrogate for changes cardiac 
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mechanics. This is the first time to our knowledge that these processes have been 
examined to this accuracy. 
 
This study provided great insight into the adverse pathophysiological mechanisms 
surrounding exercise-induced angina, facilitating a new look at therapeutic agents and 
the anti-ischaemic mechanisms of nitrates. 
 
Chapter 5: The Anti-Ischaemic Mechanism Of Nitrates 
The importance of this work centred on delineating the precise mechanism of action of 
nitrates. Previous studies have examined coronary blood flow and LV haemodynamics 
in isolation, thus it was felt extremely important to examine the coordinated 
cardiovascular response. We demonstrated that the administration of nitrates had no 
measured effect on intrinsic myocardial properties (contractile function and 
compliance); however, the beneficial effects were found to be restoration of the 
imbalance between supply and demand. Stenosis dilatation and reduced myocardial 
oxygen consumption, were driven by the vasodilator effects of nitrate, specifically 3 
mechanisms were demonstrated: 1) preload reduction through venodilatation 2) 
afterload reduction by systemic arterial vasodilation and therefore enhanced ventricular-
arterial coupling 3) increased pump efficiency both in terms of the VA interaction and 
with regard to myocardial energy transfer.  
 
Chapter 6: 3D Myocardial Deformation Imaging 
Subclinical systolic and diastolic left ventricular (LV) dysfunction have been shown to 
be independently related to atherosclerosis, providing incremental value over traditional 
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risk stratification. This was the first validation of 3D speckle tracking 
echocardiographic indices of strain with invasive measures of contractility in humans; 
although further work is required with larger scale validation, 3D STE may be useful as 
a prognostic tool. 
 
Chapter 7: Left Ventricular Partitioning Device 
Ischaemic cardiomyopathy is the end stage of ischaemic heart disease; interventions are 
limited beyond pharmacological therapy. An important measure of therapeutic efficacy 
is the demonstrable improvement in LV volume and geometry. In this chapter the 
results of the haemodynamic effects of percutaneous ventricular restoration therapy 
(PVR) were presented. We demonstrated that PVR reduces LV volumes and 
dyssynchrony through geometrical restoration and induces reverse remodelling. The 
resulting effect on LV performance is improved contractility and ejection and enhanced 
VA coupling (interaction of the ventricle with the arterial system) without the 
associated morbidity and mortality of surgery. 
 
Conclusions 
A complex interaction exists between the myocardium, coronary arteries and systemic 
vasculature. By developing novel tools that enabled simultaneous analysis of these 
components of the system we were able to describe the impact of cardiac mechanics on 
coronary blood flow and the origins of wave energies in the coronary arteries. The 
pathophysiological response to exercise in a cohort of patients with ischaemic heart 
disease demonstrated a biphasic response to exercise. The mechanism of nitrates were 
shown to be a through a combination of coronary, cardiac and systemic effects that 
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restore the supply-demand imbalance by stenosis dilatation and increased cardiac 
efficiency. PVR was shown to be a feasible therapeutic option in end-stage heart failure 
by improving chamber geometry and inducing LV reverse remodelling. 
 
Future Work 
For true simultaneous online analysis to be possible the novel software system would 
need to be integrated into the commercially available hardware; this is the next stage in 
software development. The potential for this analytical tool is vast, the work produced 
in this thesis has already been fundamental to establishing other avenues of research 
including: 1) An enhanced understanding of biventricular pacing by way of 
simultaneous LV - aortic and right ventricular - pulmonary artery flow measurements. 
2) The investigation of haemodynamic support devices during high-risk angioplasty to 
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10.1 PATIENT INFORMATION SHEET. VERSION 4.  
21/12/2015 LREC Study Number: 09/H0802/39 
 
Title of project: The Role of Nitrates in Angina Pectoris 
You are being invited to take part in a research study. Before you decide it is important 
for you to understand why the research is being done and what it will involve. Please 
read the following information carefully. Ask us if there is anything that is not clear or 
if you would like more information. You may withdraw from the study at any stage. 
 
1. What is the purpose of the study? Patients who have narrowings in their heart 
arteries may suffer with chest pains known as angina. Glyceryl trinitrate (GTN) has 
been shown to alleviate the symptoms of angina, and is usually given to patients in the 
form of a spray under the tongue. GTN has also been shown to prevent angina  when  it  
is  given  before  a  period  of  exertion;  for  example exercise. However, although GTN 
has been used successfully in the treatment of angina for many years, the exact 
mechanism via which it works remains unclear. If we can observe one particular 
mechanism via which GTN works, then this would prove very useful as this mechanism 
could then be specifically targeted by future research studies. The latest techniques in 
cardiac magnetic resonance imaging (CMR) will be used to investigate this occurrence, 
in addition to the use of a special catheter to measure pressure inside the heart and a 
special wire that measures blood flow in the heart arteries. 
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2. Why have I been chosen? You qualify for this study, because you are have 
narrowings in your heart arteries and suffer from angina. You have been shown not to 
experience “warm-up angina” on a recent exercise test. 
3. What will happen to me if I take part? There is a flowchart at the end of this 
document summarising the steps involved. 
Standard procedure: 
Continue with anti-anginal tablets. You will remain on the waiting list for an angiogram 
with possible subsequent angioplasty or heart bypass operation (if applicable). 
Study procedure: 
Any medical or surgical treatment planned for you will not be delayed because of the 
study. As a screening procedure to see if you are suitable for the study you will undergo 
one further exercise test using the same specially adapted bicycle. On this occasion just 
before the test we will give you 2 puffs of a GTN spray to see how this affects your 
performance. If it does improve things then you be invited to continue with the study. If 
it makes no difference then we shall not need you to participate further in this study.  
We may ask you to stop some of your usual anti-anginal medications prior to the 
exercise test as they  can  interfere  with  the  results.  It is possible  that  you  will  
experience  some discomfort during the exercise procedure, but this does not increase 
the risk of having a heart attack. The next stage of the study involves a cardiac MRI 
(CMR) scan, which will require an additional visit by you to our new purpose-built 
research centre at St. Thomas’ hospital. During the scan you will be asked to carry out 2 
periods of exercise similar to that performed previously on the exercise bike. This is so 
that we can see what is happening to your heart during these episodes. You may be 
asked to stop some of your anti-anginal medications as before. The scan will last about 
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1 hour in total and will involve an agent needed to provide contrast for  the  CMR  scan.  
The agent contains gadolinium, a substance widely used for such scans in medicine.  
This injection will require the insertion of a small cannula, or “drip” onto your arm. 
Before the second period of exercise, we will administer 2 sprays of GTN under your 
tongue 5 minutes before the start of the exercise. We will scan your heart with the MRI 
scanner after both sets of exercise, and will then compare the differences between the 
1st and the 2nd periods of exercise. Following the CMR scan you will return to St 
Thomas’ for your planned angiogram and/or angioplasty procedure. The procedure will 
be carried out via the main blood vessel in your wrists or groin which is the standard 
approach in many cases. During this procedure a special catheter (1.3 mm tube) will be 
placed inside the heart through one tube and is very similar to a catheter that is normally 
used during angiography to assess heart function but this can measure pressure too; in 
addition a special wire, very similar in  structure  to  the  standard  wire  that  is  used  
for  the  angioplasty procedure through another tube will be passed into the coronary 
blood vessel that contains the narrowing. This wire is designed to measure blood flow 
and it will take careful measurements while you undertake a further 2 periods of 
exercise using a specially adapted supine exercise bike. A second wire will be passed 
via the same artery, and will be used to take additional flow measurements from the 
main artery; called the aorta. As before, you may be asked to stop some of your anti-
anginal medications. Slightly different to the CMR study, you will be given 2 sprays of 
GTN during the first period of exercise. You will then have your stenting procedure as 
normal. The total time for both the treatment and the research procedures will be no 
longer than 2 hours. The standard procedure normally takes about 1 hour. You will be 
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invited to complete a feedback survey in the form of a questionnaire at the end of the 
study. 
 
4. What are the side effects of the procedure received when taking part? There are  
no  serious  risks  from  stopping  the  anti-anginal  medications  that  we  have 
authorised,  whatever  the  length  of  time  you  are  off  them.  You  may  experience  a 
worsening of your angina symptoms, but this does not increase the risk of a heart attack. 
Supervised treadmill tests are safe. However, they do carry a small risk (1 in 10,000) of 
a significant complication such as a serious heart rhythm abnormality, heart attack, or 
death. Exercise tests are widely used, however, and it is likely that you will need to 
undergo one anyway as part of your routine clinical work-up. You will undergo a total 
of 6 exercise tests over the course of the entire study. GTN given in the form of 2 sprays 
under the tongue, is used routinely by many patients who have angina to successfully 
alleviate this symptom. In this study we are expecting any anginal symptoms which 
may be experienced with the treadmill tests, to be reduced with GTN. Side effects from 
GTN may include flushing, headache, dizziness; however the standard dose of GTN 
will be used once in each study only, and therefore side effects should be no more likely 
than from one routine use in a different environment. The CMR scan is very safe and 
does not involve any exposure to X-rays. The scanner is quite enclosed and some people 
may feel uncomfortable (claustrophobic) but this is very unusual. There will be a buzzer 
for you to press if you feel unwell or uncomfortable and would like to stop the scan. 
The scanning time is about 1 hour in total. For the exercise part of the scanning 
procedure you will be taken out of the scanner, and undertake similar exercise tests as 
before. When you reach a certain point during the exercise you will be returned to the 
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scanner, but only for a very short period of time, approximately 1 minute. You will then 
come out of the scanner again and have a chance to recover from the exercise. Although 
generally very safe, there are some risks associated with the gadolinium-based contrast 
agent, which will be given by injection during the scan. Mild headache, nausea and a 
local burning sensation can occur. Rarely (less than 1in100), low blood pressure and 
light headedness occurs. This can be treated immediately with fluid given through a 
vein. Very rarely (less than 1 in 1000), patients are allergic to the contrast agent. The 
use of the special flow wire is safe and this device is used in routine clinical practice. 
For this study, it will be inserted through a small artery in your wrist instead of at the 
top of your leg, as is more usual in clinical practice. It can sometimes take a few 
minutes longer to position the wire correctly and this may involve a very small 
additional dose of x-ray radiation. In addition, it will take a further couple of minutes to 
position the additional flow wire that will also be inserted through the same cut in the 
wrist, and will be positioned in the aorta (the main blood vessel leaving the heart 
carrying oxygen-rich blood to the rest of the body. The additional dose of x-ray 
radiation has been assessed by the radiation safety team who suggest a 1 in 5,600 
chance of it being associated with any excess risk of cancer. The total radiation dose for 
both the clinical and research aspects of the study is estimated to be 12.5 millisieverts 
(mSv). The additional radiation dose is 3.1 mSv, which is equivalent to 14 months’ 
exposure to background radiation. If the procedure is performed using both wrists, you 
will have wrist band applied to both sides, thus there is a small risk of bleeding from 
either wrist (less than 5% risk of vascular complications). The exercise cycle protocol in 
the MRI scanner and in the catheterisation lab is not a routine research tool. However, 
we do not anticipate any additional risk from it. You will be monitored very carefully 
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throughout. Should you want to withdraw from the study at any point you will be 
entirely free to do so, and this will not affect your treatment in any way. 
5. What are the possible benefits of taking part? There is no direct benefit to study 
participants. The information we will get might help improve the treatment of other 
people with angina. 
6. Will my taking part in the study be kept confidential? Yes. All the information 
about your participation in this study will be kept confidential. 
7. Expenses and payments: Travel expenses will be reimbursed for the extra hospital 
visits required by this study. Otherwise there is no payment for taking part. 
8. What if there is a problem? Any complaint about the way you have been dealt with 
during the study or any possible harm you might suffer will be addressed. 
Thank you for reading this information sheet and considering taking part in this study.  
Contact address:  
Dr Tiffany Patterson  
Department of Cardiology 
6th Floor East Wing 
St Thomas' Hospital, London SE1 7EH 
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The Mechanisms of Exercise Induced Angina 
Abstract 
Although well described, the mechanisms behind the clinically observed phenomenon 
of exercise-induced angina are poorly understood. Complex haemodynamic changes 
occur during exercise that may in fact protect the heart from the deleterious effects of 
ischaemia on subsequent bouts of exercise. Potential causes include an increase in 
coronary blood flow, a reduction in cardiac work, or an adaptation of the heart muscle 
to make it more resistant to ischaemia. We intend to investigate these phenomena as 
part of a series of studies using a serial exercise protocol under a range of 
haemodynamic conditions, utilising both perfusion MRI and invasive coronary flow 
studies. We will determine changes in coronary blood flow, myocardial perfusion 
distribution and indices of cardiac work with exercise, and hope to use this data to 
improve our understanding of this clinically important phenomenon. Such work has not 
been previously performed and it will utilise our local expertise in each of these areas. 
Background 
The variable relation between exercise and angina has been recognised for more than 
200 years1. The terms “first effort”, “warm up”, or “first-hole” angina, have been used 
to describe the ability of some patients to exercise to angina, rest, and then continue 
exertion with reduced symptoms or none at all. In the experimental setting, the salient 
observation is that at the accumulated work (exercise duration) causing max ST-
segment depression on first exercise, on second exercise there is less ST depression, 
chest pain and dysrhythmia2. The traditional view is that angina is the result of an 
imbalance between the supply and demand of the myocardium for blood3, 4. However, 
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the mechanisms underlying the warm-up phenomenon are still poorly known and 
somewhat controversial. Potential causes of the warm-up phenomenon include: (1) an 
improvement of blood flow, which, in turn, may be caused by stenosis dilation, 
collateral recruitment or myocardial perfusion redistribution5-7; (2) an adaptation of the 
myocardium to ischaemia, such as that caused by ischaemic preconditioning3, 8-10; and 
(3) peripheral effects causing a slower increase of cardiac workload, such as seen during 
training11 or changes in central blood pressure.  Initial results from our own department 
suggest that changes in collateral flow have little influence2. Not all patients, however, 
seem to benefit from warm-up angina with it being clinically detectable in only about 
50 percent of patients. In those that do not demonstrate warm-up it has been postulated 
that the haemodynamic changes induced by commonly used cardiac medications such 
as nitrates, beta-blockers or calcium channel antagonists simulate many of the changes 
that underlie this phenomenon. Demonstrating these changes may greatly enhance our 
understanding of the mechanisms of angina and its relation to exercise. 
Okazaki et al9 suggested that the benefits observed during serial exercise were due to 
changes in regional myocardial oxygen consumption rather than increases in blood 
flow. The investigators, however, relied on great cardiac vein catheterisation to assess 
flow through thermodilution which has been shown to be inaccurate and highly 
dependent on the position of the catheter12. In addition, because it only assesses global 
flow this method cannot determine the changes that may occur in a particular vessel or 
the redistribution of flow between the different myocardial layers which may have a 
very important role13.  Williams et al8 performed a similar protocol but relied on rapid 
right ventricular pacing, a non-physiological surrogate for exercise,  to induce 
tachycardia stress in a small group of stable coronary disease patients with exertional 
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symptoms but not necessarily warm-up angina. They also relied on great cardiac vein 
sampling to determine global coronary flow and similarly concluded to the Okazaki 
group that warm-up angina could not be explained by an increase in coronary flow 
alone.  
The transmural distribution of myocardial blood flow from endocardium to epicardium 
is critical during exercise as the contractile forces within the heart have a 
disproportionate effect on the subendocardial layer which renders it much more 
sensitive to ischaemia23. When coronary blood flow control mechanisms are intact, the 
flow distribution across the myocardium is relatively uniform through local 
autoregulation with vasodilatation of the myocardial resistance vessels24. When this 
vasodilatory capacity is exhausted (such as during exercise), subendocardial 
conductance becomes inversely dependent on heart rate and is decreased as the diastolic 
time fraction (DTF) shortens. Subepicardial perfusion, in contrast, is generally 
unaffected by these changes25. DTF is the relative duration of diastole with respect to 
the duration of the heart cycle and decreases with increasing heart rate. In the presence 
of a coronary stenosis, the autoregulatory mechanisms regulating myocardial blood flow 
are exhausted at an earlier stage during exercise (or even at rest) rendering the 
subendocardial layer even more critically dependent on the DTF26.  Interestingly, at this 
point DTF has been shown to be dependent on distal perfusion pressure rather that the 
heart rate with no correlation found between DTF and heart rate at the ischaemic 
threshold27,28. Changes in DTF were also found to reduce microvascular resistance and 
hence improve perfusion25. It has been suggested that an increase in diastolic duration 
during ischaemia may therefore be an important mechanism for matching coronary 
supply and demand of oxygen by simultaneously decreasing demand and increasing 
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supply. It is possible that such changes contribute to the protective effects of serial 
exercise observed during warm-up angina.  
Ischaemic preconditioning (IPC), is the term used to describe the increased myocardial 
resistance to ischaemia that follows a brief episode of ischaemia. In animal models it 
protects against infarct size and arrhythmias16 and has shown to have a similar 
beneficial effect in human studies2, 17. Patients with coronary artery disease have been 
observed to exercise longer before developing angina and may develop less angina and 
ischemia during a second exercise test compared with a first test when these tests are 
separated by a brief rest period9, 18. It has been suggested that the clinical observation of 
the warm-up phenomenon may represent one aspect of IPC in humans10.  IPC, like 
warm-up angina is also unexplained by a down-regulation of contractile function or an 
increase in collateral myocardial perfusion induced by initial exercise19, 20. Warm-up 
angina, however, does not seem to be mediated by adenosine or by cardiac adenosine 
triphosphate-sensitive potassium channels21, 22 suggesting that it is mechanistically 
distinct from classic ischemic preconditioning.   
The mechanisms by which nitrates exert anti-anginal effects are widespread. In the first 
instance there is a reduction in myocardial oxygen demand, through a reduction in 
preload29-38, a reduction in afterload31,35,36,38 and a reduction in arterial pressure 
augmentation38-39. There is also an improvement in myocardial perfusion, through 
vasodilatation of epicardial coronary arteries40-45, enhanced collateral recruitment43,46, 
coronary stenosis enlargement41,43,47, improved endothelial function48, and preferential 
redistribution of blood to the subendocardium from the subepicardium49-55.  
It is postulated that the protective effects of nitrates are mechanistically similar to those 
induced by the warm-up effect on second exercise.  Nitroglycerin (NTG) is rapidly 
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converted to nitric oxide (NO) at or near the plasma membrane of vascular smooth 
muscle cells. NO activate guanylate cyclise which catalyzes the formation of cyclic 
guanosine monophosphate (cGMP); this induces a fall in intracellular calcium and 
subsequent vasodilation. Thus it may be that an increase in cGMP is central to the 
protective effects induced by nitrates and warm-up angina. 
Phosphodiesterase type 5 selective inhibitors block the degradative action of 
phosphodiesterase type 5 (PDE-5) on cGMP in vascular smooth muscle cells, and 
therefore also produce an increase in cGMP which provokes vasodilatation. PDE-5 is 
expressed in a variety of tissues including the coronary and pulmonary vasculature, as 
well as high concentrations in the corpora cavernosa. Sildenafil (a PDE-5 inhibitor) has 
been postulated to induce cardioprotection via pharmacological preconditioning; most 
probably through an increase in nitric oxide generated from endothelial and/or inducible 
nitric oxide synthases, and opening of mitochondrial ATP-sensitive potassium 
channels56,57. Cardioprotective effects observed include a reduction in myocardial 
infarction, anti-arrhythmic effects, and an improvement in ventricular functional 
recovery58. Furthermore, in a recent study PDE-5 inhibitors were shown to augment 
haemodynamic effects of calcium channel inhibitors in NO deficient rats, highlighting 
the pivotal role of the NO-cGMP pathway59. 
The current proposal aims to investigate the relationship between serial exercise and 
angina by assessing the relative influences of changes in blood flow, myocardial 
workload or intrinsic adaptation using a combination of cardiac magnetic resonance 
imaging (CMR) and invasive coronary physiological measurements, during a serial 
exercise protocol. We will then investigate the effect of a pharmacologically 
manipulated increase in cGMP on the above parameters. To induce such a reproducible 
 286		
and reliable increase in cGMP, the two most plausible methods would be to use a PDE-
5 inhibitor or a nitrate. Glyceryl trinitrate (GTN) provides the safest and easiest method 
in which to achieve such conditions. It is available for use as a sub-lingual spray, and 
produces well described haemodynamic effects with a rapid onset of action, whilst 
maintaining a good safety profile. Furthermore, as an established anti-anginal agent, 
patients with angina are familiar with its use and side effects. 
Therefore the typical haemodynamic effects induced by sublingual GTN spray will be 
examined in the second period of exercise. Patients who demonstrate the “warm-up” 
effect will be specifically excluded as they will be enrolled in a very closely related 
study (08/H0802/136  The assessment of coronary blood flow in patients with warm-up 
angina: Increased flow or reduced need?). As well as producing important data in its 
own right this study will also validate the novel methods used in the protocol to show 
that detectable differences in cardiac work and flow can be made on serial exercise. 
Subsequent studies are expected to examine further haemodynamic conditions using 
other agents that influence myocardial ischaemia on exercise including beta-blockers, If 
channel blockers and calcium channel antagonists.  
Hypotheses 
The NO-cGMP axis is central to the processes of warm-up angina and also triggers the 
related phenomenon of ischaemic preconditioning. Currently is unclear how this axis 
influences these processes. In patients with coronary artery disease and angina there are 
3 possibilities  
The typical systemic haemodynamic changes following activation of the NO-cGMP 
axis reduce cardiac work 
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The typical local coronary haemodynamic changes following activation of the NO-
cGMP axis result in improved perfusion of the subendocardium  
The activation of the NO-cGMP axis results in direct cardiac protection that manifests 
as an anti-anginal action in the absence of 1 or 2. 
Within this application we will activate the NO-cGMP axis with sublingual GTN in the 
first instance since this method is better established and likely better tolerated than 
inhibition of PDE5. 
 
Rationale for the chosen methods 
There has been very limited experimental data examining the mechanism of angina 
during serial exercise. The few studies published have either used outmoded or 
inaccurate means to determine cardiac work or coronary flow8, 9. Other more 
contemporary studies have examined changes in blood flow in patients with coronary 
disease under a range of haemodynamic conditions using adenosine60, dobutamine61, 
nitroprusside62 or rapid right ventricular pacing62 but, importantly, all of these fail to 
recreate the physiological conditions actually experienced during exercise. The artificial 
milieu induced by pharmacological vasodilatation augments the “steal” of perfusion 
from the subendocardial layer but does not provoke the simultaneous increase in oxygen 
demand required during exercise and the important consequent effects this has on 
cardiac work, heart rate, DTF and consequently perfusion13.  Actual balloon occlusion 
of the coronary artery to stimulate repetitive ischaemia has been used by our own 
department to examine coronary collateral flow during these conditions2 but once again 
this falls short of recreating the physiological conditions of exercise necessary to 
examine the phenomenon of warm-up angina. With its experience and expertise in the 
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measurement of invasive coronary indices, the latest high-resolution cardiac MRI 
perfusion techniques and an established basic sciences research programme into the 
mechanisms underlying warm-up angina and cardiac protection the host department is 
uniquely positioned to carry out such an important, albeit ambitious, research proposal.  
GTN spray has been chosen to alter the haemodynamic conditions of second exercise 
for the reasons outlined previously. 
 
Method 
Patients will be recruited from routine waiting lists for percutaneous coronary 
intervention (PCI) for single vessel coronary disease, or awaiting a routine 
treadmill−exercise test as part of the investigations for stable angina pectoris.  
Inclusion criteria: Stable, single vessel PCI (for coronary disease) 
Exclusion criteria: Unstable symptoms, severe left ventricular impairment (ejection 
fraction <30%), severe renal impairment, pacemaker (or other reason patient cannot 
undertake an MRI scan), severe co−morbidities. 
Patients will undergo a screening sequential supine exercise test to exclude those with 
significant “warm-up”. Warm up will be defined as clear ST segment depression at peak 
exercise on first effort and definitely less marked ST depression on second effort at the 
equivalent time-point. At this time-point on first and on second effort patients will 
undergo CMR and coronary physiological assessment. 
 
CMR protocol  
This will be carried out on a 3T Philips MR scanner. The study will include localisers, 
cine images and rest and exercise-stress perfusion imaging. 3 perfusion scans will be 
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carried out following each episode of exercise stress, with 0.6mg sublingual GTN given 
5 minutes before the 3rd period of exercise. A 15 minute rest period will occur after each 
exercise stress. Exercise will be carried out on an MR compatible supine ergometer 
which is mounted securely onto the MR table. Following peak exercise stress, subjects 
will be repositioned inside the MR scanner. Immediate contrast-enhanced perfusion 
imaging will be performed using a double bolus intravenous injection of non-ionic 
gadolinium (0.05-0.1mmol/kg bodyweight), and signal intensity and time to contrast 
wash in will be measured. From this data, subendocardial to subepicardial perfusion 
ratios and full perfusion quantification (ml/kg/min) will be calculated. DTF will be 
deduced from the R wave on the ECG and closure of the aortic valve. 
 
PCI procedure  
Patients will be catheterised via the right and left radial artery and a pressure−flow dual 
sensor wire (ComboWire®, Volcano therapeutics) passed into the target coronary vessel 
and a pressure-volume catheter (Inca®, CD Leycom, Netherlands) will be placed in the 
left ventricle. Baseline measurements will be taken before the patient undergoes 2 
periods of exercise, with sublingual GTN given 5 minutes before the 2nd period of 
exercise. Coronary flow and LV pressure measurements alongside ECG and central 
aortic pressure traces will be monitored continuously throughout the study. Additional 
monitoring will be performed by means of a central venous line in the pulmonary artery. 
The velocity time integral (VTI) will be measured from the peak Doppler trace obtained 
at a similar point of the coronary artery. DTF will be determined from the R-R interval 
and the dicronotic notch in the central aortic pressure trace as previously described24. 
Microvascular resistance will be defined as the ratio of mean distal coronary pressure to 
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distal velocity time integral (VTI). Rate pressure product (RPP), calculated as the 
product of heart rate and systolic pressure, will be used as an estimate of myocardial 
oxygen consumption (MvO2). The patient will then undergo PCI as planned using the 
same wire.  
 
GTN 
GTN will be administered by 2 puffs of sublingually, with a total dose of 600 
micrograms. This is the standard dose used for angina pectoris. The time to peak 
concentration occurs after 2 – 3 minutes, and the half life 4 – 5 minutes; therefore 
exercise will be performed 5 minutes following administration. Common side effects of 
GTN include flushing, headache and dizziness. Rarer side effects can include vomiting, 
diarrhoea and syncope.  
 
Exercise ECG Screening 
 
 - Exercise 1  
 - 15 mins rest  
 - Exercise 2 
 
Cardiac MR Protocol 
 
- Rest perfusion scan 
- Exercise 1 
- Stress perfusion scan  
- 15 mins rest, then 0.6mg GTN 
s/l 5 mins before Exercise 2 
- Exercise 2 
- Stress perfusion scan 
- 15 mins rest 
 
Catheter laboratory Protocol 
 
- Resting coronary flow 
- Exercise 1 
- Stress coronary flow 
- 15mins rest, then 0.6mg GTN 
s/l 5 mins before Exercise 2 
- Exercise 2 
- Stress coronary flow 
- 15 mins rest  
- PCI	
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Principal endpoints will be obtained at peak of first effort and the equivalent time of 
second effort and will include measures of myocardial blood flow: VTI, central aortic 
pressure (during cath), and, transmural contrast wash-in (during CMR), and measures of 
myocardial work: left ventricle pressure-volume relations – end systolic (ESPVR) and 
end diastolic (EDPVR) and Pressure-Volume loops (during cath), and regional wall 
motion (during CMR). 
Secondary endpoints will include an index of relative microvascular function (Pd/V), 
coronary flow reserve (CFR) and DTF (during cath) and other measures of MR 
perfusion and cardiac efficiency. 
Sample Size Calculation 
There will be differences in coronary blood flow sought between the serial exercise 
protocols as well as being compared to blood flow following PCI. The student's t−test 
will be used to compare means and seek to assess the difference between the groups.  
The main outcome will be coronary flow reserve (CFR) as measured by a Doppler 
probe in the coronary artery. From previous studies, in similar patients to whom we will 
be studying a value of 1.7 ±0.25 was recorded for the CFR (mean ± SD). As it is the 
first time that this type of intervention is suggested for CFR there is no available data 
for the equivalent post-treatment values for mean and SD. The proposed study will form 
a pilot for this novel approach and thus there is no need for formal power and sample 
size calculations. 
We aim to show a difference of 25% by measuring the CFR in the same vessel before 
and after exercise i.e. we will be using same patient as a control.  A basic sample size 
calculation has been carried out to determine the minimum required number of patients 
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to be as small as possible but at the same adequately numbered to provide the baseline 
information needed for extending our study following this pilot.  
The difference of 25% is deemed significant from other experimental scenarios and we 
ideally would like to detect that difference with a minimum of 80% power, with the 
significance set at the 95% level. Based on the available baseline data above (before 
intervention, 1.7+- 0.25) we estimated the sd of the difference after intervention as 0.7. 
This background information (diff:0.25, baseline mean =1.7, sd(diff)=0.7, power=90%, 
P-value<0.05) the desired sample size would be 29 patients. If the power were to be 
lowered to 80% the required sample size fall s to 22, hence we would be happy to settle 
for 22 pilot patients. (sample size calculations were carried out using openepi.com). 
As this calculation is based on an sd(diff) estimate we propose to adjust the figures after 
the first 10 patients have been recorded. We expect that the final number of patients 
would not exceed 58. 
29 patients were required for the initial investigation into the role of nitrates in Angina 
Pectoris (which has completed recruitement) and a further 29 patients will be required 
for this further project to perform the additional pressure-volume measurements based 
on the above sample size calculations. 
 
 
 
 
 
 
 
